

Queensland Health List of Approved Medicines

Drug	Form	Strength	Restriction
abacavir	oral liquid	20 mg/mL	* For use in accord with PBS Section 100 indications * <i>See above</i>
	tablet	300 mg	<i>See above</i>
abacavir + lamivudine	tablet	600 mg + 300 mg	* For use in accord with PBS Section 100 indications * <i>See above</i>
			<i>See above</i>
abacavir + lamivudine + zidovudine	tablet	300 mg + 150 mg + 300 mg	* For use in accord with PBS Section 100 indications * <i>See above</i>
			<i>See above</i>
abatacept	injection	250 mg	* For use in accord with PBS Section 100 indications *
abciximab	injection	10 mg/5 mL	(a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i>
			<i>See above</i>
abiraterone	tablet	250 mg	For use by medical oncologists as per the PBS indications for outpatient and discharge use only <i>See above</i>
		500 mg	<i>See above</i>
			<i>See above</i>
acamprosate	enteric tablet	333 mg	Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. <i>See above</i>
			<i>See above</i>
acarbose	tablet	50 mg	For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents <i>See above</i>
		100 mg	<i>See above</i>
			<i>See above</i>
acetazolamide	injection	500 mg	
	tablet	250 mg	
acetic acid	ear drops	3% 15mL	
	solution	2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL	

Drug	Form	Strength	Restriction
acetylcysteine	injection	2 g/10 mL 6 g/30 mL	For management of paracetamol overdose <i>See above</i> <i>See above</i>
aciclovir	cream	5%	Infectious disease physicians, haematologists and oncologists <i>See above</i>
	eye ointment	3%	For use on the advice of Ophthalmologists only. <i>See above</i>
	injection	250 mg 500 mg	Herpes simplex encephalitis Cutaneous or mucosal herpes simplex in immunosuppressed patients Disseminated herpes zoster in immunocompromised patients Varicella zoster encephalitis or pneumonia in all patients <i>See above</i> <i>See above</i>
	tablet	200 mg 800 mg	For treatment of patients with: Genital herpes simplex infections Herpes zoster in immunocompetent patients in whom the duration of rash is less than 72 hours Herpes zoster in immunocompromised patients Ophthalmic herpes zoster <i>See above</i> <i>See above</i>
acitretin	capsule	10 mg 25 mg	Specialist Dermatologists and Specialist Physicians <i>See above</i> <i>See above</i> <i>See above</i>
activated charcoal	oral liquid	200 mg/mL	250mL
activated charcoal + sorbitol	oral liquid	200 mg/mL + 400 mg/mL	250mL
adalimumab "Humira"	injection	20 mg/0.4 mL 40 mg/0.8 mL	For use in accord with PBS General Schedule/Section 100 indications <i>See above</i>
adefovir	tablet	10 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
adenosine	injection	6 mg/2 mL 30 mg/10 mL	Nuclear medicine for use in cardiac stress testing.
adrenaline (epinephrine)	injection	150 microgram/0.3 mL 300 microgram/0.3 mL 1 in 1000 (1 mg/mL) 1 in 10 000 (1 mg/10 mL) injection and minijet	Epipen Jnr brand - for anticipated emergency treatment of acute allergic reactions with anaphylaxis Epipen brand - For anticipated emergency treatment of acute allergic reactions with anaphylaxis
afibercept			

Drug	Form	Strength	Restriction
	injection	3.6 mg/0.09 mL 4 mg/0.1 mL	Specialist ophthalmologists for outpatient use as per the PBS indications. See above
agalsidase alfa	injection	3.5 mg/3.5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
agalsidase beta	injection	5 mg 35 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program See above
albendazole	tablet	200 mg 400 mg	(a) Treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm). (b) Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with <i>Echinococcus granulosus</i> (Hydatids). (c) Alternative treatment of adults and children with <i>Strongyloides stercoralis</i> . <i>See above</i> <i>See above</i> <i>See above</i>
alcohol (ethanol)	ear drops		
	gel	70% 15mL	
	injection	61.5% 75mL and 125mL	
	lotion	96% 10mL 100% 5mL	
	solution	47.5%-1% 1 litre	
	with 10% propanol - foam	absolute 1 litre industrial methylated 1 litre industrial methylated 4 litre absolute 20 litre specially methylated 70% 2 litre specially methylated (S.V.M.) 15mL specially methylated (S.V.M.) 20 litre 20 litre and 1 litre rectified (S.V.R.) 96% 2 litre and 20 litre	
alectinib	capsule	150 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications *
alemtuzumab	injection	12 mg/1.2 mL	* For use in accord with PBS Section 100 indications *
alendronate	tablet	70 mg	* For use as per the PBS indications *
alfentanil			

Drug	Form	Strength	Restriction
	injection	1 mg/2 mL	Specialist Anaesthetists and their trainees for use as an analgesic supplement given by incremental intravenous boluses or continuous infusion. * CONTROLLED DRUG *
		5 mg/10 mL	For poor risk patients (eg elderly and ischaemic heart disease) * CONTROLLED DRUG *
alginate compound (sodium alginate)	liquid	500mL liquid	For infant use only <i>See above</i> <i>See above</i>
alglucosidase alfa	injection	50 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
alimemazine (trimeprazine)			
allopurinol	tablet	100 mg 300 mg	
alogliptin	tablet	6.25 mg 12.5 mg 25 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
alprazolam	tablet	1 mg 500 microgram	Specialist Psychiatrists <i>See above</i> <i>See above</i>
alprostadil	injection	10 microgram 20 microgram 500 microgram/mL	Specialist Urologists and Spinal Injuries Units for in-hospital use for training purposes <i>See above</i> Neonatal and Paediatric Staff Specialists to use to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival.
alteplase	injection	10 mg 50 mg	a) treatment of acute ST elevation myocardial infarction;b) treatment of acute massive pulmonary embolism.c) fibrinolytic management of obstructed IV access;d) treatment of acute ischaemic stroke under the authority of a physician (including Emergency Department physicians) trained and experienced in acute stroke management or in accordance with an approved written protocol, and in line with the Australian "Clinical Guidelines for Stroke Management". * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i> <i>See above</i>
alteplase	pre-filled syringe		For prevention of central venous catheter malfunction and central venous catheter associated bacterial infection in children on maintenance haemodialysis who are under the care of Specialist Renal Physicians. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i>

Drug	Form	Strength	Restriction
aluminium hydroxide	tablet	1mg in 1mL	See above
		600 mg	For lowering of serum organic phosphates in patients with chronic renal failure See above
aluminium hydroxide + magnesium hydroxide + simethicone (double strength)	chewable tablet	400 mg + 400 mg + 40 mg	See above
aluminium hydroxide + magnesium trisilicate + magnesium hydroxide	oral liquid	250 mg/5 mL + 120 mg/5 mL + 120 mg/5 mL	
amantadine	capsule	100 mg	For the treatment of Parkinson Disease See above
ambrisentan	tablet		* For use in accord with PBS Section 100 indications *
		5 mg 10 mg	See above See above
amidotrizoic acid	solution	660 mg/mL + 100 mg/mL	For use as a radiographic contrast medium for examination of the gastrointestinal tract; For use by general surgeons for adhesive small bowel obstruction (obtain individual patient supplies from pharmacy for administration as a single 100mL dose). * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
amikacin	injection	500 mg/2 mL	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. Caution: Only use DBL brand for nebulised route as it has a lower sodium metabisulfite content. Use other brands for injectable route. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
amiloride	tablet	5 mg	
amiloride + hydrochlorothiazide	tablet	5 mg + 50 mg	
amino acids (synthamin 17) with electrolytes 100g (446 Cal.)/litre, (Na 70, K 60, Mg 5, Cl 70, Ac 150, PO4 30 mmol/L)	injection	10.35 g/500 mL + 5.75 g/500 mL + 5.15 g/500 mL + ...	For prolonged intravenous therapy when oral or enteral feeding is not possible

Drug	Form	Strength	Restriction
amino acids (Synthamin 17) without electrolytes 100g/litre (Ac 82, Cl 40mmol/L)	injection	10.35 g/500 mL + 5.75 g/500 mL + 5.15 g/500 mL + ...	For prolonged intravenous therapy when oral or enteral feeding is not possible
aminolevulinic acid	powder for oral liquid	1.5 g	Neurosurgeons who have undergone training in fluorescence guided surgery for use in patients with suspected high grade glioma in whom complete resection of enhancing tissue is feasible. <i>See above</i>
aminophylline	injection	250 mg/10 mL	
amiodarone	injection	150 mg/3 mL	All preparations restricted to Cardiologists for resistant cardiac arrhythmias <i>See above</i>
	tablet	100 mg 200 mg	<i>See above</i> <i>See above</i>
amiodarone	oral liquid suspension	5mg/mL 80mL	Paediatric cardiac specialists <i>See above</i> <i>See above</i>
amisulpride	oral liquid	100 mg/mL	* For use as per the PBS indications *
	tablet	100 mg 200 mg 400 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i>
amitriptyline	tablet	10 mg 25 mg 50 mg	
amlodipine	tablet	5 mg 10 mg	
amorolfine	solution	5%	Dermatologists for the treatment of proven fungal infections <i>See above</i> <i>See above</i>
amoxicillin	capsule	250 mg 500 mg	
	powder for oral liquid	250 mg/5 mL 500 mg/5 mL	
amoxicillin + clavulanic acid	injection	1 g + 200 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.

Drug	Form	Strength	Restriction
		2 g + 200 mg	See above
		500 mg + 100 mg	See above
	powder for oral liquid		
		125 mg/5 mL + 31.25 mg/5 mL	In conjunction with an antimicrobial stewardship (AMS) team protocol
	tablet	400 mg/5 mL + 57 mg/5 mL	See above
		500 mg + 125 mg	In conjunction with an antimicrobial stewardship (AMS) team protocol
		875 mg + 125 mg	See above
amphotericin B	injection "Fungizone"	50 mg	For treatment of fungal infections where lipid amphotericin preparations are not initially indicated * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
	lozenge "Fungilin"	10 mg	Treatment of oral moniliasis
amphotericin B	powder for tissue culture	50mg	
amphotericin B lipid complex "Abelcet"	injection	100 mg/20 mL	For treatment/prophylaxis of fungal infections * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
amphotericin B liposomal "AmBisome"	injection	50 mg	Use where therapy with "Abelcet" cannot be tolerated. For treatment/prophylaxis of fungal infections * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj See above See above
ampicillin	injection	1 g 500 mg	
amsacrine (AMSA)	injection	75mg in 1.5mL	
anakinra			* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
anastrozole	injection	100 mg/0.67 mL	See above See above * For use as per the PBS indications *
	tablet	1 mg	See above See above
antithymocyte immunoglobulin equine	injection	250 mg/5 mL	
antithymocyte immunoglobulin rabbit	injection	25 mg	Transplant Specialists, Oncologists and Haematologists for: a) Prophylaxis of graft rejection in renal transplantation patients with a history of graft rejection; and b) Treatment of steroid resistant or moderate to severe renal transplant rejection. See above See above
apomorphine	injection	20 mg/2 mL	* For use in accord with PBS Section 100 indications *
		30 mg/3 mL	See above
		50 mg/5 mL	See above
		50 mg/10 mL	See above
		100 mg/20 mL	See above
apraclonidine	eye drops	0.5% 5mL and 10mL	Specialist Ophthalmologists See above See above
aprepitant	capsule	165 mg	For use as per the PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
aqueous cream (A.P.F) with coal tar solution	cream	aqueous cream (A.P.F.) with coal tar 3% solution 100g	
aqueous cream (A.P.F.)	cream	100g 500g	
aqueous cream (A.P.F.) with salicylic acid and coal tar solution	cream	6%-6% 100g	
aqueous cream (A.P.F.) with menthol	cream	1% 100g	
aqueous cream (A.P.F.) with salicylic acid and sulfur	cream	3%-10% 100g 5%-5% 100g	
argatroban			For use in the management of acute heparin induced thrombocytopenia (HIT) in patients with end stage renal failure (ie. a calculated GFR <15mL/min). * For use in accord with Special Access

Drug	Form	Strength	Restriction
			Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	injection	250mg in 2.5mL	See above
arginine hydrochloride	injection		For pituitary function testing
		60% (15 g/25 mL)	See above
aripiprazole	modified release injection	300 mg	Specialist Psychiatrists for the treatment of schizophrenia
		400 mg	See above
	tablet	10 mg	For use as per the PBS indications following failure of brexpiprazole, risperidone, olanzapine, amisulpride or lurasidone.
		15 mg	See above
		20 mg	See above
		30 mg	See above
arsenic			* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
	injection		See above
		10 mg/10 mL	See above
artemether + lumefantrine	tablet		For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
		20 mg + 120 mg	See above
artesunate			For use in accord with Category A Special Access Scheme (SAS) arrangements. Approval from the Medical Superintendent (or delegate) must also be received in line with the Individual Patient Approval (IPA) guidelines. Initiation of therapy should be on the advice of an Infectious Diseases Physician.
			* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	powder for injection		QHMAC guidance on artesunate provided below - see 'Guidelines and Other Resources' section.
		60mg	See above
articaine + adrenaline (epinephrine)	injection		
		4% (88 mg/2.2 mL) + 1 in 100 000 (22 microgram/2.2 mL)	For dental use
artificial saliva	liquid		
		2 Litres "oralube" 125mL	
ascorbic acid	chewable tablet		
		500 mg	
asparaginase (colaspase)	injection		
		10 000 Kyowa units	
aspirin	dispersible tablet		

Drug	Form	Strength	Restriction
atazanavir	tablet	300 mg	
		100 mg	
	capsule	200 mg 300 mg	* For use in accord with PBS Section 100 indications * See above
atazanavir + cobicistat	tablet	300 mg + 150 mg	* For use in accord with PBS Section 100 indications * See above See above
atenolol	tablet	50 mg	
atenolol	oral liquid suspension	2mg/mL 200mL	Paediatric cardiac specialists See above See above
	injection	1.2 g/20 mL 840 mg/14 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above See above
atomoxetine	capsule	10 mg	For use as per the PBS indications (ADHD)
		18 mg	See above
		25 mg	See above
		40 mg	See above
		60 mg	See above
atorvastatin	tablet	10 mg	* For use as per the PBS indications * See above
		20 mg	See above
		40 mg	See above
		80 mg	See above
atovaquone + proguanil	tablet	250 mg + 100 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
atracurium	injection	25 mg/2.5 mL	Specialist Anaesthetists and Country Medical Superintendents See above
		50 mg/5 mL	See above
			See above
atropine sulfate	eye drops	1% unit dose 0.5mL x 20 and 15mL	0.5mL x 20 unit dose: For inpatient use only 15mL: Unrestricted
	injection	1.2 mg/mL 600 microgram/mL 1 mg/10 mL	

Drug	Form	Strength	Restriction
avelumab	tablet	600 microgram	For organophosphate poisoning
	injection	200 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
azacitidine	injection	100 mg	* For use in accord with PBS Section 100 indications *
			See above
azathioprine	injection	50 mg	See above
	tablet	25 mg 50 mg	
azathioprine	oral liquid suspension	5mg/mL, 100mL (QH-CP)	For oral or enteral dosing where administration of the solid dose form is not appropriate. Refer to 'Don't Rush to Crush' and local procedures for guidance. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
azithromycin	injection	500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
	powder for oral liquid	200 mg/5 mL	For use as per the PBS indications for trachoma; and For the treatment and prophylaxis of laboratory proven or suspected Bordetella pertussis infection in children and infants. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	500 mg	For treatment of Chlamydia trachomatis where alternative therapy is ineffective or inappropriate; Cystic fibrosis specialists treating cystic fibrosis patients (six years and older) as prophylaxis of exacerbations of chronic Pseudomonas aeruginosa infection; For the treatment of laboratory proven Bordetella pertussis infection in adults; For the prophylaxis of Bordetella pertussis infection in susceptible contacts of proven cases as advised by an infectious diseases or public health physician; Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		600 mg	For use in accord with PBS Section 100 indications; Specialist Staff for prophylaxis of Mycobacterium Avium Complex in severe immune deficiency
aztreonam	injection	1 g	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
baclofen			

Drug	Form	Strength	Restriction
	intrathecal injection	50 microgram/mL 10 mg/5 mL	Spinal unit patients only * For use in accord with PBS Section 100 indications *
	tablet	10 mg 25 mg	Suppression of voluntary muscle spasm in multiple sclerosis Spinal lesions causing skeletal hypertonus Spastic and dys-synergic bladder dysfunction <i>See above</i>
balanced salt solution concentrate (plus) 500mL	irrigation solution	Sodium Chloride 0.64%; Potassium Chloride 0.075%; Magnesium Chloride 0.03%; Calcium Chloride 0.048%; Sodium Acetate 0.39%; Sodium Citrate 0.17%	Ophthalmologists <i>See above</i> <i>See above</i>
balsalazide	capsule	750 mg	For use as per the PBS indications (for ulcerative colitis) <i>See above</i> <i>See above</i>
balsam of peru	ointment	15g	
basiliximab	injection	20 mg	Specialist Nephrologist staff as induction therapy for renal transplant recipients.
beclometasone	inhalation nasal spray	50 microgram/actuation 100 microgram/actuation 50 microgram/actuation	
bendamustine	injection	25 mg 100 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i>
benralizumab	injection	30 mg/mL	Respiratory physicians, clinical immunologists, allergists or general physicians experienced in the management of patients with severe asthma for discharge and outpatient use in accord with PBS Section 100 indications.
benzathine benzylpenicillin	injection	1.2 million units/2.3 mL	
benzatropine	injection tablet	2 mg/2 mL 2 mg	
benzoic acid + salicylic acid	ointment	6% + 3%	
benzoin Sumatra + storax prepared + Aloes cape			

Drug	Form	Strength	Restriction
benzoyl peroxide	tincture	9.78% + 4.6% + 6.22%	25mL
	gel	5%	50g
benzydamine	mouthwash	0.15%	200mL: For the treatment of mucositis associated with radiotherapy and cytotoxic chemotherapy <i>See above</i>
benzyl benzoate	lotion	25%	200mL <i>See above</i>
	injection	1.2 g 3 g 600 mg	<i>See above</i>
betamethasone acetate + betamethasone sodium phosphate	injection	3 mg/mL + 3.9 mg/mL (total betamethasone 5.7 mg/mL)	
	cream	0.05% 15g and 50g, 0.05% modified cream 30g	
betamethasone dipropionate	lotion	0.05%	30mL
	ointment	0.05% 15g and 50g and modified ointment 30g	Betamethasone Dipropionate (Diprosone) Ointment 15g and 50g - unrestricted Betamethasone Dipropionate Glycol (Diprosone OV) Ointment 30g - Specialist Dermatologists
	cream	0.02% 0.05% 0.1%	100g 15g 30g
betamethasone valerate	ointment	0.1%	30g
	cream	0.03%-0.9% 50g	
betamethasone valerate and clioquinol	cream	0.03%-0.9% 50g	
betaxolol	eye drops	0.25%	5mL
	tablet	10 mg	Inpatient use only. <i>See above</i> <i>See above</i>
bevacizumab	injection	100 mg/4 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
		400 mg/16 mL	See above
bicalutamide	tablet	50 mg	For metastatic (equivalent to Stage D) prostatic carcinoma in combination with GnRH (LH-RH) agonist therapy or post bilateral orchidectomy.
bicarbonate	capsule	840 mg	
	injection	8.4% (8.4 g/100 mL)	
bicarbonate + calcium lactate pentahydrate + glucose + potassium chloride + sodium chloride	solution	0.015% + 0.032% + 0.085% + ...	For initial supply post ENT surgery; and sinus irrigation for children with chronic rhinosinusitis which may co-exist with cystic fibrosis and asthma. Note: Pack of 12 sachets (starter kit) only
bicarbonate + citric acid + tartaric acid	powder for oral liquid	1.76 g + 630 mg + 720 mg + ...	
bictegravir + emtricitabine + tenofovir alafenamide	tablet	50 mg + 200 mg + 25 mg	* For use in accord with PBS Section 100 indications * See above See above
binimetinib	tablet	15 mg	Specialist oncologists * For discharge and outpatient use as per the PBS indications *
biperiden	tablet	2 mg	
bisacodyl	enema	10 mg/5 mL	For inpatient use only See above
	enteric tablet	5 mg	
	suppository	10 mg	
bisacodyl + docusate	suppository	10 mg + 100 mg	
bisacodyl-magnesium citrate (pack containing 3 x 5mg bisacodyl tablets and 1 x sachet magnesium citrate effervescent (equiv to 3g magnesium oxide) "Go Kit"	*combination pack*	pack containing 3 x 5mg bisacodyl tablets and 1 x sachet magnesium citrate effervescent (equiv to 3g magnesium oxide)	
bismuth subcitrate (colloidal)			For radiologically or endoscopically proven ulcer

Drug	Form	Strength	Restriction
	tablet		See above
bismuth subnitrate + iodoform		107.7mg	See above
	paste		
bismuth subnitrate and iodoform		250 mg/g + 500 mg/g	
	dressing		
bisoprolol		1-2-1 (12.5mm x 1m)	
	tablet		
		2.5 mg	* For use as per the PBS indications *
		5 mg	See above
		10 mg	See above
bivalirudin			
	injection		
		250 mg	For patients undergoing non-urgent percutaneous coronary intervention; On the advice of a haematologist, vascular physician or clinical pharmacologist for use as an alternative anticoagulant therapy for acute management of patients with heparin induced thrombocytopenia (HIT) in patients who have liver impairment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
bleomycin			
			Interventional radiologists and/or surgeons as a first-line sclerotherapy agent for the treatment of microcystic lymphatic malformations and as an alternative sclerotherapy agent for treatment of other subtypes of veno-lymphatic malformations (at the discretion of the treating clinician). or For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS or For treatment of malignant lymphoma or squamous carcinoma unresponsive to any other therapy or, when owing to severe depression of bone marrow, other therapy cannot be used * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	injection		See above
		15 000 international units	See above
blood detection in faeces - hematest			
	tablet		
		50	
blood detection in faeces - coloscreen			
	tape		
		pack of 2 x 100 tests	
blood detection in urine - hemastix			
	diagnostic strip		
		test strips	
bone cement with antibiotic - gentamicin 0.5g "Palacos MV+G" "Palacos R+G"			
	40g		

Drug	Form	Strength	Restriction
bone cement with antibiotic - gentamicin 1g "CMW1" "CMW2" "CMW3"	40g	gentamicin 0.5g - Palacos MV+G ; Palacos R+G	For use in hip, and high risk knee, arthroplasty.
		gentamicin 1g "CMW1" "CMW2" "CMW3"	For use in hip, and high risk knee, arthroplasty.
bone cement with antibiotic - tobramycin 1g "Antibiotic Simplex"	40g		<i>See above</i>
		tobramycin 1g "Antibiotic Simplex"	<i>See above</i>
boric acid + olive oil + zinc oxide ointment		0.25% + 25% + 7.5%	
boric acid 5% in 96% ethanol ear drops		5% 15mL	
boric acid, olive oil, zinc oxide with coal tar solution ointment		3% 100g	
boric acid, olive oil, zinc oxide with salicylic acid ointment		2.5% 100g	
boric acid, olive oil, zinc oxide with salicylic acid and coal tar solution ointment		2.5%-2.5% 50g	
bortezomib	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 mg	<i>See above</i>
		3 mg	<i>See above</i>
		3.5 mg	<i>See above</i>
bosentan	tablet		* For use in accord with PBS Section 100 indications *
		62.5 mg	<i>See above</i>
		125 mg	<i>See above</i>
botulinum toxin type A	injection	100 units	<p>a) Specialist Staff for use in accord with PBS Section 100 indications for outpatient or day patient use only</p> <p>b) Specialist Colorectal Surgeons for the treatment of female patients with chronic anal fissure (where Crohn disease has been excluded) who have failed a two month trial of conservative therapy (including glyceryl trinitrate ointment 0.2%). Maximum of two treatment doses.</p> <p>c) Specialist ophthalmologists only for protective ptosis.</p> <p>d) Specialist paediatric surgeons and paediatric gastroenterologists for treatment in children with pain (proctalgia fugax) secondary to anal sphincter spasm or anal fissure refractory to standard treatment with laxatives.</p> <p>e) Gastroenterologists for management of achalasia in patients who are not candidates for surgical myotomy or endoscopic dilatation treatment.</p>

Drug	Form	Strength	Restriction
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
box jellyfish antivenom	injection	20 000 units	
brentuximab vedotin	injection	50 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
brexpiprazole	tablet	1 mg 2 mg 3 mg 4 mg	* For use as per the PBS indications * See above See above See above
brilliant green + crystal violet	paint	0.5% + 0.5%	
brimonidine	eye drops	0.2%	5mL
bromhexine	tablet	8 mg	
bromocriptine	capsule	10 mg	
	tablet	2.5 mg	
brown snake antivenom	injection	1000 units	
budesonide	inhalation solution	1 mg/2 mL 500 microgram/2 mL	For patients with severe chronic asthma requiring long term steroid therapy and unable to use other forms of inhaled steroid therapy; Specialist Staff and emergency unit doctors for the treatment of moderate to severe croup See above See above
	powder for inhalation	100 microgram/actuation 200 microgram/actuation 400 microgram/actuation	
budesonide + formoterol (eformoterol)	inhalation	50 microgram/actuation + 3 microgram/actuation 100 microgram/actuation + 3 microgram/actuation 200 microgram/actuation + 6 microgram/actuation	* For use as per the PBS indications * See above See above See above
	powder for inhalation	100 microgram/actuation + 6 microgram/actuation	See above See above

Drug	Form	Strength	Restriction
		400 microgram/actuation + 12 microgram/actuation	See above
		200 microgram/actuation + 6 microgram/actuation 60 doses (2 packs) or 60 doses "Hospital Pack"	See above
bumetanide	tablet	1 mg	
bupivacaine	injection	0.25% (50 mg/20 mL)	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
		0.5% (20 mg/4 mL)	
		0.5% (50 mg/10 mL)	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
	injection	0.5% (100 mg/20 mL)	See above
		0.125% (250 mg/200 mL)	
		0.25% (250 mg/100 mL)	
bupivacaine + adrenaline (epinephrine)	injection	0.25% (50 mg/20 mL) + 1 in 400 000 (50 microgram/20 mL)	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
		0.5% (11 mg/2.2 mL) + 1 in 200 000 (11 microgram/2.2 mL)	Maxillofacial Surgeons
		0.5% (100 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
bupivacaine + fentanyl	injection	0.125% (25 mg/20 mL) + 100 microgram/20 mL	* CONTROLLED DRUG *
bupivacaine + fentanyl	epidural infusion	0.125% (250mcg/200mL) + 400mcg/200mL	* CONTROLLED DRUG *
		0.125% (250mcg/200mL) + 1000mcg/200mL	See above
bupivacaine + glucose "marcaine spinal 0.5% heavy"	injection	0.5% + 8% 4mL	
buprenorphine	injection	300 microgram/mL	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
	patch	5 microgram/hour	For chronic severe disabling pain not responding to non-narcotic analgesics. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		10 microgram/hour	See above
		20 microgram/hour	See above
	sublingual tablet	2 mg	a) For use as per the PBS indications for patients registered on an approved opioid treatment program; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *
		8 mg	See above
		200 microgram	For severe disabling pain in patients who, because of gastrointestinal problems, cannot be controlled on other oral narcotic analgesics. Therapy to be initiated by a Pain Clinic.

Drug	Form	Strength	Restriction
buprenorphine (Bupival Monthly)		400 microgram	* CONTROLLED DRUG * a) For use as per the PBS indications for patients registered on an approved opioid treatment program; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *
	modified release injection		* For use as per the PBS indications * for patients registered on an approved opioid treatment program. Caution: Bupival Weekly, Bupival Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable. Note: These presentations are only for administration by subcutaneous injection. * CONTROLLED DRUG *
		64 mg/0.18 mL	Queensland Clinical Guideline: Long-Acting Injection Buprenorphine in the Treatment of Opioid Dependence <i>See above</i>
		96 mg/0.27 mL 128 mg/0.36 mL	<i>See above</i> <i>See above</i> <i>See above</i>
buprenorphine (Bupival Weekly)	modified release injection		* For use as per the PBS indications * for patients registered on an approved opioid treatment program. Caution: Bupival Weekly, Bupival Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable Note: These presentations are only for administration by subcutaneous injection. * CONTROLLED DRUG *
		8 mg/0.16 mL	Queensland Clinical Guideline: Long-Acting Injection Buprenorphine in the Treatment of Opioid Dependence <i>See above</i>
		16 mg/0.32 mL	<i>See above</i>
		24 mg/0.48 mL 32 mg/0.64 mL	<i>See above</i> <i>See above</i>
buprenorphine (Sublocade)	modified release injection		* For use as per the PBS indications * for patients registered on an approved opioid treatment program. Caution: Bupival Weekly, Bupival Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable Note: These presentations are only for administration by subcutaneous injection. *CONTROLLED DRUG*
		100 mg/0.5 mL	2019 Queensland Clinical Guideline: Long-Acting Injection Buprenorphine in the Treatment of Opioid Dependence <i>See above</i>
		300 mg/1.5 mL	<i>See above</i>
buprenorphine + naloxone	sublingual film	2 mg + 500 microgram	a) For use as per the PBS indications for patients registered on an approved opioid treatment program; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *
		8 mg + 2 mg	<i>See above</i>
busulfan	tablet	2 mg	

Drug	Form	Strength	Restriction
C1 esterase inhibitor	injection	500 units	For inpatient use in line with National Blood Authority funded indications (Type I or Type II hereditary angioedema). <i>See above</i> <i>See above</i>
cabazitaxel	injection	60 mg/1.5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
cabergoline	tablet	1 mg 2 mg 500 microgram	For the treatment of Parkinson Disease <i>See above</i> Specialist endocrinologists for treatment of prolactinomas or hyperprolactinaemia as per the PBS indications where the patient is intolerant of bromocriptine despite maximum tolerated therapy; For lactation suppression as per the PBS indications
caffeine	injection	40 mg/2 mL	Specialist Paediatric Staff for use in premature babies born under 36 weeks gestation who have apnoea of prematurity when enteral caffeine is inappropriate <i>See above</i>
caffeine citrate	oral liquid solution	20mg per mL, 50mL	Specialist Paediatric Staff for use in premature babies born under 36 weeks gestation who have apnoea of prematurity
calamine lotion (B.P.)	lotion	calamine lotion (B.P)	200mL
calamine with coal tar solution	lotion	calamine with coal tar solution 3%	
calamine with zinc oxide and almond oil	cream	calamine with zinc oxide and almond oil	100g <i>See above</i> <i>See above</i>
calcipotriol	cream	0.005%	Specialist Dermatologists for use as per the PBS indications <i>See above</i> <i>See above</i>
calcipotriol + betamethasone dipropionate	gel	0.005% + 0.05%	30g: Specialist Dermatologists for the treatment of chronic stable plaque type psoriasis vulgaris of the scalp as per the PBS indications. <i>See above</i>
	ointment	0.005% + 0.05%	30g: Specialist Dermatologists for the treatment of chronic stable plaque type psoriasis vulgaris as per the PBS indications. <i>See above</i>
calcitonin salmon (salcatonin)	injection	100 units/mL	
calcitriol	capsule	0.25 microgram	

Drug	Form	Strength	Restriction
	injection		Nephrologists for use in patients with moderate to severe renal osteodystrophy who are unresponsive to maximal oral calcitriol therapy and in children too young to swallow capsules <i>See above</i>
calcium		1 microgram/mL	
	effervescent tablet	2.3 g + 1.8 g (total calcium 1 g)	For treatment of hypocalcaemia. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	tablet	1.25 g (calcium 500 mg) 1.5 g (calcium 600 mg)	
Calcium carbonate oral suspension (Auspman) 100mg/mL, 200mL	oral liquid suspension	200mL	For treatment of hypocalcaemia in children too young to swallow tablets or capsules.
calcium chloride	injection	1 g/10 mL	
calcium gluconate monohydrate	injection	953 mg/10 mL (Calcium 2.2mmol/10mL)	
calcium polystyrene sulfonate	powder	999.3 mg/g	For use when polystyrene sulfonate sodium is inappropriate. <i>See above</i>
camphor compound linctus A.P.F. with or without syrup	oral liquid	Camphor compound linctus A.P.F.	100mL <i>See above</i>
capecitabine	tablet	150 mg 500 mg	General use for TGA approved indications. <i>See above</i> <i>See above</i> <i>See above</i>
capreomycin	injection	1 g	
capsaicin	cream	0.075%	45g: For use in treatment of neuralgic pain <i>See above</i> <i>See above</i>
captopril	oral liquid	5 mg/mL	95mL: For patients unable to take a solid dose form of an ACE inhibitor <i>See above</i>
	tablet	12.5 mg 25 mg 50 mg	
carbachol	eye drops	3%	15mL <i>See above</i>
	intraocular injection	0.01% (150 microgram/1.5 mL)	Specialist Ophthalmologists <i>See above</i>

carbachol 1.5% 15mL

Drug	Form	Strength	Restriction
	eye drops	1.5% 15mL	
carbamazepine	modified release tablet	200 mg 400 mg	
	oral liquid	100 mg/5 mL	
	tablet	100 mg 200 mg	
carbimazole	tablet	5 mg	
carbomer-980	eye gel	0.2%	10g: Specialist Ophthalmologists <i>See above</i> <i>See above</i>
carboplatin	injection	50 mg/5 mL 150 mg/15 mL 450 mg/45 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
carboprost (15-methyl prostaglandin F2α)	injection	250microgram/mL	Specialist Obstetricians and Gynaecologists and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology, for second line management of severe life-threatening primary postpartum haemorrhage within the guidance of the Queensland Maternity and Neonatal Clinical Guideline "Primary Postpartum Haemorrhage". * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i> <i>See above</i>
carfilzomib	injection	30 mg 60 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i>
carmellose sodium (Cellufresh)	eye drops	0.5%	0.4mL: Specialist ophthalmologists
carmellose sodium (Celluvisc)	eye drops	1%	0.4mL: Specialist Ophthalmologists
carmustine	injection	100 mg	
carvedilol	tablet	3.125 mg 6.25 mg 12.5 mg 25 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
carvedilol	oral liquid suspension	carvedilol 1.67mg per mL	90mL: Paediatric cardiac specialists <i>See above</i> <i>See above</i>
casprofungin	injection	50 mg 70 mg	For use in adults and paediatrics on the advice of an infectious diseases physician or a clinical microbiologist for treatment of severe systemic candida infections that are resistant to fluconazole therapy, or where fluconazole is strongly contraindicated; or in accord with an infectious diseases approved protocol. <i>See above</i> <i>See above</i> <i>See above</i>
castor oil	oil	castor oil	200mL <i>See above</i> <i>See above</i>
castor oil and zinc oxide	ointment	castor oil and zinc oxide	100g <i>See above</i> <i>See above</i>
cefaclor	powder for oral liquid	125 mg/5 mL	100mL: For treatment of respiratory tract infections in patients unable to swallow cefuroxime tablets and who are hypersensitive to penicillin (excluding immediate hypersensitivity) <i>See above</i>
cefalexin	capsule powder for oral liquid	250 mg 500 mg 250 mg/5 mL	Children too young to swallow tablets or capsules <i>See above</i>
cefalotin	injection	1 g	On the advice of an infectious diseases physician or microbiologist in situations where it may be preferred to cefazolin. <i>See above</i> <i>See above</i>
cefalotin 5% eye drops 10mL	eye drops	5% 10mL	Ophthalmologists
cefazolin	injection	1 g	
cefepime	injection	1 g 2 g	(a) On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol (b) For patients under the care of Specialist Renal Physicians for empiric treatment of paediatric peritoneal dialysis peritonitis according to the statewide paediatric clinical pathway. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
cefotaxime			* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *

Drug	Form	Strength	Restriction
cefoxitin	injection		See above
		1 g	See above
		2 g	See above
ceftazidime	injection		For treatment of (a) infections caused by non-tuberculous mycobacteria; (b) biliary reconstructive surgery in children; (c) on the advice of an infectious diseases physician or a clinical microbiologist
		1 g	See above
			See above
ceftriaxone	injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		1 g	See above
		2 g	See above
cefuroxime	injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		1 g	See above
celecoxib	tablet		For treatment of respiratory tract infections in patients hypersensitive to penicillin (excluding immediate hypersensitivity)
		250 mg	See above
cerliponase alpha	capsule		See above
		200 mg	For use as a single peri-operative dose for the management of post-operative pain.
cetirizine	injection solution		For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
		150mg/5mL	
cetomacrogol	oral liquid		200mL: For use in children where other antihistamines are inappropriate.
		5 mg/5 mL	
cetomacrogol cream with clioquinol	tablet		Where other antihistamines are inappropriate.
		10 mg	
cetomacrogol with crude coal tar	cream		
		100g 500g	
cetomacrogol with salicylic acid	cream		
		1% 100g	
cetomacrogol with salicylic acid and coal tar solution	cream		
		cetomacrogol cream with crude coal tar 1% 100g	
cetomacrogol with salicylic acid and coal tar solution	cream		
		3% 100g 12% 50g	

Drug	Form	Strength	Restriction
cetuximab	injection	3%-3% 100g	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		3%-6% 100g	
		100 mg/20 mL	
cetylpyridinium + benzocaine	mouthwash	500 mg/100 mL	See above
		0.05% + 0.4%	200mL
chloral hydrate	oral liquid		
chlorambucil	tablet	1 g/10 mL	200mL
		2 mg	
chloramphenicol	ear drops	0.5%	5mL
	eye drops	0.5% 10mL	Inpatient use only
		0.5% 0.5mL x 20	
	eye ointment	1%	4g: For ophthalmic use only
chloramphenicol			
chlorhexidine	cream	1% 50g	
	digluconate alcohol free mouthwash	0.2% 200mL	Mucositis in oncology patients and in paediatric intensive therapy units, and as an antibacterial mouthwash following maxillo-facial surgery.
	gluconate mouthwash	0.2% 200mL	
	hand and body wash/skin cleanser		
	lotion	2% 125mL	
		2% 500mL	
	pre op-wash	1% 200mL obstetric	
	surgical hand scrub/surgical hand wash	4% 50 mL	
		4% 1.5L	Restricted to specially approved areas
		4% 125mL	See above
	4% 500mL	See above	
chlorhexidine in alcohol	handrub	chlorhexidine 0.5% alcohol 70% -125mL, 500mL	
	solution PINK	chlorhexidine 2% alcohol 70% - 30mL, 100mL, 500mL	
	solution RED		

Drug	Form	Strength	Restriction
chlorhexidine sterile aqueous	solution	chlorhexidine 0.5% alcohol 70% - 100mL, 500mL chlorhexidine 2% alcohol 70% - 30mL, 100mL	
		0.02% 100mL 0.02% - 500 mL, 1 Litre 0.1% - 30 mL, 100 mL, 1 Litre	Can be used for bladder irrigation
chlorhexidine + cetrimide	solution	0.015% (150 mg/L) + 0.15% (1.5 g/L) - 30mL, 500mL, 1Litre	
chloroquine	tablet	250 mg	
chlorpromazine	injection	50 mg/2 mL	
	oral liquid	5 mg/mL	100mL, 500mL To view LAM status of QH Central Pharmacy manufactured STRONG syrup: Refer to separate listing for chlorpromazine - oral liquid strong - 20mg per mL, 200mL
	tablet	10 mg 25 mg 100 mg	
chlorpromazine	oral liquid strong	20mg per mL	200mL See above See above
chlortalidone	tablet	25 mg	
cholera vaccine	oral liquid	3 mL	
ciclosporin	capsule	10 mg 25 mg 50 mg 100 mg	
		injection	50 mg/mL 250 mg/5 mL

Drug	Form	Strength	Restriction
cidofovir	oral liquid	100 mg/mL	
	injection	375 mg/5 mL	Ear, nose and throat surgeons and respiratory physicians for the treatment of recurrent respiratory papillomatosis on the approval of an infectious diseases physician or antimicrobial stewardship team. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
cinacalcet	tablet		For use in accord with PBS General Schedule/Section 100 indications
		30 mg	See above
		60 mg	See above
		90 mg	See above
cinchocaine + zinc oxide	ointment		50g
		0.5% + 20%	See above See above
ciprofloxacin	ear drops		(a) For use in paediatric patients under the care of an ENT specialist as per the PBS indications (b) For use as per the Qld Govt/RFDS Primary Clinical Care Manual in Aboriginal and Torres Strait Islander persons only.
		0.3%	See above
	injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		200 mg/100 mL	See above
		250 mg	See above
		500 mg	See above
tablet	750 mg	See above	
		See above	
cisatracurium	injection		Specialist Anaesthetists and Country Medical Superintendents
		5 mg/2.5 mL	See above
		10 mg/5 mL	See above
		150 mg/30 mL	See above
cisplatin	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		50 mg/50 mL	See above
		100 mg/100 mL	See above
citalopram	tablet		For major depressive disorders
		20 mg	See above
		40 mg	See above
citric acid	oral liquid		
		2.64 g/30 mL	For patients at risk of aspiration requiring emergency procedures

citric acid + lauryl sulfoacetate
sodium + sorbitol

Generated on: 22-Dec-2020

Drug	Form	Strength	Restriction
	enema	450 mg/5 mL + 45 mg/5 mL + 3.125 g/5 mL	
citric acid powder 1kg	powder	citric acid 1kg	Haemodialysis Unit cleaning solution
cladribine	injection	10 mg/5 mL 10 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
clarithromycin	tablet	250 mg	Haemophilus infections where alternatives such as tetracycline or erythromycin are inappropriate or not tolerated; Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults.
clindamycin	capsule	150 mg	Specialist Staff and Endorsed Podiatrists * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	cream	2%	For gynaecological conditions
	injection	600 mg/4 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
clobazam	tablet	10 mg	Specialist Neurologists for the treatment of refractory Lennox-Gastaut epilepsy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i> <i>See above</i>
clofazimine	capsule	50 mg	Only available for the World Health Organisation (WHO) program for leprosy <i>See above</i> <i>See above</i>
clomifene	tablet	50 mg	Persons approved by Director General of Health and Medical Services <i>See above</i> <i>See above</i>
clomipramine	tablet	25 mg	Cataplexy associated with narcolepsy; obsessive-compulsive disorder; phobic disorders in adults. <i>See above</i> <i>See above</i>
clonazepam	injection	1 mg/mL	
	oral liquid	2.5 mg/mL (0.1 mg/drop)	Children too young to swallow tablets; and for a) The prevention of epilepsy; and b) The treatment of anxiety, seizures, hiccups and neuropathic pain in patients unable to swallow tablets. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's

Drug	Form	Strength	Restriction
			advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
clonidine	tablet	2 mg 500 microgram	
	injection	150 microgram/mL	
clopidogrel	tablet	100 microgram 150 microgram	For use as per the PBS indications; and for use in patients undergoing arterial stenting for up to a maximum of three months. <i>See above</i> <i>See above</i>
	tablet	75 mg	
clostridium botulinum type A toxin-haemagglutinin complex	injection	300 units 500 units	For use in accord with PBS Section 100 indications for outpatient or day patient use only <i>See above</i> <i>See above</i>
clotrimazole	cream lotion	1%	20mL Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	pessary	100 mg	Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	vaginal cream	1%	35g Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
clozapine	tablet	25 mg 100 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
	solution	200mL	
coal tar solution and salicylic acid	ointment	6%-2% 100g	
cocaine	eye drops	5%	2mL * CONTROLLED DRUG *
	mouthwash	cocaine hydrochloride 2%	100mL * CONTROLLED DRUG *

Drug	Form	Strength	Restriction
	powder	cocaine hydrochloride powder 100mg	* CONTROLLED DRUG *
cocaine + atropine + phenylephrine	eye drops	cocaine 4% + atropine 4% + phenylephrine 10%	2mL * CONTROLLED DRUG * <i>See above</i> <i>See above</i>
codeine	tablet	30 mg	For gastrointestinal hypermotility disorders. Not to be used for pain control. In view of safety concerns, codeine is not recommended for use in children under 12 years of age. * CONTROLLED DRUG * <i>See above</i> <i>See above</i>
colchicine	tablet	500 microgram	
colecalfiferol	oral liquid	5 microgram/0.04 mL (200 units) 25 microgram/0.2 mL (1000 units)	15mL: For neonates on discharge 50mL
colecalfiferol	tablet	25 microgram (1000 units)	
colecalfiferol	capsule	1.25mg (50,000 units)	For individuals with Cystic Fibrosis whose vitamin D levels are <75nmol/L for Stoss Therapy (single high dose therapy). Must be taken with food and pancreatic enzyme supplementation.
colestyramine	powder for oral liquid	4 g	
colistin	injection	150 mg (4.5 million units)	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	powder for inhalation "Tadim"	1 million units	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved written protocol, as second-line treatment to nebulised tobramycin for treatment of pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis. Cases where colistimethate therapy would be appropriate include demonstrated resistance by pseudomonas to tobramycin, adverse reactions due to tobramycin or where aminoglycoside therapy is otherwise contraindicated.
colonoscopy preparation - macrogol-3350 + sodium chloride + potassium chloride + sodium sulfate + bicarbonate	powder for oral liquid	59 g + 1.46 g + 750 mg (potassium 10 mmol) + ...	
colonoscopy preparation kit - containing one sachet macrogol 3350 powder concentrate and 3 bisacodyl 5mg tablets and 1 sachet magnesium citrate "Glycoprep-C Kit"	*combination pack*		

Drug	Form	Strength	Restriction
colonoscopy preparation kit containing one sachet macrogol 3350 powder concentrate and two sachets each with sodium picosulfate 10mg and magnesium	*combination pack*	containing one sachet macrogol 3350 powder concentrate and 3 bisacodyl 5mg tablets and 1 sachet magnesium citrate "Glycoprep-C Kit"	
conjugated estrogens	tablet	300 microgram 625 microgram	
copper sulfate	crystals (large)	25g	
cornea preserving solution	solution	cornea preserving solution 20mL	For corneal transplantation only <i>See above</i> <i>See above</i>
cortisone	tablet	5 mg 25 mg	
crizotinib	capsule	200 mg 250 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
cromoglycate	eye drops inhalation	2% 5 mg/actuation	
crude coal tar in soft paraffin	ointment	1% 100g 2.5% 100g 5% 50g	
cyclizine	injection tablet	50 mg/mL 50 mg	Paediatric specialist staff for use in children as second line therapy in prevention and treatment of postoperative nausea and vomiting, and third line therapy in chemotherapy-induced emesis. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
cyclopentolate	eye drops		

Drug	Form	Strength	Restriction
cyclopentolate with phenylephrine	eye drops	0.5%	Specialist Ophthalmology staff for use in paediatric inpatients and outpatients undergoing treatment in eye clinic.
		1%	0.5mL: For inpatient use only Specialist Ophthalmologists
		0.2%-1%, 5mL (QH-CP)	<i>See above</i>
		1%-2.5%, 5mL (QH-CP)	<i>See above</i>
cyclophosphamide	injection	1 g	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		2 g	<i>See above</i>
	tablet	500 mg	<i>See above</i>
		50 mg	
cycloserine	capsule	250 mg	For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
cyproheptadine	tablet	4 mg	
cyproterone	tablet		For treatment of idiopathic precocious puberty or inoperable carcinoma of the prostate
		50 mg	<i>See above</i>
		100 mg	<i>See above</i>
cytarabine	injection	100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
dabigatran	capsule		* For use as per the PBS indications *
		75 mg	<i>See above</i>
		110 mg	<i>See above</i>
		150 mg	<i>See above</i>
dabrafenib	capsule		Specialist Oncologists for discharge and outpatient use as per the PBS indications.
		50 mg	<i>See above</i>
		75 mg	<i>See above</i>
dacarbazine	injection	200 mg	
dactinomycin (actinomycin D)	injection		

Drug	Form	Strength	Restriction
d-alpha-tocopherol	capsule	500 microgram	
		67 mg (100 units)	For malabsorption syndrome
d-alpha-tocopheryl acetate	oral liquid	115 mg/mL (156 units)	
dalteparin sodium	injection	10 000 anti-Xa units/mL	For adult use: (a) during haemodialysis; and (b) treatment of venous thromboembolism (VTE).
		2500 anti-Xa units/0.2 mL	For adult use: (a) during haemodialysis; (b) prophylaxis of venous thromboembolism (VTE) (refer to relevant QH guideline below). * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		5000 anti-Xa units/0.2 mL	For adult use: (a) during haemodialysis; (b) prophylaxis of venous thromboembolism (VTE) (refer to relevant QH guideline below); and (c) treatment of VTE. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		7500 anti-Xa units/0.75 mL	For adult use: (a) during haemodialysis; (b) prophylaxis of venous thromboembolism (VTE) (refer to relevant QH guideline below); and (c) treatment of VTE. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		12 500 anti-Xa units/0.5 mL	For adult use: (a) during haemodialysis; and (b) treatment of venous thromboembolism (VTE).
danaparoid sodium	injection		On the advice of a haematologist, vascular physician or clinical pharmacologist for use as an alternative anticoagulant therapy for acute management of patients with heparin induced thrombocytopenia (HIT) in patients with a calculated GFR 15 - 30mL/min; or for use in patients with previous HIT who are on haemodialysis. Cross reactivity testing is desirable. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		750 anti-Xa units/0.6 mL	See above See above
danazol	capsule		Treatment of visually proven (ie by laparoscopy) endometriosis if surgery has been unsuccessful or contraindicated and the required endpoint of treatment is fertility; and For primary intractable menorrhagia
		100 mg	See above
		200 mg	See above

Drug	Form	Strength	Restriction
dantrolene	capsule	25 mg 50 mg	
	injection	20 mg	Specialist Anaesthetists
dapagliflozin	tablet	10 mg	* For use as per the PBS indications *
dapsone	tablet	25 mg	
		100 mg	
darbepoetin alfa	injection	10 microgram/0.4 mL pre-filled syringe	* For use in accord with PBS Section 100 indications *
		20 microgram/0.5 mL pre-filled syringe and pen	See above
		30 microgram/0.3 mL pre-filled syringe	See above
		40 microgram/0.4 mL pre-filled syringe and pen	See above
		50 microgram/0.5 mL pre-filled syringe	See above
		60 microgram/0.3 mL pre-filled syringe and pen	See above
		80 microgram/0.4 mL pre-filled syringe and pen	See above
100 microgram/0.5 mL pre-filled syringe and pen	See above		
150 microgram/0.3 mL pre-filled syringe and pen	See above		
darunavir	tablet	150 mg	* For use in accord with PBS Section 100 indications *
		600 mg	See above
		800 mg	See above
		800 mg	See above
darunavir + cobicistat	tablet	800 mg + 150 mg	* For use in accord with PBS Section 100 indications *
			See above
			See above
darunavir + cobicistat + emtricitabine + tenofovir alafenamide	tablet	800 mg + 150 mg + 200 mg + ...	* For use in accord with PBS Section 100 indications *
			See above
dasatinib	tablet	20 mg	* For use as per the PBS indications *
		50 mg	See above
		70 mg	See above
		100 mg	See above
daunorubicin	injection	20 mg/10 mL	
death adder antivenom	injection	6000 units	
deferasirox			

Drug	Form	Strength	Restriction	
	tablet	90 mg	* For use in accord with PBS Section 100 indications *	
		180 mg	See above	
		360 mg	See above	
deferiprone	oral liquid	100 mg/mL	* For use in accord with PBS Section 100 indications *	
	tablet	1 g	See above	
degarelix	injection	500 mg	See above	
		80 mg	For the treatment of outpatients only with advanced carcinoma of the prostate in whom androgen deprivation is warranted and who comply with the PBS authority indications.	
		120 mg	See above	
denosumab	injection	60 mg/mL	* For discharge and outpatient use as per the PBS indications *	
		120 mg/1.7 mL	See above	
			See above	
desferrioxamine	injection	2 g	* For use in accord with PBS Section 100 indications *	
		500 mg	See above	
			See above	
desflurane	inhalation solution	1 mL/mL	For use by, or under the supervision of, Specialist Anaesthetists experienced in its use, preferably in day surgery and long procedures of more than four hours duration.	
			See above	
desmopressin	injection	4 microgram/mL	For use for haemostasis by specialist haematologists or on the advice of a specialist haematologist. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *	
		15 microgram/mL		
	nasal drops	100 microgram/mL		For treatment of cranial diabetes insipidus as per the PBS indications
	sublingual wafer	120 microgram		For primary nocturnal enuresis as per the PBS indications. Clinicians should bear in mind the increased bioavailability of this wafer presentation compared to the tablet.
	tablet	200 microgram		For cranial diabetes insipidus and primary nocturnal enuresis as per the PBS indications
dexamethasone	eye drops	0.1%	Specialist Ophthalmologists for discharge and outpatient use as per the PBS indications.	
	implant	700 microgram		See above
	tablet	4 mg	For special circumstances when prednisolone is not suitable	
				See above

Drug	Form	Strength	Restriction
		500 microgram	See above
dexamethasone phosphate	injection	4 mg/mL 8 mg/2 mL	
dexamethasone phosphate	oral liquid solution	1mg per mL 50mL	For use in accordance with croup protocol See above
dexamfetamine	tablet	5 mg	Schedule 8 substance restricted to treatment of narcolepsy and attention deficit hyperactivity disorder in children * CONTROLLED DRUG * See above
dexchlorpheniramine	tablet	2 mg	See above
dexmedetomidine	injection	200 microgram/2 mL 200 microgram/50 mL 400 microgram/100 mL	Intensive care specialists and anaesthetists for use not exceeding 24 hours. See above See above See above
dextran-1	injection	3 g/20 mL	
dextran-70 + hypromellose	eye drops	0.1% + 0.3% with polyquaternium 0.1% + 0.3% + 0.001%	Specialist Ophthalmologists for patients unable to tolerate alternative preparations
dextranomer in hyaluronic acid	pre-filled syringe	50mg in 1mL	Specialist paediatric surgeons, or in consultation with a specialist paediatric surgeon, for treatment of children with vesicoureteral reflux (VUR) grades II-IV. See above See above
diazepam	injection	10 mg/2 mL	
	oral liquid	1 mg/mL	Patients unable to swallow tablets
	tablet	2 mg 5 mg	
diazepam	enema	5mg in 5mL	
diazoxide	injection	300 mg/20 mL	
diclofenac	eye drops	0.1%	Specialist Ophthalmologists
	suppository	12.5 mg 25 mg	For use in children over 12 months of age. See above

Drug	Form	Strength	Restriction
		50 mg	See above
		100 mg	
dicloxacillin	capsule		For treatment of Staphylococcal infections
		250 mg	See above
		500 mg	See above
dicobalt edetate	injection		Cyanide poisoning
			See above
		300 mg/20 mL	See above
digoxin	injection		
		50 microgram/2 mL	
		500 microgram/2 mL	
	oral liquid		Children too young to swallow tablets or capsules
		50 microgram/mL	See above
	tablet		
		62.5 microgram	
		250 microgram	
digoxin-specific antibody fragment F(Ab)	injection		For the treatment of cardiac glycoside intoxication resulting in life-threatening cardiac arrhythmias; cardiac arrest; cardiac decompensation with hypotension; serum potassium >5.5mmol/L with cardiovascular instability or compromise. In the absence of these recognised indications of cardiac glycoside toxicity, digoxin immune Fab is not indicated based solely on a serum digoxin concentration.
		40 mg	See above
diltiazem	modified release capsule		
		180 mg	
		240 mg	
		360 mg	
	tablet		For angina where treatment with verapamil or nifedipine has failed
		60 mg	See above
dimercaprol	injection		
		10% 2mL	
dimethylether "Medi Freeze Tick Off"	spray		
		38mL	
dimeticone (Hedrin)	gel, 100mL		
		dimeticone 4%	
dinoprost	injection		
		5 mg/mL	Specialist Obstetricians and Gynaecologists and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology, for second line management of severe life-threatening primary postpartum haemorrhage within the guidance of the Queensland Maternity and Neonatal Clinical Guideline "Primary Postpartum Haemorrhage". Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained.

Drug	Form	Strength	Restriction
dinoprostone			Specialist Obstetricians and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology for patients with unripe cervix (Bishop score 4 or less).
	pessary		See above
	vaginal gel	10 mg	See above
		1 mg/3 g	See above
		2 mg/3 g	See above
diphenoxylate + atropine sulfate	tablet	2.5 mg + 25 microgram	
diphtheria + tetanus + pertussis + poliomyelitis vaccine "Boostrix-IPV"	injection	0.5 mL	For haematopoietic stem cell transplant recipients aged >10 years who are not eligible for National Immunisation Program (NIP) funded vaccines. See above See above
diphtheria + tetanus + pertussis acellular vaccine "Boostrix"	injection	0.5 mL	(a) For use in accord with QH policy for staff immunisation. (b) For patients ≥10 years of age who require tetanus prophylaxis and are not eligible for National Immunisation Program (NIP) funded vaccines. For children and adolescents, refer to Children's Health Queensland "Tetanus Prophylaxis in Wound Management" guideline Note: National Immunisation Program (NIP) funded vaccines should be used for all eligible patients. If using NIP vaccines ensure adherence to eligibility criteria and any documentation requirements.
diphtheria + tetanus vaccine	injection	0.5 mL	For patients >10 years who are not eligible for National Immunisation Program (NIP) funded vaccines and pertussis immunisation is not indicated. See above See above
diphtheria antitoxin	injection	10,000 units	* For use in accord with Special Access Scheme (SAS) arrangements *
dipyridamole	injection	10 mg/2 mL	For use with nuclear medicine thallium scans See above
	modified release capsule	200 mg	For secondary prevention of ischaemic stroke or transient ischaemic attacks as adjunctive therapy with aspirin or monotherapy in patients who are proven intolerant of low-dose aspirin See above
	tablet	25 mg	See above
		100 mg	See above
dipyridamole + aspirin	modified release capsule	200 mg + 25 mg	For the secondary prevention of ischaemic stroke or transient cerebral ischaemic events See above See above
disodium edetate	eye drops	3% 10mL	
disopyramide	capsule	100 mg	
		150 mg	

Drug	Form	Strength	Restriction
disopyramide	injection	50mg in 5mL	
disulfiram	effervescent tablet	200 mg	
dithranol and salicylic acid in soft paraffin	ointment	1%-2% 100g 2%-2% 100g	
dithranol in soft paraffin	ointment	0.1% 100g	
dobutamine	injection	250 mg	Intensive Care and Coronary Care Units only <i>See above</i> <i>See above</i>
docetaxel	injection	20 mg/2 mL 80 mg/4 mL 80 mg/8 mL 160 mg/8 mL 160 mg/16 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
docusate	tablet	50 mg 120 mg	
docusate + sennoside B	tablet	50 mg + 8 mg	
dolutegravir	tablet	50 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
dolutegravir + abacavir + lamivudine	tablet	50 mg + 600 mg + 300 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
dolutegravir + lamivudine	tablet	50 mg + 300 mg	* For use in accord with PBS Section 100 indications *
dolutegravir + rilpivirine	tablet	50 mg + 25 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
domperidone	tablet	10 mg	
dopamine	injection	200 mg/5 mL	
dornase alfa			* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
	inhalation solution		See above
		2.5 mg/2.5 mL	See above
dorzolamide	eye drops		Where other treatments are ineffective or inappropriate
		2%	See above
dorzolamide + timolol	eye drops		See above
		2% + 0.5%	For reduction of elevated intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension who are not adequately controlled with timolol maleate (0.5%) eye drops or latanoprost eye drops.
			See above
			See above
dosulepin (dothiepin)	capsule		
	tablet	25 mg	
		75 mg	
doxepin	capsule		
		10 mg	
	tablet	25 mg	
		50 mg	
doxorubicin	injection		
		50 mg/25 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		200 mg/100 mL	See above
doxorubicin hydrochloride (as pegylated liposomal)	injection		
		20 mg/10 mL	* For use in accord with PBS Section 100 indications *
			or
			For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS
		50 mg/25 mL	Maximum amount 100mg * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
doxycycline	tablet		
		50 mg	
		100 mg	
doxycycline	injection		For the treatment of severe infections in patients unable to take oral doxycycline on the advice of an infectious diseases physician or clinical microbiologist.
			Physicians trained in interventional radiology and with proper skills in sclerotherapy - for use in sclerotherapy for treatment of lymphatic malformations in paediatric patients.
			* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
			See above
		100mg	See above
doxylamine	tablet		For use in pregnant women for the treatment of nausea, vomiting and hyperemesis
			See above
		25 mg	See above
droperidol			(a) patients with post-operative nausea and vomiting which is not responsive to metoclopramide; and

Drug	Form	Strength	Restriction
	injection	2.5 mg/mL	(b) for use by emergency physicians or psychiatrists to sedate severely agitated patients in the emergency setting. <i>See above</i> <i>See above</i>
droperidol	injection	10mg in 2mL	For use by emergency physicians or psychiatrists to sedate severely agitated patients in the emergency setting. <i>See above</i> <i>See above</i>
dulaglutide	injection	1.5 mg/0.5 mL	* For use as per the PBS indications *
duloxetine	enteric capsule	30 mg 60 mg	Specialist Staff and Country Medical Superintendents for major depressive disorders <i>See above</i> <i>See above</i>
durvalumab	injection	120 mg/2.4 mL 500 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
dutasteride + tamsulosin	modified release capsule	500 microgram + 400 microgram	Urologists for use as per the PBS indications. Caution - prior to prescribing, confirm whether the patient has a prior history of cataract surgery or impending cataract surgery. <i>See above</i> <i>See above</i>
eculizumab	injection	300 mg/30 mL	(a) For use in accord with PBS Section 100 indications Note: For eculizumab, a Special Arrangement has been approved by the Australian Health Minister to allow PBS claims for inpatients of public hospitals. Written Complex Authority applications to the Department of Human Services are required for approval for all PBS subsidised prescribing. (b) For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program <i>See above</i> <i>See above</i>
edrophonium	injection	10mg in 1mL	Restricted by availability from manufacturer <i>See above</i> <i>See above</i>
efavirenz	oral liquid	30 mg/mL	* For use in accord with PBS Section 100 indications *
	tablet	200 mg 600 mg	* For use in accord with PBS Section 100 indications * <i>See above</i>
elbasvir + grazoprevir	tablet	50 mg + 100 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications <i>See above</i> <i>See above</i>
electrolyte replacement -oral (contains sodium chloride, potassium chloride, sodium acid citrate, glucose) "Gastrolyte"	powder for oral liquid		

Drug	Form	Strength	Restriction
electrolyte replacement oral (contains sodium chloride, potassium chloride, sodium citrate, citric acid, sucrose, glucose) "Gluco-lyte"		470 mg + 300 mg (potassium 4 mmol) + 3.56 g + ...	
	powder for oral liquid	40g sachet "Gluco-lyte"	
elosulfase alfa	injection	5 mg/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
eltrombopag	tablet	25 mg	* For use in accord with PBS Section 100 indications *
		50 mg	See above
emollient	cream	100g	
empagliflozin	tablet		* For use as per the PBS indications *
		10 mg	See above
		25 mg	See above
emtricitabine + rilpivirine + tenofovir alafenamide	tablet	200 mg + 25 mg + 25 mg	* For use in accord with PBS Section 100 indications *
			See above
emtricitabine + tenofovir alafenamide	tablet		* For use in accord with PBS Section 100 indications *
		200 mg + 10 mg	See above
		200 mg + 25 mg	See above
emulsifying ointment	ointment	100g	
encorafenib	capsule		Specilast oncologists * For discharge and outpatient use as per the PBS indications *
		50 mg	See above
		75 mg	See above
enfuvirtide	injection	90 mg	* For use in accord with PBS Section 100 indications *
			See above
enoxaparin sodium	injection	100 mg/mL	(a) paediatric patients; (b) haemodialysis; (c) acute coronary syndrome; (d) treatment of venous thromboembolism (VTE) [Note: Removal of enoxaparin for treatment of VTE remains under active consideration]. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		20 mg/0.2 mL	For use only in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with

Drug	Form	Strength	Restriction
			reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		40 mg/0.4 mL	[NOTE: Use graduated 60mg prefilled syringe for other doses smaller than 60mg.] For use only in: (a) paediatric patients; (b) haemodialysis; (c) acute coronary syndrome; (d) treatment of venous thromboembolism (VTE) [Note: Removal of enoxaparin for treatment of VTE remains under active consideration]. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		60 mg/0.6 mL	For use only in: (a) paediatric patients; (b) haemodialysis; (c) acute coronary syndrome; (d) treatment of venous thromboembolism (VTE) [Note: Removal of enoxaparin for treatment of VTE remains under active consideration]. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		80 mg/0.8 mL	(a) paediatric patients; (b) haemodialysis; (c) acute coronary syndrome; (d) treatment of venous thromboembolism (VTE) [Note: Removal of enoxaparin for treatment of VTE remains under active consideration]. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
entacapone	tablet	200 mg	Neurologists for treatment of Parkinson's Disease as adjunctive therapy in combination with levodopa-decarboxylase inhibitor combinations in patients experiencing motor fluctuations
entecavir	tablet	1 mg 500 microgram	* For use in accord with PBS Section 100 indications * (a) For use in accord with PBS Section 100 indications; (b) For use by specialist staff for the prevention of Hepatitis B reactivation in patients with serological evidence of prior infection who are receiving immunosuppressive therapy. Therapy should be in consultation with or managed by a Hepatology or Infectious Diseases Service and follow established protocols for treatment duration, monitoring whilst on therapy and follow up. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
enteral nutrition products and food supplements	(various formulations)	see link below for specific products available	Please see LAM attachment Enteral Nutrition and Food Supplements list to view which specific products. This list includes products, forms and packs sizes that are available on the list of approved medicines. https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/approved-list/nutrition-and-food
enzalutamide	capsule	40 mg	Medical Oncologists * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i>
ephedrine	hydrochloride injection	30 mg/mL	Ephedrine Hydrochloride Note: Preference the more cost-effective ephedrine hydrochloride 30mg/mL injection over ephedrine sulfate 30mg/mL injection if clinically appropriate.

Drug	Form	Strength	Restriction
	sulfate injection	30 mg/10 mL 30 mg/mL	Note: Consider their different TGA approved indications and routes of administration. Ephedrine Hydrochloride 10mL pre-filled syringe Ephedrine Sulfate Note: Preference the more cost-effective ephedrine hydrochloride 30mg/mL injection over ephedrine sulfate 30mg/mL injection if clinically appropriate. Note: Consider their different TGA approved indications and routes of administration.
ephedrine and potassium iodide	mixture A.P.F.	1mg-25mg per mL 200mL	
epirubicin	injection	50 mg/25 mL 100 mg/50 mL 200 mg/100 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
epoetin alfa	injection	10 000 units/mL 40 000 units/mL 1000 units/0.5 mL 2000 units/0.5 mL 3000 units/0.3 mL 4000 units/0.4 mL 5000 units/0.5 mL 6000 units/0.6 mL 8000 units/0.8 mL 20 000 units/0.5 mL	* For use in accord with PBS Section 100 indications * See above See above See above See above See above See above See above See above See above
epoprostenol	injection	1.5 mg 500 microgram	* For use in accord with PBS Section 100 indications * See above See above See above
eptifibatide	injection	20 mg/10 mL 75 mg/100 mL	For use commencing immediately prior to percutaneous intervention with intracoronary stenting and not to exceed 24 hours infusion. See above See above See above
ergometrine	injection	500 microgram/mL	
eribulin	injection	1 mg/2 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
erlotinib	tablet	25 mg 100 mg 150 mg	* For use as per the PBS indications * See above See above See above See above

Drug	Form	Strength	Restriction
ertapenem			On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
	injection	1 g	See above See above
erythromycin	enteric capsule	250 mg	
	injection	1 g	
erythromycin ethylsuccinate	powder for oral liquid	200 mg/5 mL	Children too young to swallow tablets or capsules
escitalopram	tablet	10 mg	* For use as per the PBS indications *
		20 mg	See above
esmolol	injection	100 mg/10 mL	Specialists in Anaesthetics, Cardiology or Intensive Care
esomeprazole	enteric tablet		
		20 mg	Pack of 7: For use in line with the proton pump inhibitor (PPI) flowchart, available on the QH website. Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months.
esomeprazole and clarithromycin and amoxicillin	tablet		For eradication of Helicobacter pylori in newly diagnosed or past duodenal or gastric ulcers
		Pack containing 14 esomeprazole enteric coated tablets 20mg, 14 clarithromycin tablets 500mg, and 28 amoxicillin capsules 500mg	See above See above
estradiol	gel	0.1% (1 mg/g)	For use when oral oestrogen therapy cannot be tolerated or is contraindicated
	modified release pessary "Vagifem Low"	10 microgram	
	patch	25 microgram/24 hours	For use when oral oestrogen therapy cannot be tolerated or is contraindicated
	tablet	1 mg 2 mg	
estradiol + norethisterone acetate	tablet	1 mg + 500 microgram 2 mg + 1 mg	
estradiol, ... (Trisequens)	tablet		
		1 mg 2 mg 2 mg + 1 mg	
estriol	cream		

Drug	Form	Strength	Restriction
etacrynic acid		0.1% (1 mg/g)	
	tablet		
etanercept		25 mg	
	injection	25 mg pre-filled syringe	Specialist Staff for use in accord with PBS Section 100 indications (paediatric use) (for patients under 18 years who have severe active polyarticular course juvenile chronic arthritis)
		50mg pre-filled syringe and auto-injector	For use in accord with PBS Section 100 indications (Continuing therapy in patients 18 years and older who were diagnosed with active polyarticular course juvenile chronic arthritis in childhood).
ethambutol	tablet	100 mg	
		400 mg	
ethosuximide	capsule		
	oral liquid	250 mg	Children too young to swallow tablets or capsules
		250 mg/5 mL	<i>See above</i>
etonogestrel	implant		Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception.
		68 mg	<i>See above</i>
etoposide	capsule	50 mg	
		100 mg	
	injection	1.136 g (etoposide 1 g)	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
	injection	100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
etravirine	tablet		
		200 mg	* For use in accord with PBS Section 100 indications *
everolimus	tablet	1 mg	* For use in accord with PBS Section 100 indications *
		5 mg	Outpatient use for breast cancer only * For use as per the PBS indications * All other use must be on an Individual Patient Approval basis.
		10 mg	<i>See above</i>
		250 microgram	* For use in accord with PBS Section 100 indications *
		500 microgram	<i>See above</i>
		750 microgram	<i>See above</i>
evolocumab	injection		Outpatient: * For discharge and outpatient use as per the PBS indications *
		140 mg/mL	<i>See above</i>
exemestane			For treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate and a non-steroidal aromatase inhibitor.

Drug	Form	Strength	Restriction
ezetimibe	tablet	25 mg	See above See above * For use as per the PBS indications *
	tablet	10 mg	See above See above
famciclovir	tablet	125 mg	Treatment of immunocompetent patients with herpes zoster in whom the duration of rash is less than 72 hours Intermittent treatment of moderate to severe recurrent genital herpes Herpes zoster in immunocompromised patients Ophthalmic herpes zoster
		250 mg	See above
fat emulsion - olive oil and soya oil (eg 'Clinoleic')	injection	80 g/500 mL + 20 g/500 mL	For intravenous therapy when 'SMOFlipid' cannot be used and oral or enteral feeding is not possible.
felodipine	modified release tablet	2.5 mg	
		5 mg	
		10 mg	
fenofibrate	tablet	48 mg	
		145 mg	
fentanyl	injection	100 microgram/2 mL	For severe disabling pain not responsive to non-narcotic analgesics. For intranasal use in paediatric patients in the Emergency Department. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		500 microgram/10 mL	Specialist Staff for severe disabling pain not responsive to non-narcotic analgesics. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	patch	12 microgram/hour	For use in pain clinics Patients requiring palliative care who are intolerant of morphine or where morphine is inappropriate. * CONTROLLED DRUG *
		25 microgram/hour	See above
		50 microgram/hour	See above
		75 microgram/hour	See above
	sublingual tablet	100 microgram/hour	See above
		100 microgram	Palliative Care Physicians and Radiation Oncology Staff for use as per the PBS indications. * CONTROLLED DRUG *
		200 microgram	See above
		300 microgram	See above
		400 microgram	See above

Drug	Form	Strength	Restriction
fentanyl	intravenous infusion injection	600 microgram	See above
		800 microgram	See above
		10 micrograms/mL 100mL	* CONTROLLED DRUG * See above
ferric carboxymaltose	injection		For use in day treatment units only for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used.
		1 g/20 mL	See above
		500 mg/10 mL	See above
ferrous fumarate + folic acid	tablet		
		310 mg (iron 100 mg) + 350 microgram	
ferrous sulfate	modified release tablet	325 mg (iron 105 mg)	
	oral liquid		250mL: Children too young to swallow tablets or capsules
		30 mg/mL (iron 6 mg/mL)	See above
fexofenadine	tablet		
		60 mg	Where other antihistamines are inappropriate
filgrastim (Neupogen)	injection		Vials: Neupogen brand for use ONLY in paediatric patients where lenograstim is considered clinically unsuitable, in accord with PBS Section 100 indications. Prefilled syringe (PFS): Use Zarzio brand
		300 microgram/mL, vial	See above
		480 microgram/1.6 mL, vial	See above
filgrastim (Zarzio)	injection		* For use in accord with PBS Section 100 indications *
		300 microgram/0.5 mL	See above
		480 microgram/0.5 mL	See above
fingolimod	capsule		* For discharge and outpatient use as per the PBS indications *
		500 microgram	See above
flecainide	injection		
		150 mg/15 mL	
		50 mg 100 mg	
flecainide acetate "rosemont"	oral liquid solution		Paediatric cardiac specialists for use in accord with Special Access Scheme (SAS) arrangements * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		5mg per mL 300mL	See above
flucloxacillin	capsule		All preparations restricted to treatment of Staphylococcal infections
		250 mg	See above
		500 mg	See above
	injection		See above

Drug	Form	Strength	Restriction
		1 g	See above
		500 mg	See above
	powder for oral liquid		See above
		125 mg/5 mL	See above
		250 mg/5 mL	See above
flucloxacillin			All preparations restricted to treatment of Staphylococcal infections
	injection		See above
		250mg	See above
fluconazole			
	capsule		
		50 mg	(g) inpatient use as part of a single 150mg oral dose for the acute treatment of uncomplicated vaginal candidiasis; (h) for use by Sexual Health Services as part of a single 150mg oral fluconazole dose for the acute treatment of microbiologically confirmed uncomplicated vaginal candidiasis.
		100 mg	(g) inpatient use as part of a single 150mg oral dose for the acute treatment of uncomplicated vaginal candidiasis; (h) for use by Sexual Health Services as part of a single 150mg oral fluconazole dose for the acute treatment of microbiologically confirmed uncomplicated vaginal candidiasis.
		200 mg	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
	injection		
		100 mg/50 mL	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
		200 mg/100 mL	See above
	powder for oral liquid		
		50 mg/5 mL	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy But only for: Patients who cannot swallow capsules and meet one of the above criteria
flucytosine			For systemic yeast infections and subcutaneous mycoses (Prescribers please note: Danger of drug resistance - laboratory monitoring recommended)
	injection		See above
		2.5 g/250 mL	See above
flucytosine			For use in accord with Special Access Scheme (SAS) arrangements
	capsule		See above
		500mg	See above
fludarabine			

Drug	Form	Strength	Restriction
	injection	50 mg	For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS Intermediate or high risk chronic lymphocytic leukaemia where first line treatment (including either cyclo-phosphamide or chlorambucil) has proven ineffective or is contraindicated OR For Specialist Haematologists for use in induction and consolidation in relapsed and/or refractory acute myeloid leukaemia, or in patients with contraindication to anthracyclines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	50 mg/2 mL 10 mg	<i>See above</i> General use for TGA approved indications; and Specialist Haematologists for the treatment of relapsed and/or refractory low grade lymphoma in patients who have received at least 2 alternate prior therapies. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
fludrocortisone acetate	tablet	100 microgram	
flumazenil	injection	500 microgram/5 mL	Inpatient: For inpatient use only.
flumetasone pivalate + clioquinol	ear drops	0.02% + 1%	
fluorescein	diagnostic strip	1 mg	
	eye drops	2%	Inpatient: 0.5mL: For inpatient use only
	injection	500 mg/5 mL	
fluorometholone in polyvinyl alcohol	eye drops	0.1%-1.4% 5mL	Specialist Ophthalmologists <i>See above</i> <i>See above</i>
fluorouracil	cream	5%	50g <i>See above</i>
	injection	1 g/20 mL 2.5 g/50 mL 5 g/100 mL 500 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
fluoxetine	capsule		For major depressive disorders or obsessive compulsive disorder.

Drug	Form	Strength	Restriction
	tablet	20 mg	See above
			Inpatient: For inpatients unable to swallow capsules - to treat major depressive disorders or obsessive compulsive disorder.
flupentixol decanoate	injection	20 mg	See above
			Specialist Psychiatrists where other antipsychotic agents are ineffective or contraindicated
		20 mg/mL	See above
		100 mg/mL	See above
		40 mg/2 mL	See above
flutamide	tablet		For use in conjunction with LHRH agonists for treatment of advanced prostatic carcinoma
			See above
		250 mg	See above
fluticasone propionate	inhalation		For patients experiencing side effects on alternative inhaled corticosteroids
		50 microgram/actuation	See above
		125 microgram/actuation	See above
		250 microgram/actuation	See above
	powder for inhalation		See above
		100 microgram/actuation	See above
		250 microgram/actuation	See above
fluticasone propionate + salmeterol	inhalation		
		50 microgram/actuation + 25 microgram/actuation	* For use as per the PBS indications *
		125 microgram/actuation + 25 microgram/actuation	See above
		250 microgram/actuation + 25 microgram/actuation	(a) For initiation by specialist physicians in patients with severe asthma in line with PBS asthma criteria; (b) For continuation of therapy in existing patients, but consider reducing dose of fluticasone.
	powder for inhalation		
		100 microgram/actuation + 50 microgram/actuation	* For use as per the PBS indications *
		250 microgram/actuation + 50 microgram/actuation	See above
fluvoxamine	tablet		For major depressive disorders or obsessive compulsive disorder.
			See above
		50 mg	See above
		100 mg	See above
folic acid	injection		
		15 mg/mL	
	tablet		
		5 mg	
		500 microgram	
folic acid folinic acid	injection		
		1 g/100 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
		15 mg/2 mL	
		50 mg/5 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *

Drug	Form	Strength	Restriction
		100 mg/10 mL	See above
		300 mg/30 mL	See above
	tablet	15 mg	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
fondaparinux	injection	2.5 mg/0.5 mL	(a) Patients with NSTEMI/ACS undergoing invasive or medical management (except for those going directly for emergency (<120 min) invasive management [PCI])) (b) On the advice of a haematologist, vascular physician or clinical pharmacologist for use as an alternative anticoagulant therapy for acute management of patients with heparin induced thrombocytopenia (HIT) in patients with a calculated GFR >30mL/min who cannot take oral treatment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
formaldehyde	solution	4% 2 litre 37% 2 litre	
formoterol (eformoterol)	powder for inhalation	6 microgram/actuation 12 microgram/actuation	For patients with frequent episodes of asthma who are concurrently being treated with inhaled corticosteroids See above
fosamprenavir	tablet	700 mg	* For use in accord with PBS Section 100 indications *
fosaprepitant	injection	150 mg	For use where the enteral route is not suitable, providing use is in line with the following: For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
fosfomycin	granules	3 g	For treatment of urinary tract infections with isolates resistant to all other appropriate antibiotics, or in patients intolerant to all other oral options * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * See above See above
fotemustine	injection	208 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
framycetin sulfate + gramicidin + dexamethasone	ear drops	0.5% + 0.005% + 0.05%	
funnel web spider antivenom	injection	125 units	
furosemide (frusemide)	injection	20 mg/2 mL	

Drug	Form	Strength	Restriction
	oral liquid	250 mg/25 mL	
	tablet	10 mg/mL	30mL
		20 mg 40 mg 500 mg	
fusidate	tablet	250 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
gabapentin	capsule		a) partial epilepsy not controlled by other drugs as per the PBS indications; b) continuation of existing patients being treated for neuropathic pain; c) pain management in paediatric patients under the acute and/or persistent pain service. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * Note: Initiate pregabalin in preference to gabapentin for neuropathic pain where clinically appropriate. Caution: Consider potential for abuse or diversion with this medicine.
		100 mg 300 mg 400 mg	See above See above See above
galsulfase	injection	5 mg/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program Preferably on the advice of an Infectious Diseases Physician or a Clinical Microbiologist; and In accord with PBS Section 100 indications.
ganciclovir	injection	500 mg	See above See above
gelatin + pectin + carmellose sodium	paste	16.7% + 16.7% + 16.7% - 5g and 15g	
gemcitabine	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above See above
		1 g/26.3 mL 2 g/52.6 mL 200 mg/5.3 mL	
gemeprost	pessary	1 mg	Specialist Obstetricians with approval of Medical Superintendent Note: Special storage requirement of below -10 degrees centigrade See above See above
gemfibrozil	tablet	600 mg	
gentamicin	eye drops	0.3%	

Drug	Form	Strength	Restriction
gentamicin	injection	80 mg/2 mL	For short term treatment (up to 72 hrs maximum); ongoing treatment on the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
	eye drops	1.5% 10mL	Ophthalmologists <i>See above</i> <i>See above</i>
gentian alkaline	(A.P.F. 14) 200mL	200mL	
glecaprevir + pibrentasvir	tablet	100 mg + 40 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications
gliclazide	modified release tablet	30 mg 60 mg	
	tablet	80 mg	
glimepiride	tablet	1 mg 2 mg 3 mg 4 mg	
	injection	1 mg	
glucagon hydrochloride	injection	1 mg	
glucose	oral gel	40% (15g glucose in 37.5g tube) - Glutose 15®	Paediatric Use - for initial supply; for newly diagnosed diabetics; and Paediatricians and registered midwives for newborn hypoglycaemia - for buccal use only. <i>See above</i>
	injection	50% 50mL 50% 50mL minijet	
glucose	intravenous infusion	5% (200 Cal per litre) 1 Litre 5% (200 Cal per litre) 100mL (Double Pack) 5% (200 Cal per litre) 100mL (Single Pack) 5% (200 Cal per litre) 250mL 5% (200 Cal per litre) 250mL (non-PVC) 5% (200 Cal per litre) 500mL 10% (400 Cal per litre) 500mL 25% (1000 Cal per litre) 1 Litre 50% (2000 Cal per litre) 500mL	
	diagnostic strip	1 diagnostic strip	(a) For diabetic clinic (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. <i>See above</i> <i>See above</i>
glucose and ketone indicator urine	diagnostic strip	1 diagnostic strip	"FreeStyle Optium H" - Hospital use (a) For use in hospitals and clinics.

Drug	Form	Strength	Restriction
			(b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. "FreeStyle Optium" - Community use For use in remote area aboriginal health services - Stock can be ordered through "Healthy Living NT", in accord with National Diabetes Services Scheme (NDSS) supply arrangements.
	diagnostic strip	1 diagnostic strip	See above See above
glucose indicator urine	diagnostic strip	1 diagnostic strip	
glutaral (glutaraldehyde)	buffered solution	2% 5 litre	For specific instrument decontamination (eg Endoscopes) in a controlled environment
glycerol	suppository	1.4 g 2.8 g 700 mg	
glycerol	ear drops	7mL	
	liquid	sterile 14mL 200mL	
glycerol + magnesium sulfate dried	paste	44% + 48%	
glyceryl trinitrate	injection	50 mg/10 mL	Note: Special giving sets are required for the administration of this preparation See above
	ointment	0.2%	
	patch	5 mg/24 hours 10 mg/24 hours	
	spray	400 microgram/actuation	* For discharge and outpatient use as per the PBS indications * See above
	sublingual tablet	600 microgram	As of August 2020: QHMAC endorses use of the S19A 300microgram glyceryl trinitrate sublingual tablet while supplies of the 600microgram tablet are not available See above
glycine	solution	1.5% (30 g/2 L)	Bladder irrigation during transurethral resection
glycopyrronium bromide (glycopyrrolate)	injection	200 microgram/mL	
glycopyrronium bromide (glycopyrrolate) + neostigmine	injection	500 microgram/mL + 2.5 mg/mL	

Drug	Form	Strength	Restriction
golimumab	injection	100 mg/mL 50 mg/0.5 mL	* For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i>
goserelin	implant	3.6 mg 10.8 mg	For (a) advanced carcinoma of the prostate - for outpatient use only (b) Short term treatment (up to 6 months) of visually proven endometriosis for patients who cannot tolerate intranasal nafarelin (c) Hormone dependent breast cancer in line with the PBS indications For discharge and outpatient use as per the PBS indications.
granisetron	injection	3 mg/3 mL	For patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
griseofulvin	tablet	125 mg 500 mg	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists in a shared care arrangement for use in recalcitrant laboratory proven tinea infections. <i>See above</i> <i>See above</i> <i>See above</i>
guanfacine	modified release tablet	1 mg 2 mg 3 mg 4 mg	* For discharge and outpatient use as per the PBS indications (ADHD) * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
haemodiafiltration fluid (containing 1.2mmol/L phosphate) "Phoxilium"	intravenous infusion injection	5000mL	Intensive care staff for use in ICU patients who require continuous renal replacement therapy <i>See above</i> <i>See above</i>
haemofiltration citrate replacement fluid (calcium free) "PrismOcal"	intravenous infusion injection	5000mL	Intensive Care Staff for use in ICU patients who require haemofiltration and where systemic anticoagulation is contraindicated. <i>See above</i> <i>See above</i>
haemofiltration citrate replacement fluid (citrate 10, citric acid 2, sodium 136, chloride 106 mmol/L) "Prismocitrate 10/2"	intravenous infusion injection	5000mL	Intensive Care Staff for use in ICU patients who are critically ill with acute kidney injury/acute renal failure requiring haemofiltration and who are not able to receive systemic anticoagulation without significant risk of bleeding and death. <i>See above</i> <i>See above</i>
haemofiltration replacement fluid "Hemosol B0"	intravenous infusion injection	5000mL	
Haemophilus B influenza vaccine	injection	0.5 mL	At risk patients <i>See above</i> <i>See above</i>
haloperidol	injection		

Drug	Form	Strength	Restriction
haloperidol decanoate	oral liquid	5 mg/mL	For inpatient use only.
	tablet	2 mg/mL	
		1.5 mg	Caution: Avoid use for behavioural disturbance in dementia.
		5 mg	
		500 microgram	
haloperidol decanoate	injection	50 mg/mL	
		150 mg/3 mL	
heparin	injection	1000 units/mL	
		5000 units/mL	
		5000 units/0.2 mL	
		5000 units/5 mL	
		25 000 units/5 mL	
heparin	intravenous infusion	25 000 units in 50mL pre-filled syringe	
		1000 units in 0.9% sodium chloride 500mL	
hepatitis B vaccine	injection	10 microgram/0.5 mL, Paediatric Formulation	For use in chronic kidney disease Stage 4 and 5 patients likely to progress to renal replacement therapy, dialysis patients, haematopoietic stem cell transplant recipients, and people with HIV infection.
		20 microgram/1mL	
		40 microgram/1mL, Dialysis Formulation	
homatropine	eye drops	2% 0.5mL	For inpatient use only. <i>See above</i>
homatropine	eye drops	1% 5mL	
		2% 15mL	
human chorionic gonadotrophin	injection	1500 units	
		5000 units	
human papillomavirus quadrivalent vaccine	injection	0.5 mL	For suitable haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock
hyaluronidase	injection	1500 units	
hydralazine	injection	20 mg	
	tablet	25 mg	
		50 mg	

Drug	Form	Strength	Restriction
hydrochlorothiazide	tablet	25 mg	
hydrochlorothiazide + triamterene	tablet	25 mg + 50 mg	
hydrocortisone	tablet	4 mg 20 mg	For adrenal hyperplasia <i>See above</i> <i>See above</i>
hydrocortisone acetate	cream	1%	30g
	enema	10%	
	eye ointment	1%	
	ointment	1%	30g
hydrocortisone sodium succinate	injection	100 mg	
hydrogen peroxide	solution	6% 175mL sterile 3% (10 vol) 30mL	For use in neurosurgery.
hydrogen peroxide	mouthwash	3% 200mL	
hydromorphone	injection	2 mg/mL 10 mg/mL	For use in palliative care, oncology and pain clinics, for patients in whom morphine is inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * For use in palliative care, oncology and pain clinics, for patients in whom morphine is inappropriate or not tolerated. Caution: The risk of drug dependence is high. Caution: This is a high potency injection * CONTROLLED DRUG *
	modified release tablet	4 mg 8 mg 16 mg 32 mg 64 mg	For use by palliative care physicians and chronic pain specialists only. Not to be held on imprest except in stand-alone palliative care units. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
	oral liquid	1 mg/mL	Specialist Staff for use in palliative care, oncology and pain clinics, for patients in whom morphine is inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	tablet		

Drug	Form	Strength	Restriction
		2 mg	For use by palliative care physicians and chronic pain specialists only. Not to be held on imprest except in stand-alone palliative care units. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		4 mg	See above
		8 mg	See above
hydroxocobalamin	injection		
		1 mg/mL	
hydroxocobalamin "cyanokit"	injection		
		2.5g x 2	For cyanide poisoning
hydroxycarbamide (hydroxyurea)	capsule		
		500 mg	
hydroxychloroquine			Temporarily restricted, while a declared public health emergency in relation to coronavirus disease (COVID-19) is in place, to prescribing by the following authorised specialists: a) Rheumatologists b) Immunologists c) Dermatologists specifically treating patients with cutaneous lupus d) Nephrologists specifically treating patients with SLE e) Infectious diseases specialists for treatment of patients with Q fever f) Prescribers providing ongoing therapy for patients with SLE or severe RA NOTE: For prescribers involved in COVID-19 randomised controlled clinical trials, access to hydroxychloroquine stock will be available/managed through the clinical trial. For further information refer to "Queensland Health Medicines Advisory Committee Guidance on the use of Hydroxychloroquine" dated 17 April 2020. Also, this document is available on QHEPS via the List of Approved Medicines (LAM) homepage at: https://qheps.health.qld.gov.au/medicines/services/lam
	tablet		See above
		200 mg	See above
hydroxypropylmethyl-cellulose	injection		Ophthalmologists See above
		20mg per mL 1mL	See above
hyoscine butylbromide	injection		
	tablet	20 mg/mL	
		10 mg	For inpatient use only
hyoscine hydrobromide	injection		
		400 microgram/mL	
hypromellose	eye drops		
		0.5%	
hypromellose + carbomer-980	eye gel		
		0.3% + 0.2%	
ibandronate	injection		* For use in accord with PBS Section 100 indications * See above
		6 mg/6 mL	
ibrutinib	capsule		Specialist haematologists for discharge and outpatient use as per the PBS indications

Drug	Form	Strength	Restriction
ibuprofen	oral liquid tablet	140 mg	See above
		100 mg/5 mL	Paediatric inpatient use.
		200 mg 400 mg	
icatibant	injection - pre-filled syringe	30 mg/3 mL	For outpatient use, as per the PBS indications. See above
icodextrin + sodium chloride + sodium lactate + calcium chloride + magnesium chloride	peritoneal dialysis solution		For peritoneal dialysis patients with refractory fluid retention despite fluid restriction, the use of high percentage glucose dialysates and high doses of loop diuretics.
		187.5 g/2.5 L + 13.5 g/2.5 L + 11.25 g/2.5 L + ...	See above See above
idarubicin	capsule	5 mg	For acute myelogenous leukaemia (AML). See above
		10 mg	See above
	injection	5 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		10 mg/10 mL	See above See above
idarucizumab	injection		Specialist Staff or rural senior medical officers for management of serious bleeding in patients anticoagulated with dabigatran or for reversal of dabigatran when emergency invasive procedures are required that cannot await restoration of normal haemostasis expected on withholding dabigatran. Note: Dose is 5 g (two x 2.5 g vials).
		2.5 g/50 mL	See above See above
idursulfase	injection	6 mg/3 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
ifosfamide	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 g 2 g	See above See above
iloprost	inhalation solution		* For use in accord with PBS Section 100 indications *
		20 microgram/2 mL	See above See above
imatinib	tablet		* For use as per the PBS indications *
		100 mg 400 mg	See above See above
imiglucerase	injection	200 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
		400 units	See above
imipenem + cilastatin			On the advice of an infectious diseases physician for use in atypical mycobacteria or nocardia.

Drug	Form	Strength	Restriction
imipramine	injection	500 mg + 500 mg	See above
	tablet	10 mg 25 mg	See above
imiquimod	cream	5% 250mg Sachet (12)	For use as per the PBS indications (for superficial basal cell carcinoma); Sexual Health Physicians, Infectious Disease Physicians or Gynaecologists - where other therapy has failed.
incobotulinumtoxinA	injection	100 units	For use in accord with PBS Section 100 indications for outpatient or day patient use only
indapamide	modified release tablet	1.5 mg	
indigo carmine	injection	40mg in 5mL (0.8%)	
indocyanine green			Surgical consultants, hepatologists and registrars for patients undergoing pre-operative assessment for liver resection; Gynaecological oncologists for intraoperative mapping of suspected cervical or endometrial cancer and biopsy of sentinel lymph nodes. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	powder for injection	25mg in 5mL	See above
indometacin	capsule	25 mg	
	injection	1 mg	
	suppository	100 mg	
infliximab (Renflexis)	powder for injection	100 mg	For discharge and outpatients only, in accord with PBS Section 100 indications. In children under 14 years with Crohn disease or ulcerative colitis, it is recommended a paediatric gastroenterologist is consulted prior to initiation of infliximab.
influenza virus polyvalent vaccine			FOR STOCK PURCHASED FROM CENTRAL PHARMACY: At risk patients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and hospital staff
	injection	0.5mL	FOR NIP FUNDED VIVAS STOCK: High risk persons who meet NIP eligibility criteria and would benefit from opportunistic vaccination. NOTE: If using VIVAS stock ensure adherence to eligibility criteria and any documentation requirements Refer: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/service-providers/influenza
insulin aspart (Novorapid Flexpen)			See above
	injection		See above

Drug	Form	Strength	Restriction
insulin aspart (Novorapid Penfill)	injection	100 units/mL	
insulin aspart (Novorapid)	injection	100 units/mL	
insulin aspart + insulin aspart protamine (Novomix 30 Flexpen)	injection	100 units/mL	For paediatric use only.
insulin aspart + insulin aspart protamine (Novomix 30 Penfill)	injection	30 units/mL + 70 units/mL pen device	
insulin detemir (Levemir Flexpen)	injection	30 units/mL + 70 units/mL	
insulin detemir (Levemir Penfill)	injection	100 units/mL	Type 1 diabetes
insulin glargine (Lantus Solostar)	injection	100 units/mL	Type 1 diabetes
insulin glargine (Lantus)	injection	100 units/mL	Note: Optisulin is an alternative brand to Lantus. Note: From 1 July 2020, Lantus brand will be removed from the PBS.
insulin glargine (Optisulin Solostar)	injection	100 units/mL	Note: Optisulin is an alternative brand to Lantus. Note: From 1 July 2020, Lantus brand will be removed from the PBS.
insulin glargine (Optisulin)	injection	100 units/mL	Note: Optisulin is an alternative brand to Lantus. Note: From 1 July 2020, Lantus brand will be removed from the PBS.
insulin glargine (Toujeo Solostar)	injection	300 units/mL	* For discharge and outpatient use as per the PBS indications * For continuing therapy in inpatients already established on this high-concentration insulin who are able to self-administer or in conjunction with a local facility prescribing protocol. Initiation in inpatients requires IPA approval. Caution: High-concentration insulin. The insulin is NOT to be withdrawn from the prefill device using a needle and syringe. A dose adjustment may be required when converting between glargine 100 units/mL and glargine 300 units/mL — seek advice from an endocrinologist if required.
insulin glulisine (Apidra Solostar)	injection	100 units/mL	
insulin isophane human (Protaphane Innolet)	injection		

Drug	Form	Strength	Restriction
insulin isophane human (Protaphane Novolet)	injection	100 units/mL	
insulin isophane human (Protaphane Penfill)	injection	100 units/mL	
insulin isophane human (Protaphane)	injection	100 units/mL	
insulin isophane human + insulin neutral human (Mixtard 30/70 Innolet)	injection	100 units/mL	For paediatric use only.
insulin isophane human + insulin neutral human (Mixtard 30/70 Penfill)	injection	70 units/mL + 30 units/mL	
insulin isophane human + insulin neutral human (Mixtard 50/50 Penfill)	injection	70 units/mL + 30 units/mL	
insulin lispro (Humalog Kwikpen)	injection	50 units/mL + 50 units/mL	
insulin lispro (Humalog)	injection	100 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix25 Kwikpen)	injection	100 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix25)	injection	25 units/mL + 75 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix50 Kwikpen)	injection	25 units/mL + 75 units/mL	
insulin lispro + insulin lispro protamine (Humalog Mix50)	injection	50 units/mL + 50 units/mL	
insulin neutral human (Actrapid Penfill)	injection	50 units/mL + 50 units/mL	

Drug	Form	Strength	Restriction
interferon alfa-2a	injection	100 units/mL	
		3 million units/0.5 mL (11.111 microgram)	Clinical Haematologists and Oncologists for treatment of hairy cell leukaemia Clinical Haematologists and Oncologists for inpatient or commencement treatment of essential thrombocytosis For use in accord with PBS Section 100 indications For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
		4.5 million units/0.5 mL (16.667 microgram)	Clinical Haematologists and Oncologists for treatment of hairy cell leukaemia; Clinical Haematologists and Oncologists for inpatient or commencement treatment of essential thrombocytosis
		6 million units/0.5 mL (22.222 microgram)	See above
		9 million units/0.5 mL (33.333 microgram)	Clinical Haematologists and Oncologists for treatment of hairy cell leukaemia Clinical Haematologists and Oncologists for inpatient or commencement treatment of essential thrombocytosis For use in accord with PBS Section 100 indications For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
interferon alfa-2b	injection	10 million units/mL (38.462 microgram)	Clinical Haematologists and Oncologists for treatment of hairy cell leukaemia
interferon gamma-1b	injection		* For use in accord with PBS Section 100 indications *
		2 million units/0.5 mL (100 microgram)	See above
intraocular staining solution "membrane blue"	intraocular solution for injection	0.5mL	Specialist Ophthalmologists
iodine and boric acid	powder for insufflation	Iodine 0.75% Potassium Iodide 0.75% Boric Acid 98.5% - 10g	
iodine and lactose	powder for insufflation	Iodine 0.8% Potassium Iodide 0.4% Lactose 98.8% - 10g	
iodine and potassium	solution alcoholic	2.5% -2.5%, 500mL	
	solution aqueous (Lugol's)	5% - 10%, 100mL	
	solution sterile	5% - 10%, 50mL	
ipecacuanha	emetic syrup (A.P.F.)	100mL	
ipilimumab	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		50 mg/10 mL	See above
		200 mg/40 mL	See above
ipratropium			

Drug	Form	Strength	Restriction
	inhalation		
	inhalation solution	21 microgram/actuation	
		250 microgram/mL	For use where treatment with this drug delivered from an oral pressurised inhalation device via a large volume spacer is inappropriate.
	nasal spray	500 microgram/mL	See above
irbesartan		22 microgram/actuation	For use by Sleep Physicians for the treatment of persistent nasal symptoms due to CPAP therapy
	tablet		For patients unable to tolerate ACE inhibitors because of cough or angioedema, or patients intolerant of other antihypertensive therapy.
		75 mg	See above
		150 mg	See above
irinotecan		300 mg	See above
	injection	40 mg/2 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg/5 mL	See above
500 mg/25 mL		See above	
iron polymaltose	injection		
		100 mg/2 mL	For treatment of iron deficiency when oral iron preparations are ineffective or cannot be used.
iron sucrose			For treatment of iron deficiency when oral iron preparations are ineffective or cannot be used; or Gastroenterologists and Renal Physicians for use in patients less than 14 years of age for:
			a) Persistent iron deficiency anaemia despite oral supplementation; and
			b) iron deficiency of such severity that resolution with oral supplementation is not practical or is detrimental to patient wellbeing. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	injection		See above
		100 mg/5 mL	See above
isoflurane	inhalation solution		
		1 mL/mL	
isoniazid	tablet		
		100 mg	
isoniazid			For children who cannot swallow tablets.
	solution		See above
		20mg per mL 100mL	See above
isoprenaline	injection		
		1 in 5000 (200 microgram/mL)	
		1 in 5000 (1 mg/5 mL)	
isosorbide mononitrate	modified release tablet		
		60 mg	
		120 mg	
isotretinoin	capsule		Specialist Dermatologists and Specialist Physicians for severe cystic acne only.

Drug	Form	Strength	Restriction
			Caution: This drug causes birth defects. Isotretinoin has been reported to cause other frequent and potentially serious toxicity
		10 mg	See above
		20 mg	See above
itraconazole	oral liquid	10 mg/mL	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for patients who cannot swallow capsules and meet one of the following criteria; (a) aspergillosis, sporotrichosis or histoplasmosis infections (b) treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients NOTE: This preparation is not interchangeable with other itraconazole preparations.
itraconazole (Lozanoc)	capsule	50 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for (a) aspergillosis, sporotrichosis or histoplasmosis infections (b) treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients. NOTE: This preparation is not interchangeable with other itraconazole preparations.
itraconazole (Sporanox)	capsule	100 mg	For paediatric patients only, on the advice of an Infectious Diseases Physician or a Clinical Microbiologist for: aspergillosis, sporotrichosis or histoplasmosis infections. NOTE: This preparation is not interchangeable with other itraconazole preparations. See above
ivabradine	tablet	5 mg	Cardiologists and Radiologists to reduce heart rate in patients in sinus rhythm undergoing CT coronary angiography who do not respond to maximal doses of betablockers or are unable to tolerate beta blockers (or when a beta blocker is contraindicated); For use in chronic heart failure, as per the PBS indications.
		7.5 mg	For use in chronic heart failure, as per the PBS indications.
ivacaftor	granules	50 mg	* For use in accord with PBS Section 100 indications * See above
		75 mg	See above
	tablet	150 mg	See above
ivermectin	tablet	3 mg	Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with <i>Strongyloides stercoralis</i> or <i>Sarcoptes scabiei</i> (Crusted scabies).
ketamine			(a) For use as a general anaesthetic agent in areas where anaesthesia is delivered; (b) For use as an analgesic adjuvant under the supervision of an acute pain service, or in emergency departments, where standard analgesics in appropriate doses are insufficient to control pain; (c) For use as an analgesic adjuvant in the treatment of persistent pain under the supervision of specialists in pain medicine and palliative care; (d) For use in the field by practitioners trained to administer ketamine in emergency situations

Drug	Form	Strength	Restriction
	injection	200 mg/2 mL	where standard anaesthetic and analgesic agents are contraindicated. The above restrictions apply to the parenteral route. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * See above See above
ketoconazole	shampoo	2%	For immunologically compromised patients; For use as per the PBS indications
ketone indicator - blood	diagnostic strip	test strips	(a) For diagnosis and management of diabetic ketoacidosis (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
ketoprofen	modified release capsule	100 mg 200 mg	
ketorolac	injection	10 mg/mL 30 mg/mL	For postoperative pain where commonly indicated opioids are best avoided * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * (a) postoperative pain where commonly indicated opioids are best avoided; and (b) management of migraine or ureteric colic, as a single dose, when oral NSAID therapy is not tolerated or is considered inappropriate. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
king brown snake antivenom	injection	18 000 units	
labetalol	injection	50 mg/10 mL	The emergency treatment of severe hypertension when prompt and urgent reduction of blood pressure is essential
	tablet	100 mg 200 mg	
lacosamide	injection	200 mg/20 mL	Specialist Neurology Staff as an adjunctive treatment for epilepsy when oral lacosamide has already been established but is temporarily not feasible.
	tablet	50 mg 100 mg 150 mg 200 mg	Specialist Neurology Staff as an adjunctive treatment for epilepsy as per the PBS indications. See above See above See above

Drug	Form	Strength	Restriction
lactulose	oral liquid	3.34 g/5 mL	
lamivudine	oral liquid	10 mg/mL	* For use in accord with PBS Section 100 indications *
	tablet	100 mg	* For use in accord with PBS Section 100 indications *
		150 mg	<i>See above</i>
	300 mg	<i>See above</i>	
lamivudine + zidovudine	tablet		* For use in accord with PBS Section 100 indications *
		150 mg + 300 mg	<i>See above</i>
lamotrigine	tablet	5 mg	For epilepsy not controlled by other drugs
		25 mg	<i>See above</i>
		50 mg	<i>See above</i>
		100 mg	<i>See above</i>
			<i>See above</i>
		200 mg	<i>See above</i>
lanreotide	injection		* For use in accord with PBS Section 100 indications *
		60 mg/0.5 mL	<i>See above</i>
		90 mg/0.5 mL	<i>See above</i>
	modified release injection	120 mg/0.5 mL	<i>See above</i>
			<i>See above</i>
		30 mg	<i>See above</i>
lanthanum	chewable tablet		For use in accord with PBS Section 100 indications (for initiation and stabilisation of treatment); For use as per the PBS indications (for maintenance therapy).
		1 g	<i>See above</i>
		500 mg	<i>See above</i>
		750 mg	<i>See above</i>
lapatinib	tablet		* For use as per the PBS indications *
		250 mg	<i>See above</i>
laronidase	injection	500 units/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
latanoprost	eye drops		Specialist Ophthalmologists as monotherapy for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of or insufficiently responsive to other intraocular pressure medication.
		0.005%	<i>See above</i>
latanoprost + timolol	eye drops		For reduction of elevated intra-ocular pressure as per the PBS indications.
		0.005% + 0.5%	<i>See above</i>

Drug	Form	Strength	Restriction
ledipasvir + sofosbuvir	tablet	90 mg + 400 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications <i>See above</i> <i>See above</i>
leflunomide	tablet	10 mg 20 mg Pack > 100 mg x3 + 20mg x30	Specialist Rheumatologist Staff for use when other disease modifying drugs are inappropriate <i>See above</i> <i>See above</i> <i>See above</i>
lenalidomide	capsule	5 mg 10 mg 15 mg 25 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
lenvatinib	capsule	4 mg 10 mg	Specialist oncologists and hepatologists for discharge and outpatient use as per the PBS indications. Specialist oncologists for discharge and outpatient use in patients with locally advanced or metastatic differentiated thyroid cancer, as per the PBS indications.
lercanidipine	tablet	10 mg 20 mg	
letrozole	tablet	2.5 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i>
leuprorelin	modified release injection	7.5 mg intramuscular depot and subcutaneous depot 22.5 mg intramuscular depot and subcutaneous depot 30 mg intramuscular depot and subcutaneous depot and intramuscular paediatric depot 45 mg subcutaneous depot	* For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines. INTRAMUSCULAR DEPOT 22.5mg For discharge and outpatient use as per the PBS indications; Paediatric Endocrinologists and Paediatricians under the supervision of a Paediatric Endocrinologist, for pubertal suppression in children and adolescents with persistent gender dysphoria (note that therapy MUST have been initiated by the Statewide CHQ Gender Service); Endocrinologists and Physicians under the supervision of an Endocrinologist for ongoing maintenance of pubertal suppression in patients with persistent gender dysphoria previously initiated by the Statewide CHQ Gender Service. When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au). SUBCUTANEOUS DEPOT 22.5mg * For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines. * For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines. <i>See above</i>
levamisole	tablet	50mg	For carcinoma of the colon
levetiracetam			

Drug	Form	Strength	Restriction
	injection		
	oral liquid	500 mg/5 mL	
	tablet	100 mg/mL	For partial epilepsy not controlled by other drugs when other oral dosage forms are inappropriate.
		1 g	For partial epilepsy not controlled by other drugs
		250 mg	See above
		500 mg	See above
levobupivacaine	injection	25 mg/10 mL 50 mg/10 mL 75 mg/10 mL 250 mg/200 mL	
levocarnitine	capsule	500 mg	For use on the advice of a metabolic physician or gastroenterologist.
levocarnitine	injection	1g in 5mL	For use on the advice of a metabolic physician or gastroenterologist.
	liquid	100mg per mL	For use on the advice of a metabolic physician or gastroenterologist.
levodopa + benserazide	capsule	50 mg + 12.5 mg 100 mg + 25 mg 200 mg + 50 mg	
	dispersible tablet	50 mg + 12.5 mg	For use in Parkinson disease for patients who have difficulty swallowing tablets or who require administration of medications via an enteral feeding tube
	modified release capsule	100 mg + 25 mg	Patients not adequately controlled by other levodopa/decarboxylase inhibitors
	tablet	100 mg + 25 mg 200 mg + 50 mg	
levodopa + carbidopa	intestinal gel	20 mg/mL + 5 mg/mL	* For use as per the PBS indications *
	modified release tablet	200 mg + 50 mg	Patients not adequately controlled by other levodopa/decarboxylase inhibitors
	tablet	100 mg + 25 mg 250 mg + 25 mg	
levodopa + carbidopa + entacapone	tablet	50 mg + 12.5 mg + 200 mg	Neurologists for Parkinson's disease in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-dose effect; Parkinson's disease in patients stabilised on concomitant treatment with levodopa-decarboxylase inhibitor combinations and entacapone.
		100 mg + 25 mg + 200 mg	See above
		150 mg + 37.5 mg + 200 mg	See above

Drug	Form	Strength	Restriction
levonorgestrel	intrauterine drug delivery system	52 mg	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception.
	tablet	1.5 mg 30 microgram	For use as an emergency oral contraceptive within 72 hours of unprotected intercourse Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. Suitable choice for women unable to use oestrogen hormonal methods of contraception.
levonorgestrel + ethinylestradiol	tablet	125 microgram + 50 microgram	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception.
		150 microgram + 30 microgram	See above
levothyroxine	tablet	50 microgram	
		75 microgram	
		100 microgram	
		200 microgram	
lidocaine (lignocaine)	cream	4%	For use in adults and children over one month of age for provision of topical anaesthesia of intact skin prior to painful dermal procedures; For use in infants less than one month of age (second line to sucrose oral solution) for the provision of topical anaesthesia of intact skin prior to painful dermal procedures.
		gel	2%
	injection	0.5% (25 mg/5 mL)	
		1% (50 mg/5 mL)	
		1% (200 mg/20 mL)	
		2% (40 mg/2 mL)	
		2% (100 mg/5 mL)	
	lotion	2% (400 mg/20 mL)	
		10% (500 mg/5 mL)	Cardiac arrhythmias
		4%	
ointment	5%		
	10%	For dental use	
oral liquid	2%		
spray	10%	For inpatient use only	
lidocaine (lignocaine) + adrenaline (epinephrine)	injection	0.5% (100 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	
		1% (50 mg/5 mL) + 1 in 100 000 (50 microgram/5 mL)	
		1% (200 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	

Drug	Form	Strength	Restriction
lidocaine (lignocaine) + cetrimide		2% (44 mg/2.2 mL) + 1 in 80 000 (27.5 microgram/2.2 mL)	
	dressings	2% (400 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	
	gel	5% + 0.15%	For dental use
lidocaine (lignocaine) + chlorhexidine		50mg + 0.15%	For dental use
	gel	2% + 0.05%	
lidocaine (lignocaine) + fluorescein			Ophthalmologists
	eye drops	4% + 0.25%	See above See above
lidocaine (lignocaine) + glucose	injection	0.4% (2 g/500 mL) + 5% (25 g/500 mL)	
lidocaine (lignocaine) + phenylephrine		5% + 0.5%	
	nasal spray		
lidocaine (lignocaine) + prilocaine		2.5% + 2.5%	For Insertion of grommets Difficult and repeated venipunctures Skin grafts
	cream	2.5% + 2.5%	
	gel	2.5% + 2.5%	For dental use
	patch	25 mg/g + 2.5%	For Insertion of grommets Difficult and repeated venipunctures Skin grafts
lidocaine (lignocaine), tetracaine (amethocaine), epinephrine (adrenaline) "Laceraine"	sterile topical solution	4%-0.5%-0.1%	For topical anaesthesia during suturing of uncomplicated lacerations on the face and scalp in children. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
lincomycin	injection	600 mg/2 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
linezolid	tablet	600 mg	(a) On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol; (b) For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases,

Drug	Form	Strength	Restriction
			Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
liothyronine	tablet	20 microgram	
liothyronine	injection	20mcg	For use according to Special Access Scheme (SAS) requirements.
lipegfilgrastim	injection	6 mg/0.6 mL	For discharge, outpatients and day therapy use only, in accord with PBS Section 100 indications.
lisinopril	tablet	5 mg 10 mg 20 mg	Paediatric cardiac specialists See above See above
lisinopril	oral liquid suspension	1mg per mL, 100mL	Paediatric cardiac specialists
lithium carbonate	modified release tablet	450 mg	
	tablet	250 mg	
lomustine	capsule	10 mg 40 mg 100 mg	
loperamide	capsule	2 mg	
lopinavir + ritonavir	oral liquid	400 mg/5 mL + 100 mg/5 mL	* For use in accord with PBS Section 100 indications *
	tablet	100 mg + 25 mg 200 mg + 50 mg	* For use in accord with PBS Section 100 indications * See above
loratadine	tablet	10 mg	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists where other antihistamines are inappropriate. See above
lorazepam	tablet	1 mg	(a) use with cancer chemotherapy; (b) use with anaesthetics;

Drug	Form	Strength	Restriction
			(c) use in ICU; (d) use for acute agitation in mental health settings in line with state-wide guidelines; (e) Specialist Palliative Care practitioners for sublingual use when swallowing is not possible.
lorazepam	injection	2mg in 1mL	For rapid tranquilisation of disturbed behaviour and acute agitation in mental health settings in line with state-wide guidelines. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
lorlatinib	tablet	25 mg 100 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
lubricating gel sterile	prefilled syringe sachet tube	6mL and 11mL prefilled syringe 2.7g sachet 42g tube	For use in operating theatres for patients under general anaesthetic.
lumacaftor + ivacaftor	granules tablet	100 mg + 125 mg 150 mg + 188 mg 100 mg + 125 mg 200 mg + 125 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> * For use in accord with PBS Section 100 indications * <i>See above</i>
lurasidone	tablet	40 mg 80 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
macitentan	tablet	10 mg	* For use in accord with PBS Section 100 indications *
macrogol-3350	powder for oral liquid	17 g	For use in patients who are (a) unresponsive to existing combinations of laxatives; or (b) on large doses of opioid analgesics.
macrogol-3350 + sodium chloride + bicarbonate + potassium chloride	powder for oral liquid	13.125 g + 350.7 mg + 178.5 mg + ...	For use in patients who are (a) unresponsive to existing combinations of laxatives; or (b) on large doses of opioid analgesics.
magnesium	injection tablet	480 mg/5 mL magnesium 37.4 mg tablet (magnesium aspartate 500mg)	
magnesium	compound mixture QH-CP	0.4mmol/mL 200mL	Hypomagnesaemia

Drug	Form	Strength	Restriction
magnesium + zinc	capsule	564.2 mg (magnesium 337 mg) + 175 mg (magnesium 36 mg) + 135 mg (magnesium 400 mg) + ...	For patients with high dose magnesium requirements.
	injection	2.47 g/5 mL	
magnesium sulfate	powder "epsom salts"	1 g/g	
	lotion	0.5%	Organophosphate head lice preparation
magnesium trisilicate malathion	injection	20% (100 g/500 mL)	
	powder for inhalation	pack containing 40mg capsules x 280 and 2 inhalers "bronchitol"	* For use in accord with PBS Section 100 indications *
mannitol	diagnostic kit including capsules and inhalation device	capsules plus inhalation device	For bronchial provocation tests in respiratory laboratories
	tablets	150 mg 300 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
mannitol "Aridol"	injection	1 each 1 each	(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant. . <i>See above</i> <i>See above</i>
	tablets	1 each 1 each	<i>See above</i> <i>See above</i>
maraviroc	oral liquid	100 mg/5 mL	Alternative treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm).
	tablet	100 mg	Alternative treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm).
measles + mumps + rubella live vaccine	injection	1 each 1 each	(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant. . <i>See above</i> <i>See above</i>
	tablets	1 each 1 each	<i>See above</i> <i>See above</i>
mebendazole	oral liquid	100 mg/5 mL	Alternative treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm).
	tablet	100 mg	Alternative treatment of adults and children with <i>Ancylostoma caninum</i> (Eosinophilic enterocolitis), <i>Ancylostoma duodenale</i> / <i>Necator americanus</i> (Hookworm), <i>Ascaris lumbricoides</i> (Roundworm), <i>Trichuris trichiuria</i> (Whipworm) or <i>Enterobius vermicularis</i> (Pinworm).
medroxyprogesterone	injection	150 mg/mL	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception.
	tablet		

Drug	Form	Strength	Restriction
mefenamic acid	capsule	2.5 mg	
		5 mg	
		10 mg	
		100 mg	
		200 mg	
		500 mg	
mefloquine	tablet	250 mg	Gynaecologists
		250 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
melphalan	injection	50 mg	
	tablet		
	2 mg 5 mg		
meningococcal A + meningococcal C + meningococcal W135 + meningococcal Y conjugate vaccine	injection		For use in persons with anatomical or functional asplenia, haematopoietic stem cell transplant recipients, or requiring treatment with eculizumab.
meningococcal B 4 component vaccine	injection		See above
	injection		For use in persons with anatomical or functional asplenia or requiring treatment with eculizumab.
mepivacaine	injection	0.5 mL	See above
		3% (66 mg/2.2 mL)	For dental use
mepivacaine + adrenaline (epinephrine)	injection	2% (44 mg/2.2 mL) + 1 in 100 000 (22 microgram/2.2 mL)	For dental use
mepivacaine caudal	injection		
mepolizumab	injection	1.5% 20mL	
		100 mg	
mercaptopurine	oral liquid		*For discharge and outpatient use in accord with PBS Section 100 indications.*
		20 mg/mL	
		50 mg	
meropenem	injection	50 mg	Oncology consultants and paediatricians for paediatric patients where the solid dose form is unsuitable
		1 g	
			On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
			See above

Drug	Form	Strength	Restriction
		500 mg	See above
mesalazine	enema	1 g/application	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation. Caution: These items may not be linking to the correct MIMs dosing information. Refer to brand specific dosing information - the different brands are NOT interchangeable.
		1 g/100 mL	See above
		2 g/60 mL	See above
	enteric tablet	500 mg	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate.
	modified release granules	1 g	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate. Caution: These items may not be linking to the correct MIMs dosing information. Refer to brand specific dosing information - the different brands are NOT interchangeable.
		2 g	See above
		500 mg	See above
	modified release tablet	1 g	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate.
		1.2 g	Gastroenterologists for use in ulcerative colitis as per the PBS indications.
	suppository	1 g	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation.
mesna	injection	1 g/10 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
		400 mg/4 mL	See above
	tablet	400 mg	Specialist Oncology / Haematology Staff
mesterolone	tablet	25 mg	
metaraminol	injection	10 mg/mL	Note: The 5mg/10mL presentation is available as a vial and a pre-filled syringe
		3 mg/6 mL	See above
		5 mg/10 mL	See above
metformin	modified release tablet	1 g	For discharge and outpatient use only
		500 mg	
	tablet	1 g	
		500 mg	
		850 mg	
methacholine	broncho provocation test set of 6x10mL		

Drug	Form	Strength	Restriction
		0.25, 0.5, 1, 2, 4 and 8mg/mL	Specialist Staff for diagnostic use
methadone	injection	10 mg/mL	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
	syrup and oral solution not containing sorbitol, sugar, preservatives or alcohol	5 mg/mL	a) For use as per the PBS indications for patients registered on an approved opioid treatment program; b) For patients in burns units; c) For patients in Specialist pain clinics. * CONTROLLED DRUG *
	tablet	10 mg	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
methenamine hippurate (hexamine hippurate)	tablet	1 g	Prescribers Note Acidification of urine not necessary with use For treatment of paracetamol overdose
methionine	tablet	500mg	See above See above
methotrexate	injection	1 g/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		5 mg/2 mL	See above
		5 g/50 mL	See above
		7.5 mg/0.15 mL	(a) For discharge and outpatient use as per the PBS indications; (b) For use by, or in consultation with, a paediatric rheumatologist for children with juvenile idiopathic arthritis or non-infectious (inflammatory) uveitis. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg/0.2 mL	Caution: This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. See above
		15 mg/0.3 mL	See above
		20 mg/0.4 mL	See above
		50 mg/2 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * or Specialist Rheumatologists; Specialist Staff for pharmacological management of ectopic pregnancy. When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au)
		500 mg/20 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *

Drug	Form	Strength	Restriction
	tablet	2.5 mg 10 mg	
methoxsalen	injection	200 microgram/10 mL	* For use in accord with PBS Section 100 indications * Caution: This drug is for ex vivo administration and must not be injected directly into the patient.
methoxy polyethylene glycol-epoetin beta (Mircera)	injection	30 microgram/0.3 mL 50 microgram/0.3 mL 75 microgram/0.3 mL 100 microgram/0.3 mL 120 microgram/0.3 mL 200 microgram/0.3 mL 360 microgram/0.6 mL	For use in accord with PBS Section 100 indications for patients who reside in remote areas. Mircera® is — methoxy polyethylene glycol-epoetin beta <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
methoxyflurane	inhalation solution	99.9% (999 mg/g)	(a) Specialist staff and registrars in the haematology unit for analgesia during bone marrow biopsy procedures; (b) Specialist staff, registrars, and registered nurses with extended scope in gynaecology, for the relief of pain in patients requiring gynaecology procedures. (c) For use by clinicians in rural and remote locations to provide short-term pain relief to patients with acute pain in the pre-hospital and facility setting, in line with authorisation requirements and the Health (Drugs and Poisons) Regulation 1996. NOTE: Not to be used in combination with other sedating agents.
methyl salicylate	liniment	25%	
methyl dopa	tablet	250 mg	
methyl dopa	tablet	125mg	
methylene blue	injection	50 mg/5 mL	
methylphenidate	modified release capsule	10 mg 20 mg 30 mg 40 mg	For use as per the PBS indications (ADHD) * CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i>
	modified release tablet	18 mg 27 mg 36 mg 54 mg	For use as per the PBS indications (ADHD) * CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i>
	tablet		

Drug	Form	Strength	Restriction
		10 mg	a) The treatment of narcolepsy; b) Use as per the PBS indications (ADHD) and in accordance with State/Territory law. * CONTROLLED DRUG *
methylprednisolone	methylprednisolone sodium succinate injection	1 g 40 mg 500 mg	
methylprednisolone acetate	modified release injection	40 mg/mL	For intralesional; intra-articular use <i>See above</i> <i>See above</i>
methylrosanilinium chloride (crystal violet C14255)	paint	0.6% 25mL	
methylrosanilinium chloride (crystal violet C14255) and brilliant green (bonneys blue)	paint	0.5%-0.5% in 45% Ethanol, 100mL	
metoclopramide	injection	10 mg/2 mL	
	tablet	10 mg	
metoprolol	injection	5 mg/5 mL	
	modified release tablet	23.75 mg 47.5 mg 95 mg 190 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
	tablet	50 mg 100 mg	
metoprolol	oral liquid	10mg per mL, 100mL	Paediatric cardiac specialists <i>See above</i> <i>See above</i>
metronidazole	injection	500 mg/100 mL	
	oral liquid	200 mg/5 mL	
	tablet	200 mg 400 mg	
metronidazole	suppository	500mg	
mexiletine	capsule		

Drug	Form	Strength	Restriction
		150mg	* For use in accord with Special Access Scheme (SAS) arrangements *
		250mg	See above
mianserin	tablet		For severe depression.
		10 mg	See above
		20 mg	See above
micafungin	injection		
		50 mg	For paediatric use on the advice of an Infectious Diseases Physician or a Clinical Microbiologist for prophylaxis or treatment of severe systemic candida infections that are resistant to fluconazole therapy, or where fluconazole is strongly contraindicated; or in accord with an infectious diseases approved protocol.
miconazole	cream 25g	2%	Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	cream 30g	2%	For use as per the PBS indications for the treatment of a fungal or a yeast infection in an Aboriginal or Torres Strait Islander person. Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	oral gel	2%	For systemic fungal infections susceptible to this agent
midazolam	injection		
		5 mg/mL	Glass ampoule 5mg/mL Specialist Staff for use in procedures, palliative care patients, emergency departments and mental health facilities Plastic ampoule 5mg/mL Intranasal, sublingual or sub-buccal administration for: a) The emergency treatment of acute seizures in both adults and children; and b) Specialist Paediatricians for outpatient management of prolonged seizures in children. Limit of 10 ampoules per supply. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		5 mg/5 mL	For use in intensive care units
		15 mg/3 mL	See above
		50 mg/10 mL	
midostaurin	capsule		
		25 mg	* For use in accord with PBS Section 100 indications * Note: Contact Central Pharmacy for advice on the required process to order inpatient stock.
mifepristone	tablet		
		200 mg	Specialist obstetric and gynaecology staff who are registered with the MS-2 Step Prescribing Program for use in the termination of an intra-uterine pregnancy, in sequential combination with misoprostol, as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy. Specialist obstetrics and gynaecology staff who are registered with the MS-2 Step Prescribing Program for use in the medical management of second trimester pregnancy loss, in sequential

Drug	Form	Strength	Restriction
mifepristone and misoprostol "MS-2 Step"	tablet	(Composite Pack) 200mg (1) and 200microgram (4)	combination with misoprostol, as per the Queensland Maternity and Neonatal Clinical Guideline for early pregnancy loss. Specialist obstetric and gynaecology staff who are registered with the MS-2 Step Prescribing Program for use in the termination of an intra-uterine pregnancy, as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy. Refer to separate LAM listings of mifepristone tablet 200mg and misoprostol tablet 200 microgram if required for use in the medical management of second trimester pregnancy loss. <i>See above</i> <i>See above</i>
migalastat	capsule	123 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
miglustat	capsule	100 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program <i>See above</i> <i>See above</i>
milrinone	injection	10 mg/10 mL	Specialist Physicians where other positive inotropes have been shown to be ineffective
minocycline	tablet	50 mg	
minoxidil	tablet	10 mg	
mirtazapine	orally disintegrating tablet	15 mg 30 mg	For patients with major depressive disorders who have swallowing difficulties or require monitoring for compliance <i>See above</i> <i>See above</i>
	tablet	15 mg 30 mg 45 mg	For major depressive disorders <i>See above</i> <i>See above</i> <i>See above</i>
misoprostol	tablet	200 microgram	(a) For reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and in whom NSAID therapy is essential; (b) For second line management of primary post partum haemorrhage; (c) Specialist Staff for the therapeutic termination of pregnancy as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy (d) Specialist Staff for the management of missed abortion, as per the Queensland Maternity and Neonatal Clinical Guideline for early pregnancy loss. (e) Specialist obstetrics and gynaecology staff for cervical dilation prior to intrauterine surgical intervention. [Note: not for routine use prior to IUD insertion] * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
mitomycin	injection	2 mg 10 mg	

Drug	Form	Strength	Restriction
mitozantrone	injection	20 mg	
		20 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		25 mg/12.5 mL	See above
mivacurium	injection	20 mg/10 mL	Specialist Anaesthetists for short duration procedures in Day Surgery Units
moclobemide	tablet		For major depressive disorders
		150 mg	See above
		300 mg	See above
mometasone	cream		
	lotion	0.1% 15g and 50g	
	ointment	0.1%	
		0.1% 15g and 50g	
monobasic sodium phosphate + dibasic sodium phosphate	enema	19 g/118 mL + 7 g/118 mL	a) Adult patients for bowel preparation for colonoscopy; b) For the treatment of severe constipation/impaction which is unresponsive to, or inappropriate for, treatment with oral laxatives; c) For palliative care patients on long term opioid analgesia resulting in an ongoing problem with faecal impaction, after trying first line oral and rectal laxatives; d) For addition to dialysate to increase phosphate levels in haemodialysis patients, particularly those who dialyse for extended times. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	oral liquid	417.8 mg/mL + 95.6 mg/mL	Adult patients for bowel preparation for colonoscopy
monsel's ferric subsulfate			Gynaecologists and their registrars for gynaecological procedures
	gel	21%, 15mL	See above See above
morphine	injection	10 mg/mL	* CONTROLLED DRUG *
	injection	5 mg/mL 30 mg/mL	For use in neonates and paediatric patients only * CONTROLLED DRUG * * CONTROLLED DRUG *
	injection	120 mg/1.5 mL	Use in syringe pumps only for severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	intrathecal injection	500 microgram/mL	Anaesthetists for intrathecal postoperative analgesia. * CONTROLLED DRUG ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *

Drug	Form	Strength	Restriction
	modified release capsule	10 mg	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
		20 mg	See above
		50 mg	See above
		100 mg	See above
	modified release granules	20 mg	For severe disabling pain not responsive to non-narcotic analgesics in patients unable to swallow tablets Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		30 mg	See above
		60 mg	See above
		100 mg	See above
		200 mg	See above
	modified release tablet	5 mg	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
		10 mg	See above
		15 mg	See above
		30 mg	See above
		60 mg	See above
		100 mg	See above
		200 mg	See above
	oral liquid	1 mg/mL	Specialist paediatricians for use in neonates with neonatal abstinence syndrome. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * * CONTROLLED DRUG *
		2 mg/mL	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. * Prescribers Note: Higher strength Morphine mixtures can be made available from the Pharmacy Dept on request Pharmacists note: Higher strength Morphine mixtures than those listed can be ordered from the Central Drug Store if needed * CONTROLLED DRUG *
		5 mg/mL	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. * Prescribers Note: Higher strength Morphine mixtures can be made available from the Pharmacy Dept on request Pharmacists note: Higher strength Morphine mixtures than those listed can be ordered from the Central Drug Store if needed * CONTROLLED DRUG *
		10 mg/mL	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. * Prescribers Note: Higher strength Morphine mixtures can be made available from the Pharmacy Dept on request Pharmacists note: Higher strength Morphine mixtures than those listed can be ordered from the Central Drug Store if needed ** CONTROLLED DRUG *

Drug	Form	Strength	Restriction
	tablet	10 mg	Severe disabling pain due to cancer not responding to non-narcotic analgesics. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		20 mg	See above
morphine	intravenous infusion injection	1mg/1mL 100mL	
moxifloxacin			For use after approval by an Infectious Diseases Physician or a Clinical Microbiologist or in accord with an Infectious Diseases approved protocol: a) For empirical therapy of patients with community acquired pneumonia or acute bacterial meningitis who have immediate hypersensitivity to penicillin and cannot be given cephalosporin; b) For patients with an infection caused by an organism with proven resistance to antibiotic agents apart from moxifloxacin, or who have severe allergy to standard agents where moxifloxacin is the most appropriate therapy available; OR For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	injection	400 mg/250 mL	See above
	tablet	400 mg	See above
moxonidine	tablet	200 microgram	As add-on therapy for severe refractory hypertension except in congestive heart failure
		400 microgram	See above
multi-test urine strips (for pH, Protein, Glucose, Ketone, Bilirubin and Urobilinogen)	diagnostic strip	strip	
mupirocin	ointment	ointment 15g and nasal ointment 3g	Mupirocin 2% ointment 15g - unrestricted Mupirocin 2% nasal ointment 3g - For decolonisation of MRSA following approval by Infectious Diseases Physicians, Clinical Microbiologists or infection control practitioners or in accord with recommended practices for the prevention and control of infections in dialysis settings; and on the advice of Infectious Diseases Physicians or Clinical Microbiologists to assist in preventing recurrent furunculosis.
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Connaught strain	injection	81 mg	Specialist Urologists for bladder cancer See above See above

Drug	Form	Strength	Restriction
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Tice strain	injection	500 million CFU	Specialist Urologists for bladder cancer; * For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * <i>See above</i> <i>See above</i>
Mycobacterium bovis (BCG) live vaccine	injection	1.5 mg	For vaccination after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9722 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available at: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/diseases/tuberculosis/contact-a-service <i>See above</i> <i>See above</i>
mycophenolate	enteric tablet	180 mg	(a) for patients with lupus nephritis as per the PBS Section 100 indications; (b) for continuation of therapy in existing transplant patients.
	powder for oral liquid	360 mg 1 g/5 mL	<i>See above</i> For use in accord with PBS Section 100 indications only; and for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine.
mycophenolate (Cellcept)	capsule	250 mg	For use in accord with PBS Section 100 indications for existing transplant patients who have been stabilised on solid oral dosage forms of CellCept®; and for existing liver transplant patients who are intolerant of, or unsuitable for, treatment with azathioprine.
	tablet	500 mg	For use in accord with PBS Section 100 indications for existing transplant patients who have been stabilised on solid oral dosage forms of CellCept®; and for existing liver transplant patients who are intolerant of, or unsuitable for, treatment with azathioprine.
mycophenolate (Mycophenolate Mofetil (Pharmacor))	capsule	250 mg	For use in accord with PBS Section 100 indications only; and for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine; and on an individual patient basis for other indications approved by local medicines committees.
	tablet	500 mg	For use in accord with PBS Section 100 indications only; for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine; and on an individual patient basis for other indications approved by local medicines committees.
nadolol	tablet		For use in patients under paediatric cardiac specialist care, for the treatment of congenital long QT syndrome and other hereditary malignant arrhythmic conditions. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *

Drug	Form	Strength	Restriction
		40mg	See above
		80mg	See above
nafarelin	nasal spray	200 microgram/actuation	For treatment of visually proven endometriosis
naloxone	injection	1 mg/mL	For discharge and outpatient use.
	nasal spray	400 microgram/mL	
		1.8 mg/actuation	For use in discharge and outpatients.
naltrexone	tablet	50 mg	Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.
nanoparticle albumin-bound paclitaxel	injection	100 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
naproxen	tablet	250 mg 500 mg	
natalizumab	injection	300 mg/15 mL	For use in accord with PBS Section 100 indications (for multiple sclerosis) Note: There are additional mandatory requirements regarding this medication. Full details are available from the manufacturer.
neomycin sulfate	tablet	500 mg	
neostigmine	injection	2.5 mg/mL 500 microgram/mL	
netupitant + palonosetron	capsule	300 mg + 500 microgram	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
nevirapine	modified release tablet	400 mg	* For use in accord with PBS Section 100 indications * See above
	oral liquid	10 mg/mL	See above
	tablet	200 mg	See above
nicorandil	tablet	10 mg 20 mg	As a second line agent when conventional antianginal therapy is ineffective See above See above See above

Drug	Form	Strength	Restriction
nicotine	chewing gum	4 mg	Inpatient: For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway.
	inhalation	15 mg	Inpatient: 4 cartridge pack for short term use in mental health inpatients in high dependency units or psychiatric intensive care units.
	lozenge	4 mg	Inpatient: For use in mental health patients who cannot use or tolerate nicotine chewing gum 4mg for management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway.
	patch	21 mg/24 hours	Inpatient: For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway; and Outpatient: * For discharge and outpatient use as per the PBS indications * where the patient has committed to quit and has entered, or is entering, the necessary counselling and support program.
nicotinic acid	tablet	250 mg	
nifedipine	modified release tablet	20 mg	For use in tocolysis only. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		30 mg	
		60 mg	
tablet / capsule	10 mg	See above	
	20 mg	See above	
nilotinib	capsule	150 mg	Specialist Haematologists for use as per the PBS indications.
		200 mg	See above
nimodipine	injection	10 mg/50 mL	Specialist Neurosurgeons
	tablet	30 mg	Specialist Neurosurgeons
nitisinone	capsule	2 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program See above
		5 mg	See above
		10 mg	See above
		20 mg	See above
	oral liquid		See above
	tablet	4 mg/mL	See above
		2 mg	See above
5 mg		See above	
		10 mg	See above
nitrazepam			

Drug	Form	Strength	Restriction
	tablet	5 mg	
nitrofurantoin	capsule	50 mg 100 mg	
nitroprusside	injection	50 mg	
nivolumab	injection	40 mg/4 mL 100 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
noradrenaline (norepinephrine)	injection	1 in 1000 (2 mg/2 mL)	
norethisterone	tablet	5 mg 350 microgram	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. Suitable choice for women unable to use oestrogen hormonal methods of contraception.
norethisterone + ethinylestradiol	tablet	1 mg + 35 microgram 500 microgram + 35 microgram	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. See above
norethisterone + mestranol	tablet	1 mg + 50 microgram	
norfloxacin	tablet	400 mg	For serious bacterial urinary tract infections unresponsive to other agents wherever possible on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
normal immunoglobulin	injection	5 g/100 mL 10 g/200 mL 320 mg/2 mL 800 mg/5 mL	
nortriptyline	tablet	10 mg 25 mg	
nusinersen	injection	12 mg/5 mL	* For use in accord with PBS Section 100 indications *
nystatin	cream	100 000 units/g	15g
	oral liquid	100 000 units/mL	24mL: For children and Specialist Staff for adults
	tablet		

Drug	Form	Strength	Restriction
	vaginal cream	500 000 units 20 000 units/g	75g. Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment
oatmeal colloidal.	application	100% 1kg	For use with children with burns
obinutuzumab	injection	1 g/40 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
ocrelizumab	injection	300 mg/10 mL	* For use in accord with PBS Section 100 indications *
ocriplasmin	intraocular injection	375 microgram/0.3 mL	Specialist ophthalmologists for outpatient use as per the PBS indications
octreotide	injection	50 microgram/mL 100 microgram/mL 500 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	modified release injection	10 mg 20 mg 30 mg	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. (c) For use in chyle leaks post surgery. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
ofloxacin	eye drops	0.3%	For use in accord with PBS Section 100 indications only to treat vasoactive intestinal peptide secreting tumour (VIPoma) and for continuation of therapy in existing patients. <i>See above</i> <i>See above</i>
olanzapine	injection		

Drug	Form	Strength	Restriction
		10 mg	For use in acute mental health settings for disturbed behaviour and agitation in people with acute schizophrenia or acute mania when traditional agents are contraindicated (eg. past history of neuroleptic malignant syndrome or severe extrapyramidal side effects). The use of parenteral olanzapine does not necessitate the ongoing use of oral olanzapine.
	modified release injection	210 mg	Specialist Psychiatrists for schizophrenia in patients who have been prescribed oral olanzapine (as a second or third line antipsychotic) and have responded to this therapy, but are non-compliant. Patients must consent to remain on site for at least two hours after each injection for physical observations.
		300 mg	<i>See above</i>
	orally disintegrating tablet	405 mg	<i>See above</i>
		5 mg	(a) For use as per the PBS indications; (b) For use in acute mental health settings for disturbed behaviour and agitation in line with statewide guidelines; (c) For use in alcohol and drug withdrawal in line with statewide guidelines. (d) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * [NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
		10 mg	<i>See above</i>
		20 mg	* For use as per the PBS indications * [NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
	tablet	2.5 mg	* For use as per the PBS indications *
		5 mg	(a) For use as per the PBS indications; (b) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		7.5 mg	* For use as per the PBS indications *
		10 mg	(a) For use as per the PBS indications; (b) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	wafer	5 mg	(a) For use as per the PBS indications; (b) For use in acute mental health settings for disturbed behaviour and agitation in line with statewide guidelines;

Drug	Form	Strength	Restriction
			(c) For use in alcohol and drug withdrawal in line with statewide guidelines. (d) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * [NOTE]Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
		10 mg 20 mg	<i>See above</i> * For use as per the PBS indications * [NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
olaparib	capsule	50 mg	* For discharge and outpatient use as per the PBS indications *
omalizumab	injection	150 mg/mL 75 mg/0.5 mL	* For discharge and outpatient use in accord with PBS Section 100 indications.* <i>See above</i> <i>See above</i>
omeprazole	enteric capsule	20 mg	Only for compounding suspension if Central Pharmacy supply is unavailable. Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months.
	enteric tablet	10 mg 20 mg	For use in line with the proton pump inhibitor (PPI) flowchart, available on the QH website. Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months. <i>See above</i>
	injection	40 mg	For use in children (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
omeprazole QH-CP	oral liquid suspension	2mg per mL 100mL	For use in line with the proton pump inhibitor (PPI) flowchart, available on the QH website. Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months.
ondansetron	injection	4 mg/2 mL	General use for TGA approved indications; and for (a) nonspecific nausea and vomiting and (b) second line therapy in hyperemesis gravidarum. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		8 mg/4 mL	(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications; (b) Use for postoperative nausea and vomiting (PONV).
	oral liquid	4 mg/5 mL	50mL: For use in children who cannot use any other forms of ondansetron.

Drug	Form	Strength	Restriction
	orally disintegrating tablet	4 mg	<p>* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p> <p>(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications; (b) use in postoperative nausea and vomiting (PONV) in (i) adult patients not responsive to alternative oral antiemetic therapy and who cannot use other forms of ondansetron; and (ii) children; (c) Use within Emergency Departments for acute gastroenteritis in children up to age sixteen years when frequent vomiting is interfering with oral rehydration therapy. It is recommended that the Children's Health Queensland Flowchart - Emergency Management of Children with Acute Gastroenteritis be consulted and followed.</p> <p>* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p>
	tablet	8 mg	For patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
		4 mg	<p>(a) Patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications; (b) use in postoperative nausea and vomiting (PONV) in (i) adult patients not responsive to alternative oral antiemetic therapy; and (ii) children. (c) second line therapy in hyperemesis gravidarum.</p> <p>* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p>
		8 mg	For patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
ornipressin	injection	5 units/mL	
orphenadrine	modified release tablet	100 mg	
ortho-phthalaldehyde chemical disinfectant	solution	0.5%, 5 litre	
oseltamivir	capsule	30 mg	<p>On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases / Clinical Microbiology approved protocol for:</p> <p>a) Treatment of inpatients who have clinically suspected or laboratory proven influenza who are at high risk of severe disease (not for general use in Emergency Departments unless admission is intended); and</p> <p>b) Prophylaxis of inpatients who are close contacts of inpatients with laboratory proven influenza on the advice of an infectious diseases physician, clinical microbiologist or infection control practitioner. Oseltamivir therapy should be ceased if influenza polymerase chain reaction (PCR) test of a nasopharyngeal swab or aspirate is negative.</p> <p>OR</p> <p>In accord with a QH pandemic influenza protocol.</p>
		45 mg	See above
		75 mg	See above
	powder for oral liquid		

Drug	Form	Strength	Restriction
		6 mg/mL	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases / Clinical Microbiology approved protocol for: a) Treatment of inpatients who have clinically suspected or laboratory proven influenza who are at high risk of severe disease (not for general use in Emergency Departments unless admission is intended); and b) Prophylaxis of inpatients who are close contacts of inpatients with laboratory proven influenza on the advice of an infectious diseases physician, clinical microbiologist or infection control practitioner. Oseltamivir therapy should be ceased if influenza polymerase chain reaction (PCR) test of a nasopharyngeal swab or aspirate is negative. OR In accord with a QH pandemic influenza protocol.
oxaliplatin	injection	50 mg 100 mg/20 mL 200 mg/40 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above
oxazepam	tablet	15 mg 30 mg	
oxcarbazepine	oral liquid	60 mg/mL	250mL: For epilepsy not controlled by other drugs
	tablet	150 mg 300 mg 600 mg	For epilepsy not controlled by other drugs See above See above
oxybuprocaine	eye drops	0.4%	Inpatient: 0.5mL: For inpatient use only
oxybutynin	tablet	5 mg	Treatment of detrusor overactivity where conservative measures have failed
oxycodone	capsule	10 mg	Inpatient: Palliative care physicians for use in designated stand-alone palliative care units All other inpatient use requires individual patient approval. Outpatient: For palliative patients on discharge or in outpatient clinics. * CONTROLLED DRUG *
	injection	20 mg 10 mg/mL	See above For use by Pain or Palliative Medicine Specialists and Oncologists where (a) morphine or hydromorphone is contraindicated or provides inadequate analgesia; or (b) transdermal opioids provide inadequate analgesia. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	modified release tablet	20 mg/2 mL 10 mg 15 mg 20 mg	See above * For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
			See above See above

Drug	Form	Strength	Restriction
		30 mg	See above
		40 mg	See above
	oral liquid	80 mg	For use on the advice of a palliative care physician * CONTROLLED DRUG *
		1 mg/mL 20mL and 250mL	20mL pack size For paediatric use - for severe disabling pain not responsive to non-narcotic analgesics in patients who: a) cannot swallow tablets or capsules and b) are intolerant to morphine or for whom morphine is thought to be inappropriate. Caution: The risk of drug dependence is high.
			250mL pack size For severe disabling pain not responsive to non-narcotic analgesics in patients who: a) cannot swallow tablets or capsules or b) are intolerant to morphine or for whom morphine is thought to be inappropriate. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	5 mg	A maximum quantity of 10 tablets for discharge and outpatient use. * For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
oxycodone + naloxone	modified release tablet	2.5 mg + 1.25 mg	* For severe disabling pain not responsive to non-narcotic analgesics Caution: The risk of drug dependence is high. ** CONTROLLED DRUG *
		5 mg + 2.5 mg	See above
		10 mg + 5 mg	See above
		15 mg + 7.5 mg	See above
		20 mg + 10 mg	See above
		30 mg + 15 mg	See above
		40 mg + 20 mg	See above
		60 mg + 30 mg	For discharge and outpatient use on the advice of a palliative care physician. * CONTROLLED DRUG *
		80 mg + 40 mg	See above
oxyquinoline sulfate, acetic acid and ricinoleic acidIc "Aci-gel"	jelly	0.025%-0.94%-0.75%, 100g	
oxytocin	injection	5 units/mL 10 units/mL	
oxytocin + ergometrine	injection	5 units/mL + 500 microgram/mL	
paclitaxel	injection	30 mg/5 mL 100 mg/16.67 mL 100 mg/16.7 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above See above

Drug	Form	Strength	Restriction		
palbociclib	capsule	150 mg/25 mL	See above		
		300 mg/50 mL	See above		
		75 mg	* For discharge and outpatient use as per the PBS indications * Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients. Caution: For patients admitted to hospital on palbociclib, seek advice from a medical oncologist before continuing therapy.		
paliperidone	modified release injection	100 mg	See above		
		125 mg	See above		
		25 mg	Specialist Psychiatrists for the treatment of schizophrenia.		
		50 mg	See above		
		75 mg	See above		
		100 mg	See above		
		150 mg	See above		
		175 mg/0.875 mL	See above		
palonosetron	injection	250 microgram/5 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *		
		pamidronate disodium	injection	15 mg/5 mL	(a) treatment of Paget's Disease; (b) severe hypercalcaemia; (c) in accord with PBS Section 100 indications
				30 mg/10 mL	See above
				90 mg/10 mL	(a) severe hypercalcaemia; (b) use in accord with PBS Section 100 indications
		pancreatic extract "Creon"	enteric capsule	5000 units + 4000 units + 300 units	
				10 000 units + 8000 units + 600 units	
25 000 units + 18 000 units + 1000 units					
40 000 units + 25 000 units + 1600 units					
pancuronium	injection	4 mg/2 mL	Specialist Anaesthetists and Country Medical Superintendents		
panitumumab	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *		
		100 mg/5 mL	See above		
		400 mg/20 mL	See above		
pantoprazole	enteric tablet	20 mg	For use in line with the proton pump inhibitor (PPI) flowchart, available on the QH website.		

Drug	Form	Strength	Restriction
			Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months.
	injection	40 mg	See above
		40 mg	For use (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
papaverine	injection	30 mg/mL 120 mg/10 mL	
para-aminosalicylic acid	powder for oral liquid	4g	For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
paracetamol	effervescent tablet	500 mg	For patients with cancer therapy associated mucositis; patients unable to swallow tablets; and in pre-operative areas for use in preference to IV paracetamol.
	injection	1 g/100 mL 500 mg/50 mL	For a maximum of 48 hours for patients unable to take paracetamol by the oral or nasogastric route. For use by Anaesthetists for a maximum of 48 hours in the perioperative period only when patients are unable to take paracetamol by the oral or nasogastric route, and rectal paracetamol is not suitable. Conversion to oral paracetamol should occur within the 48 hours wherever possible. To be stocked only in theatres, post anaesthetic care units (PACU) and intensive care units (ICU).
	oral liquid	50 mg/mL	Care should be taken to avoid accidental overdosage. Caution: - This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. - There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
		100 mg/mL	Care should be taken to avoid accidental overdosage. Caution: There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
		120 mg/5 mL	Children too young to swallow tablets or capsules Care should be taken to avoid accidental overdosage. Caution: - This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. - There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19).

Drug	Form	Strength	Restriction
	suppository	125 mg 250 mg 500 mg	Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
	tablet	500 mg	
paracetamol + codeine	tablet	500 mg + 30 mg	In view of safety concerns, codeine is not recommended for use in children under 12 years of age or in children up to 18 years of age after tonsillectomy and/or adenoidectomy.
paraffin	eye ointment	1 g/g	
paraffin	cream	100g and 500g	
	eye drops	7.5mL	
	liquid	5g tube 200mL	
	oral liquid emulsion	50% 450mL 33% 200mL and 500mL	
paraffin white soft	application	5g sterile tube, 100g, 470g/500g	
paraffin white soft and paraffin liquid	ointment	50%-50%, 500g	Epidermolysis Bullosa patients only. <i>See above</i> <i>See above</i>
paraffin yellow soft	application	100g	
paraldehyde	injection	5 mL/5 mL	(Do not use with plastic syringe - only glass)
parecoxib	injection	40 mg	For use as a single peri-operative dose for the management of post-operative pain.
PARENTERAL NUTRITION ADULT SOLUTION WITH ELECTROLYTES: amino acids 25.3g/L, glucose 82.5g/L, clinoleic, electrolytes mmol/L (Na 21.0, K 16.0, Ca 2.0, Mg 2.2, PO4 8.5), 700kcal/L (eg 'PeriOlimel N4-600E')	intravenous infusion	2L	For use by a Parenteral Nutrition team (or local equivalent) in adult patients unable to maintain nutrition orally or enterally and in whom central parenteral nutrition is either not readily available (i.e. no central access) or the presumed duration of parenteral nutrition is between 3 to 7 days.

Drug	Form	Strength	Restriction
PARENTERAL NUTRITION STANDARD ADULT SOLUTION - alternate lipid source, higher protein - with electrolytes; Amino acids 50-60g/L, glucose 100-125g/L, electrolytes mmol/L (Na 35-40, K 30, Ca 2-4, Mg 4-5, PO4 10-15), 1000-1200kcal/L (eg 'Olimel N9')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible and when patients require a higher kcal:g nitrogen ratio (eg burns, neurosurgery, BMT) or when a product containing fish oil is not suitable.
PARENTERAL NUTRITION STANDARD ADULT SOLUTION - alternate lipid source, higher protein - without electrolytes; Amino acids 50-60g/L, glucose 100-125g/L, 1000-1200kcal/L (eg 'Olimel N9 electrolyte free')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible and when patients require a higher kcal:g nitrogen ratio (eg burns, neurosurgery, BMT) or when a product containing fish oil is not suitable.
PARENTERAL NUTRITION STANDARD ADULT SOLUTION WITH ELECTROLYTES: Fat emulsion with amino acids 40-50g/L, glucose 100-125g/L, electrolytes mmol/L (Na 35-40, K 30, Ca 2-4, Mg 4-5, PO4 10-15), 1000-1200kcal/L (eg 'SMOFKabiven')	intravenous infusion	1L 2L	For intravenous therapy when oral or enteral feeding is not possible. See above
PARENTERAL NUTRITION STANDARD ADULT SOLUTION WITHOUT ELECTROLYTES: Fat emulsion with amino acids 40-50g/L, glucose 100-125g/L, 1000-1200kcal/L (eg 'SMOFKabiven electrolyte free')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, high energy density, high protein, high glucose, with electrolytes (30/200): Amino Acids 30g/L, Glucose 200g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 59.2, Acet 58.5) 917kcal/L			

Drug	Form	Strength	Restriction
	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, low energy density, low protein, low glucose, with electrolytes (20/100): Amino acids 20g/L, Glucose 100g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 47.4, Acet 50.4) 479kcal/L	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, medium energy density, medium protein, medium glucose, with electrolytes (25/150): Amino acids 25g/L, Glucose 150g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 57.2, Acet 54.5) 699kcal/L	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
paroxetine	tablet	20 mg	For major depressive disorders or obsessive-compulsive disorder or panic disorder
pasireotide	modified release injection	20 mg 40 mg 60 mg	* For use in accord with PBS Section 100 indications * See above See above
patent blue V	injection	50 mg/2 mL	Lymphangiography See above
pazopanib	tablet	200 mg 400 mg	* For discharge and outpatient use as per the PBS indications * See above See above
pegaspargase	injection	3750 units 3750 units/5 mL	Haematologists, for the treatment of Acute Lymphoblastic Leukaemia. See above See above
pegfilgrastim (Neulasta)	injection	6 mg/0.6 mL	For discharge, outpatients and day therapy use only, in accord with PBS Section 100 indications.
peginterferon alfa-2a	injection		

Drug	Form	Strength	Restriction
pegvisomant	injection	135 microgram/0.5 mL	For discharge and outpatients only, in accord with PBS Section 100 indications
			* For use in accord with PBS Section 100 indications *
		10 mg	See above
		15 mg	See above
pembrolizumab	injection	20 mg	See above
			* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg/4 mL	See above
pemetrexed	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 g	See above
		100 mg	See above
		500 mg	See above
penicillamine	tablet	125 mg	
		250 mg	
pentamidine	injection		
		300 mg	On the advice of an infectious diseases physician or a clinical microbiologist as second line therapy for treatment of severe Pneumocystis jirovecii pneumonia or prophylaxis
PEP starter pack A	tablet		For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			See above
		Kit containing 3 x tenofovir with emtricitabine tablet 300mg-200mg	See above
PEP starter pack B	tablet		For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			See above
		Kit containing 3 x tenofovir with emtricitabine tablet 300mg-200mg PLUS 6 x raltegravir tablet 400mg	See above
perhexiline	tablet		
		100 mg	
periciazine	tablet		Specialist Psychiatrists
		2.5 mg	See above
		10 mg	See above

Drug	Form	Strength	Restriction		
perindopril	tablet	2.5 mg			
		5 mg			
		10 mg			
perindopril + indapamide	tablet	5 mg + 1.25 mg	Hypertension in patients who are not adequately controlled with either indapamide or perindopril monotherapy.		
permethrin	cream	5%			
	lotion				
pertuzumab	injection	420 mg/14 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *		
pethidine	injection	50 mg/mL	Anaesthetists, Obstetricians and Country Medical Superintendents. Use in general ward areas and Emergency Departments is discouraged. * CONTROLLED DRUG * See above		
		100 mg/2 mL			
pheniramine	oral liquid	15 mg/5 mL			
	tablet	45.3 mg			
phenobarbital (phenobarbitone)	injection	200 mg/mL	Patients unable to swallow tablets		
				oral liquid	15 mg/5 mL
				tablet	30 mg
phenol	injection	5% in Oil 5mL	Anaesthetists		
		6%, 5mL (aqueous)			
		10% in Meglumine lothalamate 60%, 10mL			
phenoxybenzamine	capsule	10 mg	For treatment of severe vasospastic disorders		
phenoxymethylpenicillin	capsule	250 mg	Children too young to swallow tablets or capsules See above		
		500 mg			
	oral liquid	125 mg/5 mL 250 mg/5 mL			
phentolamine	injection				

Drug	Form	Strength	Restriction
		10 mg/mL	* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
phenylephrine	eye drops	2.5% 10%	For inpatient use only. See above
	injection	10 mg/mL (1%)	For anaesthetics
phenylephrine	nasal drops	0.25% 15mL	
phenytoin	capsule	30 mg 100 mg	
	chewable tablet	50 mg	
	injection	100 mg/2 mL 250 mg/5 mL	
	oral liquid	30 mg/5 mL	Children too young to swallow tablets or capsules
phosphate	injection	sodium dihydrogen phosphate (No K Phos) - (10mL vial contains - phosphate 10mmol, sodium 10mmol)	
phosphate (Elemental Phosphorus 436mg per 50mL, Na 434 mmol/L, PO4 280 mmol/L) Parfitt's Mixture	mixture	50mL	
phosphorus	effervescent tablet	500 mg	
physostigmine	injection	1mg in 2mL	
phytomenadione	capsule	10 mg	
	injection	10 mg/mL 2 mg/0.2 mL	
picosulfate	oral liquid	7.5 mg/mL	For constipation in palliative care patients where other agents are not tolerated.
picosulfate + magnesium oxide + citric acid	powder for oral liquid	10 mg + 3.5 g + 12 g	On the advice of a paediatric gastroenterologist for use in paediatric patients requiring bowel cleansing prior to bowel examination by endoscopy, radiography or surgery.
pilocarpine			

Drug	Form	Strength	Restriction
	eye drops	1% 2% 3% 4%	
	eye drops minims	2%	For inpatient use only.
pilocarpine	eye drops	0.125% 15mL	
pimecrolimus	cream	1%	Dermatologists * For discharge and outpatient use as per the PBS indications *
pindolol	tablet	5 mg 15 mg	
pioglitazone	tablet	15 mg 30 mg 45 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
piperacillin + tazobactam	injection	4 g + 500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
pirfenidone	capsule	267 mg	* For discharge and outpatient use as per the PBS indications *
pizotifen	tablet	500 microgram	
plague vaccine	injection	1.5 x 1,000,000,000 organisms in 0.5mL	
plastic wound dressing	spray	aerosol	
plerixafor	injection	24 mg/1.2 mL	* For use in accord with PBS Section 100 indications *
pneumococcal 13 valent conjugate vaccine	injection	0.5 mL	Patients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and are at highest increased risk of invasive pneumococcal disease due to (i) functional or anatomical asplenia, (ii) cochlear implant, (iii) unrepairable cerebrospinal fluid leak, (iv) stem cell transplant, (v) HIV with CD4 count <200, (vi) solid organ transplant - to be given pre-transplant in cardiac, lung and high-risk (ABO-incompatible or paired kidney exchange program) renal patients. <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
pneumococcal 23 valent vaccine			For persons who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and are at high risk of pneumococcal infections.
	injection	0.5 mL	See above See above
podophyllotoxin	application	0.15%, cream 5g 0.5%, paint 3.5mL	
poloxamer	oral liquid	100 mg/mL	Children too young to swallow tablets or capsules
polyvalent Australian snake antivenom	injection	1 each	
polyvinyl alcohol	eye drops	1.4%	
	eye drops	1.4% with 0.6%, 0.4mL	Where other ocular lubricants are inappropriate
pomalidomide	capsule	3 mg 4 mg	* For use in accord with PBS Section 100 indications * See above
	tablet	15 mg 45 mg	* For discharge and outpatient use as per the PBS indications * See above
poractant alfa	intratracheal suspension	120 mg/1.5 mL 240 mg/3 mL	For use in respiratory distress in neonates on the advice of a neonatologist (which can be retrospective) See above See above
posaconazole	injection	300 mg/16.7 mL	After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy and where oral therapy is unsuitable or gastrointestinal disease causes impaired absorption. Patients should be transitioned to oral posaconazole as soon as feasible.
	modified release tablet	100 mg	(a) After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy; or (b) As part of an infectious diseases approved protocol for prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients who are at high risk of developing these infections, defined as follows: (i) Neutropenic patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome. (ii) Graft versus host disease (GVHD) patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy

Drug	Form	Strength	Restriction
	oral liquid	40 mg/mL	<p>after allogeneic haematopoietic stem cell transplant for up to 6 months. Extension past this time requires individual patient approval. NOTE: This preparation is not interchangeable with other posaconazole preparations.</p> <p>(a) After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy; or (b) As part of an infectious diseases approved protocol for prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients who are at high risk of developing these infections, defined as follows: (i) Neutropenic patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome. (ii) Graft versus host disease (GVHD) patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant for up to 6 months. Extension past this time requires individual patient approval. NOTE: This preparation is not interchangeable with other posaconazole preparations.</p>
potassium acetate	injection	2.45 g/5 mL (potassium 25 mmol)	
potassium chloride	injection	750 mg/10 mL (potassium 10 mmol)	For use only in critical care, oncology/haematology and paediatric high dependency units for the replacement of potassium when an intravenous potassium premix preparation does not fulfil the needs of the patient.
	modified release tablet	600 mg (potassium 8 mmol)	
potassium chloride	intravenous infusion	<p>20mmol/L (0.15%) in Sodium Chloride 0.9% and Glucose 5%</p> <p>20mmol/L (0.15%) in Sodium Chloride 0.9% (Potassium 20, Sodium 154, Chloride 174 mmol per litre)</p> <p>40mmol/L (0.298%) in Sodium Chloride 0.9% (Sodium 150, Potassium 40, Chloride 190 mmol per litre)</p> <p>10mmol/100mL in Sodium Chloride 0.29% (Potassium 10, Sodium 5, Chloride 15 mmol per 100mL bag)</p> <p>20mmol/L (0.15%) in Sodium Chloride 0.3% and Glucose 3.3% (125 Cal per litre) (Potassium 20, Sodium 51, Chloride 71 mmol per litre)</p> <p>20mmol/L (0.15%) in Sodium Chloride 0.45% and Glucose 5% (200 Cal per litre) (Potassium 20, Sodium 77, Chloride 97mmol per litre)</p> <p>40mmol/L (0.298%) in Sodium Chloride 0.3% and Glucose 3.3% (125 Cal per litre) (Sodium 50, Potassium 40, Chloride 90 mmol per litre)</p> <p>40mmol/100mL (2.98%) in Sodium Chloride 0.9% (Sodium 15, Potassium 40, Chloride 55 mmol per 100mL)</p>	For use only via a central line in critical care or in oncology/haematology units or under the authorisation of a consultant if the patient is in a non-critical care environment, for severe hypokalaemia (serum potassium equal to or less than 2.5mmol/L). Appropriate monitoring is required.
	oral liquid	10% (20mmol potassium in 15mL), 500mL	For potassium supplementation via tube feeding
	solution		

Drug	Form	Strength	Restriction
		29.824%, 125mL	Haemodialysis Unit only
potassium chloride + potassium bicarbonate + potassium carbonate	effervescent tablet	595 mg + 384 mg + 152 mg (total potassium 14 mmol)	
potassium chloride + sodium chloride	injection		
potassium chloride + sodium chloride + glucose	injection		
potassium citrate	modified release tablet	1.08 g (potassium 10 mmol)	For the prevention of renal calculi in patients with hypocitraturia.
potassium citrate	oral liquid solution	2g/10mL	Carbohydrate Containing Formula (APF) (2g/10mL, 200mL): For the prevention of renal calculi in patients with hypocitraturia. Carbohydrate Free Formula (QH-CP) (2g/10mL, 200mL): Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of the QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
potassium permanganate	powder	1 g/g	
povidone-iodine	alcoholic solution	10% in 70% Ethanol, 500mL	
	aqueous solution	5%, 100mL steri-tube 10%, 30mL 10%, 500mL	
	aqueous swab	pack 100 10%	
	ointment sachet	10%, 1.5g 10%, 25g	
	surgical hand wash	7.5%, 1.5L 7.5%, 500mL	
	swab stick	swab	
pralatrexate	injection	20 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
pralidoxime iodide	injection	2.5% (500 mg/20 mL)	
pramipexole	modified release tablet	1.5 mg 3 mg	For the treatment of Parkinson disease as per the PBS indications. See above

Drug	Form	Strength	Restriction
		4.5 mg	See above
		375 microgram	See above
		750 microgram	See above
	tablet		
		1 mg	For the treatment of Parkinson Disease as per the PBS indications
		125 microgram	For the treatment of Parkinson Disease and severe primary restless legs as per the PBS indications
		250 microgram	See above
pravastatin	tablet		
		20 mg	* For use as per the PBS indications *
		40 mg	See above
praziquantel	tablet		
		600 mg	Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with Schistosomiasis, Hymenolepis nana (Dwarf tapeworm), Taenia saginata, Opisthorchis viverrine or Clonorchis sinensis or as an adjunct to surgical therapy of hydatid disease.
prazosin	tablet		
		1 mg	
		2 mg	
		5 mg	
prednisolone	tablet		
		1 mg	
		5 mg	
		25 mg	
prednisolone acetate + phenylephrine	eye drops		
		1% + 0.12%	Specialist Ophthalmologists
prednisolone sodium phosphate	enema		
		20 mg/100 mL	
	eye drops		
		0.5%	Specialist Ophthalmologists
	oral liquid		
		5 mg/mL	
	suppository		
		5 mg	
pregabalin	capsule		
		25 mg	* For use as per the PBS indications * Note: Initiate pregabalin in preference to gabapentin for neuropathic pain where clinically appropriate. Caution: Consider potential for abuse or diversion with this medicine.
		75 mg	See above
		150 mg	See above
		300 mg	See above
prilocaine	injection		
		0.5% (250 mg/50 mL)	

Drug	Form	Strength	Restriction
prilocaine + felypressin	injection	3% (66 mg/2.2 mL) + 0.066 units/2.2 mL	For dental use
primaquine	tablet	7.5 mg	
primidone	tablet	250 mg	
probenecid	tablet	500 mg	
procaine benzylpenicillin (procaine penicillin)	injection	1.5 g/3.4 mL	
procarbazine	capsule	50 mg	
prochlorperazine	injection	12.5 mg/mL	
	suppository	25 mg	
	tablet	5 mg	
progesterone	pessary	200 mg	Obstetricians for prevention of preterm birth in women with shortened cervix and those with short cervixes in singleton pregnancies.
promethazine	injection	50 mg/2 mL	Caution - not to be used for anaphylaxis.
	oral liquid	5 mg/5 mL	Patients over two years of age unable to swallow tablets or capsules.
	tablet	10 mg 25 mg	
propantheline	tablet	15 mg	
propofol	injection	1 g/100 mL 200 mg/20 mL 500 mg/50 mL	
propranolol	tablet	10 mg 40 mg 160 mg	
propranolol	oral liquid	10mg in 5mL, 100mL	For paediatric use only.

propylthiouracil

Generated on: 22-Dec-2020

Drug	Form	Strength	Restriction
	tablet	50 mg	For use in adult patients only, second line to carbimazole except for the following cases: (a) patients who are in their first trimester of pregnancy; (b) patients who are allergic to or intolerant of carbimazole; (c) thyroid storm
protamine sulfate	injection	50 mg/5 mL	
prothionamide	tablet	250mg	For treatment after approval by the Medical Advisory Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: NDPC@health.qld.gov.au Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
pseudoephedrine	tablet	60 mg	Patients with autonomic insufficiency
psyllium husk powder	powder for oral liquid		
psyllium husk powder	powder for oral liquid sachet	5g	
pyrantel	tablet	125 mg	Alternative treatment of adults and children with Enterobius vermicularis (Pinworm), Ancylostoma caninum (Eosinophilic enterocolitis), Ancylostoma duodenale/Necator americanus (Hookworm) or Ascaris lumbricoides (Roundworm).
		250 mg	See above
pyrazinamide	tablet	500 mg	
pyridostigmine	modified release tablet	180 mg	
	tablet	10 mg	
		60 mg	
pyridoxine	tablet	25 mg	
pyrimethamine	tablet	25 mg	
quetiapine	modified release tablet	50 mg	For use in schizophrenia following failure of brexpiprazole, risperidone, olanzapine, amisulpride or lurasidone; For use in bipolar disorder as per the PBS indications and for bipolar depression as per the TGA indications.
		150 mg	See above
		200 mg	See above

Drug	Form	Strength	Restriction
	tablet	300 mg	See above
		400 mg	See above
		25 mg	See above
		100 mg	See above
		200 mg	See above
quinine	injection		For the treatment of malaria. See above
	tablet	600 mg/10 mL (6%)	See above
		300 mg	See above
raltegravir	chewable tablet	25 mg	* For use in accord with PBS Section 100 indications *
		100 mg	See above
	tablet	400 mg	For use in accord with PBS Section 100 indications For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		600 mg	* For use in accord with PBS Section 100 indications *
raltitrexed	injection	2 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
ramipril	tablet	1.25 mg	
		2.5 mg	
		5 mg	
		10 mg	
ranibizumab	injection	1.65 mg/0.165 mL 2.3 mg/0.23 mL	* For use as per the PBS indications *
ranitidine	injection	50 mg/2 mL 50 mg/5 mL	
		150 mg/10 mL	Patients unable to swallow tablets
	tablet	150 mg	
rasagiline	tablet	1 mg	For Parkinson disease as per the PBS indications
rasburicase	injection		

Drug	Form	Strength	Restriction
red back spider antivenom	injection	1.5 mg	For use in paediatric patients on the advice of a haematologist or paediatric oncologist, to prevent and treat hyperuricaemia manifestations of tumour lysis syndrome. For use in adult patients, this medicine is not LAM listed - individual patient approval is required. QHMAC guidance on rasburicase use in children and adults is provided below - see 'Guidelines and Other Resources' section.
remifentanyl	injection	500 units	Specialist Anaesthetists for use during induction and/or maintenance of general anaesthesia when endotracheal intubation and controlled ventilation are anticipated * CONTROLLED DRUG * <i>See above</i>
		1 mg	<i>See above</i>
		2 mg	<i>See above</i>
		5 mg	<i>See above</i>
rh immunoglobulin	injection	250mg in 1mL	Rh(D)-negative mother without anti-D antibodies with an Rh(D)-positive baby; a) Following abortion or threatened abortion after 8 weeks gestation b) After manipulations during pregnancy; or c) After (Rh) mismatched transfusions especially in premenopausal females
ribavirin	tablet	400 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications. <i>See above</i>
		600 mg	<i>See above</i>
ribociclib	tablet	200 mg	* For discharge and outpatient use as per the PBS indications * Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients. Caution: For patients admitted to hospital on ribociclib, seek advice from a medical oncologist before continuing therapy.
rifabutin	capsule	150 mg	For use in accord with PBS Section 100 indications; For use as part of combination therapy for Helicobacter Pylori when first-line therapy has failed or for proven resistance to Helicobacter Pylori combination therapy; or * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
rifampicin	capsule	150 mg	a) Treatment of TB and leprosy b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; c) all other infections on the advice of an infectious diseases physician, clinical microbiologist, or in conjunction with an antimicrobial stewardship (AMS) team protocol
		300 mg	a) Treatment of TB and leprosy [available as a component of the leprosy WHO calendar packs]; b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; c) all other infections on the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol
	injection	600 mg	For treatment of infections on the advice of an Infectious Diseases Physician or a Clinical Microbiologist

Drug	Form	Strength	Restriction
	oral liquid	100 mg/5 mL	a) Children too young to swallow tablets or capsules * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults.
rifaximin	tablet	550 mg	* For discharge and outpatient use as per the PBS indications *
rilpivirine	tablet	25 mg	* For use in accord with PBS Section 100 indications *
ringers solution (compound sodium chloride)	injection sterile irrigation solution	500mL Pour bottle	
riociguat	tablet		* For use in accord with PBS Section 100 indications *
		1 mg	See above
		1.5 mg	See above
		2 mg	See above
		2.5 mg	See above
		500 microgram	See above
risedronate	tablet	35 mg	* For use as per the PBS indications *
risperidone	modified release injection	25 mg	Specialist Psychiatrists for: a) Schizophrenia for continuation therapy in inpatients, for initiation in inpatients when paliperidone is not clinically suitable, and for outpatient use b) Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder.
		37.5 mg	See above
		50 mg	See above
	oral liquid	1 mg/mL	30mL: Specialist psychiatrists and paediatricians for (a) behavioural disturbances; (b) schizophrenia; (c) bipolar disorder; and (d) autism. The PBS indications of risperidone oral solution 1mg per mL, 100mL should be consulted and followed.
	tablet	1 mg	* For use as per the PBS indications *
		2 mg	See above
		3 mg	See above
		4 mg	See above
		500 microgram	(a) For use as per the PBS indications; (b) For the symptomatic management of severe behavioural disturbance secondary to delirium when non-pharmacological strategies have been unsuccessful and in consultation with a

Drug	Form	Strength	Restriction
			geriatrician or psychiatrist. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
ritonavir	oral liquid	600 mg/7.5 mL	* For use in accord with PBS Section 100 indications *
	tablet	100 mg	* For use in accord with PBS Section 100 indications *
rituximab	injection	1.4 g/11.7 mL	For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
		100 mg/10 mL	(a) * For use in accord with PBS Section 100 indications * OR * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *; (b) On the advice of a haematologist for thrombotic thrombocytopenia purpura (TTP) in patients with suboptimal response to standard treatment (e.g. plasma exchange and high-dose steroids) or with relapsed disease; (c) Nephrologists for induction of remission, or management of relapse of nephrotic syndrome where the underlying abnormality is confirmed to be membranous nephropathy.
		500 mg/50 mL	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i>
rivaroxaban	tablet	10 mg	For use as per the PBS indications; or Venous thromboembolism (VTE) prophylaxis for inpatients previously diagnosed with heparin induced thrombocytopenia (HIT). * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		15 mg	For use as per the PBS indications; or On the advice of a haematologist, vascular physician or clinical pharmacologist for use as an alternative anticoagulant therapy for acute management of patients with heparin induced thrombocytopenia (HIT) in patients with a calculated GFR >30mL/min. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		20 mg	<i>See above</i>
rocuronium	injection	50 mg/5 mL	Emergency Specialists, Specialist Anaesthetists and Country Medical Superintendents.
		100 mg/10 mL	Specialist Anaesthetists and Country Medical Superintendents.
romiplostim	injection	250 microgram	Outpatient and discharge use only * For use in accord with PBS Section 100 indications * <i>See above</i>
		500 microgram	<i>See above</i>
ropivacaine			

Drug	Form	Strength	Restriction
	injection	20 mg/10 mL 40 mg/20 mL 75 mg/10 mL 100 mg/10 mL 150 mg/20 mL 200 mg/20 mL 200 mg/100 mL 400 mg/200 mL	
ropivacaine + fentanyl	epidural infusion	200 mg/100 mL + 200 microgram/100 mL 400 mg/200 mL + 400 microgram/200 mL 400 mg/200 mL + 800 microgram/200 mL	* CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i>
ropivacaine + fentanyl (Baxter)	epidural infusion	ropivacaine + fentanyl (Baxter) epidural infusion, 0.1% + 400 microgram/200mL, 200mL	For use in epidural anaesthesia * CONTROLLED DRUG *
rosuvastatin	tablet	5 mg 10 mg 20 mg 40 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
rotigotine	patch	2 mg/24 hours 4 mg/24 hours 6 mg/24 hours 8 mg/24 hours	(a) For discharge and outpatient use as per the PBS indications; (b) For inpatient use, on the advice of a neurologist or geriatrician, where oral or nasogastric therapy is not possible/suitable. <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
roxithromycin	dispersible tablet tablet	50 mg 150 mg 300 mg	
rufinamide	tablet	200 mg 400 mg	Neurologists for use as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut Syndrome in patients 4 years of age or older, such patients having had appropriate trials of standard antiepileptic therapies for this condition (valproate, lamotrigine, topiramate, clobazam) unless intolerable side effects or contraindicated. <i>See above</i> <i>See above</i>
ruxolitinib	tablet	5 mg 10 mg 15 mg 20 mg	For use as per the PBS indications. Not for initiation in inpatients. <i>See above</i> <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
sacubitril + valsartan	tablet		* For use as per the PBS indications *
		24.3 mg + 25.7 mg	See above
		48.6 mg + 51.4 mg	See above
		97.2 mg + 102.8 mg	See above
salbutamol	inhalation	100 microgram/actuation	
	inhalation solution	2.5 mg/2.5 mL	For use where treatment with this drug delivered from an oral pressurised inhalation device via a large volume spacer is inappropriate.
	injection	5 mg/2.5 mL	See above
		500 microgram/mL	
	oral liquid	5 mg/5 mL	Obstetric use only
salicylic acid	oral gel	2 mg/5 mL	Children too young to swallow tablets or capsules
		8.7%	15g
salicylic acid	ointment	(in Soft Paraffin) 3%, 100g (in Soft Paraffin) 5%, 100g (in Soft Paraffin) 12%, 50g (in Soft Paraffin) 20%, 50g	
	paste	(in Paraffin Base) 2% in Zinc Oxide Co Paste, 100g	Lassar's Paste
salicylic acid and lactic acid (A.P.F.)	application	paint 20%-20%, 15mL	
salmeterol	powder for inhalation		For patients with frequent episodes of asthma who are concurrently being treated with inhaled corticosteroids
		50 microgram/actuation	See above See above
saquinavir	tablet	500 mg	* For use in accord with PBS Section 100 indications *
sea snake antivenom	injection	1000 units	
secukinumab	injection	150 mg/mL	* For discharge and outpatient use as per the PBS indications *
semaglutide	injection	1.34 mg/mL, 4mg/3mL (1mg per dose prefilled pen)	* For use as per the PBS indications *
		1.34 mg/mL, 2mg/1.5mL (0.25mg or 0.5mg per dose prefilled pen)	See above
senna leaf powder + fig + date	bar		

Drug	Form	Strength	Restriction
sennoside B	tablet	1 g/10 g + 3 g/10 g + 3 g/10 g	For inpatient use only.
		7.5 mg	
sertraline	tablet	50 mg	For major depressive disorders or obsessive-compulsive disorder or panic disorder where other treatments have failed or are inappropriate.
		100 mg	<i>See above</i> <i>See above</i>
sesame oil	nasal spray	1 mL/mL	Patients undergoing radiotherapy to nose and sinuses; for postoperative use following sinus surgery; and for use in inpatients only for the relief of nasal symptoms associated with continuous positive airway pressure (CPAP) therapy.
			<i>See above</i>
sevelamer	tablet	800 mg	For use in accord with PBS Section 100 indications (for initiation and stabilisation of treatment); For use as per the PBS indications (for maintenance therapy).
sevoflurane	inhalation solution	1 mL/mL	For use down to a minimum fresh gas flow of one litre per minute. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
sildenafil	tablet	20 mg	(a) For use in accord with PBS Section 100 indications; (b) For use under the guidance of paediatric cardiac specialists.
sildenafil	oral liquid suspension	2mg per mL, 200mL	Paediatric cardiac specialists
silicone	cream	2.5% 500mL	For back rubbing
silver nitrate	stick		
silver nitrate silver sulfadiazine	cream	1% 50g, 500g	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
simethicone	oral liquid	100 mg/mL	Specialist radiological and endoscopic procedures
	powder	125 mg	Specialist radiological and endoscopic procedures
simvastatin	tablet		* For use as per the PBS indications *
		20 mg	<i>See above</i>
		40 mg	<i>See above</i>
sirolimus	oral liquid	1 mg/mL	* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
	tablet	1 mg 2 mg 500 microgram	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
sirolimus in white soft paraffin QH-CP	ointment	0.1% 50g 0.5% 50g	(a) For use in therapy initiated by Tuberous Sclerosis Complex Clinic specialists (paediatric neurologists, renal physicians and dermatologists) in patients with tuberous sclerosis for topical treatment of facial angiofibroma and other dermatological manifestations. (b) Renal physicians and dermatologists for use in adult patients with tuberous sclerosis for topical treatment of facial angiofibroma and other dermatological manifestations. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i> <i>See above</i>
sitagliptin	tablet	25 mg 50 mg 100 mg	For initiation, only when used in combination with insulin, in line with PBS criteria. For continuing use in established patients as per the PBS indications. Note: Initiate alogliptin in preference to sitagliptin for patients requiring a DPP-4 inhibitor who are not using insulin <i>See above</i> <i>See above</i> <i>See above</i>
sodium acetate	injection	1.64 g/10 mL	
sodium alginate + bicarbonate + calcium carbonate	oral liquid	500 mg/10 mL + 213 mg/10 mL + 325 mg/10 mL 500 mg/10 mL + 267 mg/10 mL + 160 mg/10 mL	For infant use only <i>See above</i> <i>See above</i>
sodium aurothiomalate	injection	10 mg/0.5 mL 20 mg/0.5 mL 50 mg/0.5 mL	
sodium bicarbonate	ear drops	3% in 75% Glycerol, 15mL	
	mouthwash	1% 500mL	
	oral liquid	8.4%, 200mL	
sodium calcium edetate	injection	200mg/mL, 5mL	
sodium chloride	injection	(154 mmol per /litre) Injection in plastic 0.9% (45 mg/5 mL) 0.9% (90 mg/10 mL) 20% (2 g/10 mL)	For use in Eye Wards; Eye Outpatients and Eye Casualty
	soluble tablet		

Drug	Form	Strength	Restriction
sodium chloride		600 mg	
	eye drops	5% 10mL	Specialist Ophthalmologists
	inhalation solution	sterile 6% solution for nebulisation 10mL sachet	For use in patients with cystic fibrosis, infants with acute bronchiolitis and for sputum induction as required.
	injection	0.9% (154 mmol per /litre) Injection in glass 50mL 0.9% (154 mmol per /litre) in glass 100mL 0.9% (154 mmol per /litre) in plastic 100mL	For use in Eye Wards; Eye Outpatients and Eye Casualty
	intravenous infusion injection	0.9% (154 mmol per litre) 1 Litre 0.9% (154 mmol per litre) 50mL 0.9% (154 mmol per litre) 250mL 0.9% (154 mmol per litre) 500mL 3% (510 mmol per litre) 250mL	
	irrigation solution	sterile 0.9% 1 Litre pour bottle sterile uromatic 0.9% 2 Litre sterile uromatic 0.9% 3 Litre sterile 0.9% 100mL sterile 0.9% 500mL	
	pre-filled syringe	0.9%, 5mL "BD PosiFlush SP Pre-filled Saline Syringe"	
sodium chloride "auspman brand"	oral liquid	2mmol/mL, 100mL	For treatment of hyponatraemia in paediatric patients who are unable to swallow tablets when intravenous therapy is not indicated <i>See above</i> <i>See above</i>
sodium chloride + potassium chloride + calcium chloride + magnesium chloride + acetate + citric acid	solution	6.4 mg/mL + 750 microgram/mL + 480 microgram/mL +30mL: Eye casualty only ... 120mL: Ophthalmologists	
sodium chloride + potassium citrate monohydrate + glucose + citric acid	oral liquid	156.2 mg/62.5 mL + 137.5 mg/62.5 mL (potassium 1.3 Paediatric Use mmol) + 1 g/62.5 mL + ...	
sodium chloride + sodium gluconate + sodium acetate trihydrate + potassium chloride + magnesium chloride	injection	5.26 g/L + 5.02 g/L + 3.68 g/L + ...	
sodium chloride + sodium gluconate + sodium acetate trihydrate + potassium chloride + magnesium chloride + glucose	injection	5.26 g/L + 5.02 g/L + 3.68 g/L + ...	On the advice of paediatric intensivists.

Drug	Form	Strength	Restriction
sodium chloride with electrolytes - Sodium Chloride 0.64%, Potassium Chloride 0.075%, Magnesium Chloride 0.03%, Calcium Chloride 0.048%, Sodium Acetate 0.39%, Sodium Citrate 0.17% (Balanced Sterile Salt Solution) (Single use only)	irrigation solution		15mL: Eye Casualty 250mL and 500mL: Ophthalmologists
		Sodium Chloride 0.64%, Potassium Chloride 0.075%, Magnesium Chloride 0.03%, Calcium Chloride 0.048%, Sodium Acetate 0.39%, Sodium Citrate 0.17% (Balanced Sterile Salt Solution) (Single use only)	See above See above
sodium chloride with glucose	intravenous infusion injection	sodium chloride 0.9% and glucose 1% 1 Litre sodium 0.9% chloride and glucose 5% (200 Cal per litre) (Sodium 154, Chloride 154 mmol per litre) sodium chloride 0.3% and glucose 3.3% (125 Cal per litre) (Sodium 51, Chloride 51 mmol per litre) 1 Litre sodium chloride 0.3% and glucose 3.3% (125 Cal per litre) (Sodium 51, Chloride 51 mmol per litre) 500mL sodium chloride 0.45% and glucose 5% (200 Cal per litre) (Sodium 154, Chloride 154 mmol per litre) 1Litre	For paediatric perioperative use only.
sodium hyaluronate	intraocular injection	"Healon" 10mg/mL, 0.4mL "Healon" 10mg/mL, 0.85mL "Amvisc Plus" 16mg/mL, 0.8mL (M.W.=5,000,000) "Healon GV" 14mg/mL, 0.55mL	Specialist Ophthalmologists See above See above Specialist Ophthalmologists where alternatives are inappropriate
sodium hyaluronate - chondroitin	intraocular injection	3% - 4%, 0.5mL	Specialist Ophthalmologists
sodium hyaluronate - sodium chondroitin sulfate and sodium hyaluronate "Duovisc Viscoelastic System"	intraocular injection	3%-4%, 0.35mL and 1%, 0.4mL 3%-4%, 0.5mL and 1%, 0.55mL	Specialist Ophthalmologists See above
sodium hypochlorite	solution	1% 100mL 2% 500mL, 5 Litres	
	tablet for disinfectant solution	tablet for Disinfectant Solution	Patients with spinal cord injury
sodium lactate compound solution (Hartmann's Solution) and glucose 5% (200 Cal per litre) (Sodium 131, Potassium 5, Calcium 2, Chloride 111, Lactate 29 mmol per litre)	intravenous infusion injection	1 Litre	

Drug	Form	Strength	Restriction
sodium lactate compound solution (Sodium 131, Potassium 5, Calcium 2, Chloride 111, Lactate 29 mmol per Litre) "Hartmann's Solution"	intravenous infusion injection	1 Litre 500mL	
sodium polystyrene sulfonate	powder	999.3 mg/g	
sodium tetradecyl sulfate	injection	3% (60 mg/2 mL)	
sodium thiosulfate	injection	25% (2.5 g/10 mL)	As second line treatment for cyanide poisoning.
sodium thiosulfate	lotion	20%, 100mL	
sofosbuvir + velpatasvir	tablet	400 mg + 100 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications.
sofosbuvir + velpatasvir + voxilaprevir	tablet	400 mg + 100 mg + 100 mg	* For discharge and outpatient use in accord with PBS General Schedule/Section 100 indications *
somatropin	injection	1 mg 1.2 mg 1.33 mg 1.4 mg 1.6 mg 1.8 mg 2 mg 3 mg 4 mg 5 mg 6 mg 8 mg 10 mg 12 mg 24 mg 400 microgram 600 microgram 800 microgram 5 mg/1.5 mL 5 mg/1.5 mL 6 mg/1.03 mL	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
		10 mg/1.5 mL	See above
		10 mg/1.5 mL	See above
		10 mg/2 mL	See above
		12 mg/1.5 mL	See above
		15 mg/1.5 mL	See above
		15 mg/1.5 mL	See above
		20 mg/2.5 mL	See above
sorafenib	tablet	200 mg	Specialist Oncologists for outpatient use for advanced hepatocellular carcinoma only, as per the PBS indications. All other use must be on an Individual Patient Approval basis.
sotalol	injection	40 mg/4 mL	
	tablet	80 mg 160 mg	
sotalol	oral liquid suspension	5mg per mL, 192mL	Paediatric cardiac specialists
soya oil	fat emulsion (eg 'intralipid')	20% (100 g/500 mL)	Anaesthetists and Emergency Department Specialists for the management of severe local anaesthetic toxicity.
soya oil + medium chain triglycerides + olive oil + fish oil natural	injection	6 g/100 mL + 6 g/100 mL + 5 g/100 mL + ... 30 g/500 mL + 30 g/500 mL + 25 g/500 mL + ...	Note: 100mL is to be used in neonates only For intravenous therapy when oral or enteral feeding is not possible.
spacer device inhalation	spacer device inhalation	airflow space chamber with child mask airflow space chamber with infant mask breath-a-tech adult mask breath-a-tech child mask breath-a-tech for use with asthma inhalers la petite e-chamber volumatic For Ventolin and Becotide Aerosols	
spironolactone	tablet	25 mg 100 mg	
spironolactone	oral liquid suspension	2.5mg per mL, 50mL	Patients unable to swallow tablets
sterculia	granules	620 mg/g	
stonefish antivenom	injection	2000 units	
streptokinase			

Drug	Form	Strength	Restriction
	injection	250 000 units	
streptomycin sulfate	injection	1g	* For use in accord with Special Access Scheme (SAS) arrangements *
succinylated gelatin	injection	20 g/500 mL	Plasma substitute as an alternative to plasma protein
sucralfate	tablet	1 g	
sucroferric oxyhydroxide	chewable tablet	2.5 g (iron 500 mg)	* For use in accord with PBS Section 100 indications *
sucrose	oral liquid solution	24% 2mL	
sufentanil	injection	250microgram in 5mL	Palliative Care Specialists and Medical Oncologists for the control of severe disabling pain when other opioids are inappropriate or not tolerated. Caution: The risk of drug dependence is high. CONTROLLED DRUG Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained.
sugammadex	injection	200 mg/2 mL	For paediatric use by credentialed anaesthetists and Emergency Physicians for emergency reversal of rocuronium in patients who cannot be intubated and cannot be oxygenated. All other use of sugammadex must be on an Individual Patient Approval basis, with approval by the Director of Anaesthetics, the Director of Emergency Medicine or nominated representative, and in line with the SWAPNET guideline. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		500 mg/5 mL	Note: Only limited stock may be held outside pharmacy - on the difficult intubation trolley. For use by credentialed anaesthetists and Emergency Physicians for emergency reversal of rocuronium in patients who cannot be intubated and cannot be oxygenated. All other use of sugammadex must be on an Individual Patient Approval basis, with approval by the Director of Anaesthetics, the Director of Emergency Medicine or nominated representative, and in line with the SWAPNET guideline. Note: Only limited stock may be held outside pharmacy - on the difficult intubation trolley.
sulfadiazine	tablet	500 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
sulfasalazine	enteric tablet	500 mg	
	tablet	500 mg	
sulthiame	tablet		

Drug	Form	Strength	Restriction
sumatriptan		50 mg 200 mg	
	injection		For use in hospital under medical supervision
	nasal spray	6 mg/0.5 mL	For migraine attacks in patients aged 12 years and older, where oral treatment with a triptan is not tolerated.
	tablet	20 mg/actuation 50 mg	Treatment of migraine attacks in patients failing other therapy.
sunitinib	capsule	12.5 mg	For discharge and outpatient use in patients with pancreatic neuroendocrine tumours or gastrointestinal stromal tumours, as per the PBS indications.
		25 mg	See above
		50 mg	See above
sunscreen (SPF 30+) cream lotion lip stick	cream	100g	
	lip stick	5g	
	lotion	100mL or 125mL	
sunscreen (SPF30+) methoxycinnamate	application	(SPF30+)	
suxamethonium	injection	100 mg/2 mL	
tacrolimus	capsule	1 mg 5 mg 500 microgram	
		modified release capsule	1 mg 3 mg 5 mg 500 microgram
	oral liquid suspension	1mg in 1mL, 100mL	For use in paediatric patients.
tadalafil	tablet	20 mg	* For use in accord with PBS Section 100 indications *
taipan snake antivenom	injection	12 000 units	
talc	powder	3g aerosol 4g	

Drug	Form	Strength	Restriction
taliglucerase alfa	injection	200 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
tamoxifen	tablet	10 mg 20 mg	
tapentadol	modified release tablet	50 mg 100 mg 150 mg 200 mg 250 mg	Persistent pain specialists for chronic severe disabling pain not responsive to non-narcotic analgesics. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * See above See above See above See above
taurolidine + citrate 4% (TauroLock)	catheter lock solution	3mL & 5mL	For use as a line lock for patients with end stage renal failure on haemodialysis with current or prior heparin induced thrombocytopenia/thrombosis (HIT). <i>See above</i>
teduglutide	injection	5 mg	For discharge and outpatient use in accord with PBS Section 100 indications.
teicoplanin	injection	400 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
telmisartan	tablet	40 mg 80 mg	For patients unable to tolerate ACE inhibitors because of cough or angioedema, or patients intolerant of other antihypertensive therapy. <i>See above</i> <i>See above</i> <i>See above</i>
temazepam	tablet	10 mg	
temozolomide	capsule	5 mg 20 mg 100 mg 140 mg 250 mg	* For use as per the PBS indications * See above See above See above See above
tenecteplase	injection	40 mg	a) treatment of acute ST elevation myocardial infarction; b) fibrinolytic management of obstructed IV access. c) treatment of acute ischaemic stroke with large arterial obstruction documented by angiography prior to emergency endovascular clot retrieval. Dose 0.25mg/kg to maximum 25mg; d) treatment of acute ischaemic stroke in rural hospitals under telehealth consultation with a physician (including Emergency Department physicians) trained and experienced in acute stroke management. Thrombolysis may be initiated within four and a half hours after the onset of stroke

Drug	Form	Strength	Restriction
			symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques. Dose 0.25mg/kg to maximum 25mg. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		50 mg	a) treatment of acute ST elevation myocardial infarction; b) fibrinolytic management of obstructed IV access.
teniposide	injection	50 mg/5 mL	
tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat	tablet	10 mg + 200 mg + 150 mg + ...	* For use in accord with PBS Section 100 indications *
tenofovir disoproxil	tablet	291 mg	* For use in accord with PBS Section 100 indications *
tenofovir disoproxil + emtricitabine	tablet	291 mg + 200 mg	For use in accord with PBS Section 100 indications; For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
tenofovir disoproxil + emtricitabine + efavirenz	tablet	300 mg + 200 mg + 600 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
terbinafine	cream	1%	* For use as per the PBS indications *
	tablet	250 mg	Specialist Staff and Endorsed Podiatrists in a shared care arrangement for (i) microbiologically proven chronic onychomycosis; (ii) extensive tinea unresponsive to griseofulvin or in patients intolerant of griseofulvin
terbutaline	injection	500 microgram/mL	General use for TGA approved indications; and for treatment of uterine hyperstimulation / tachysystole. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	powder for inhalation	500 microgram/actuation	
teriparatide	injection	250 microgram/mL, 2.4 mL pen device	

Drug	Form	Strength	Restriction
terlipressin	injection	850 microgram/5 mL	For discharge and outpatient use as per the PBS indications. Patients must be made fully aware of the 18 month maximum length of PBS subsidised treatment.
testosterone	gel	1% (12.5 mg/actuation) 1% (50 mg/5 g)	* For use as per the PBS indications * See above
testosterone enantate	injection	250 mg/mL	Only for use in confirmed testosterone deficiency.
tetanus immunoglobulin	injection	250 units 4000 units	
tetrabenazine	tablet	25 mg	
tetracaine	spray solution	1%, 15mL	
tetracaine (amethocaine)	eye drops	1%	Specialist Ophthalmologists
tetracosactide (tetracosactrin)	injection	250 microgram/mL	
	modified release injection	1 mg/mL	
tetracycline	capsule	250 mg	
tezacaftor + ivacaftor	tablet	100 mg + 150 mg	* For use in accord with PBS Section 100 indications *
thalidomide	capsule	50 mg 100 mg	* For use in accord with PBS Section 100 indications * See above See above
theophylline	modified release tablet	250 mg 300 mg	
	oral liquid	133.3 mg/25 mL	To be used where tablets are unsuitable
thiabendazole (tiabendazole)	tablet	500mg	
thiamine	injection 100mg/1mL	100 mg/mL	For use only in paediatric patients

Drug	Form	Strength	Restriction
	tablet	100 mg	
thiamine	injection 300mg/3mL	300mg/3mL	
thiopental	injection	470 mg (equiv 500mg thiopental sodium and sodium carbonate)	Note: The amount of active ingredient differs between brands of thiopental sodium. Refer to Queensland Health memorandum dated 25/11/19
thrombin "Aspen"	application	5000 units	Requires SAS category A approval
thymol + benzoic acid + bicarbonate	mouthwash	1.5 mg/mL + 8 mg/mL + 3 mg/mL	
tiagabine	tablet	5 mg 10 mg 15 mg	For partial epilepsy not controlled by other drugs See above See above
ticagrelor	dispersible tablet	90 mg	(a) For inpatient use in combination with aspirin for treatment of STEMI and high risk non-ST elevation acute coronary syndrome; (b) Use by the Queensland Ambulance Service (QAS) in accordance with the QAS Ticagrelor Drug Therapy Protocol; (c) Interventional radiologists or neurosurgical specialists for inpatient use in proven clopidogrel non-responders identified by the multiplate / VerifyNow P2Y12 assay post neuro-endovascular stent insertion. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	90 mg	(a) To be used in combination with aspirin for treatment of STEMI and high risk non-ST elevation acute coronary syndrome; (b) Interventional radiologists or neurosurgical specialists for use in proven clopidogrel non-responders identified by the multiplate / VerifyNow P2Y12 assay post neuro-endovascular stent insertion. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
tiger snake antivenom	injection	3000 units	
timolol	eye drops	0.25% 0.5%	
tinidazole	tablet		

Drug	Form	Strength	Restriction
tioguanine		500 mg	* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	tablet		
tipranavir		40 mg	For treatment of leukaemia
	capsule		
tirofiban		250 mg	* For use in accord with PBS Section 100 indications *
	injection		
tobramycin		12.5 mg/50 mL	Patients with high-risk acute coronary syndromes (as defined by new transient or persistent ST or T-wave ECG changes and ischaemic pain lasting at least 20 minutes within the previous 12 hours) who are either: 1) undergoing percutaneous coronary intervention (PCI); or 2) continuing to experience repeated episodes of ischaemic chest pain despite maximal medical therapy including combination anti-platelet therapy and therapeutic dose heparin.
	eye drops		
		0.3%	Ophthalmologists
	eye ointment		
		0.3%	Ophthalmologists
	inhalation solution		
		300 mg/5 mL	Specialist respiratory staff or physicians in regional centres with approval from the specialist cystic fibrosis physician for discharge and outpatient use (including use for training purposes in outpatient clinics) for the management of cystic fibrosis patients with Pseudomonas aeruginosa infections as per the PBS indications.
	injection		
		80 mg/2 mL	Preservative Free Specialist respiratory staff for nebulised use as treatment of pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis in situations where patients are intolerant to other tobramycin products; and on the advice of an infectious diseases physician for inhalation in non-CF bronchiectasis patients with pseudomonas aeruginosa infection. Injection On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	powder for inhalation		
		28 mg	Specialist respiratory staff or physicians in regional centres with approval from the specialist cystic fibrosis physician for discharge and outpatient use (including use for training purposes in outpatient clinics) for the management of cystic fibrosis patients with Pseudomonas aeruginosa infections as per the PBS indications.
tocilizumab	injection	80 mg/4 mL	* For use in accord with PBS Section 100 indications *
		200 mg/10 mL	See above
		400 mg/20 mL	See above
tolnaftate	cream		
		1%	

Drug	Form	Strength	Restriction
	lotion	1%	
topiramate	capsule	15 mg 25 mg	For epilepsy not controlled by other drugs <i>See above</i>
	tablet	25 mg 50 mg 100 mg 200 mg	<i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
topiramate	oral liquid suspension	5mg/mL, 100mL (QH-CP)	For epilepsy not controlled by other medications where: (a) Solid dose forms cannot be swallowed whole; OR (b) Administration via an enteral feeding tube is required AND dispersing the tablet/capsule is considered inappropriate. Refer to 'Don't Rush to Crush' and local procedures for guidance. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
topotecan	injection	4 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
trace elements with iron - chromium + copper + iron + manganese + iodine + fluoride + molybdenum + selenium + zinc	injection	53.33 microgram/10 mL + 1.02 mg/10 mL + 5.4 mg/10 mL + ...	
tramadol	capsule	50 mg	For post operative pain and for pain clinics
	injection	100 mg/2 mL	For short term treatment of acute pain
	modified release tablet	100 mg 150 mg 200 mg	For post operative pain and for pain clinics <i>See above</i> <i>See above</i>
trametinib	tablet	2 mg 500 microgram	Specialist Oncologists for discharge and outpatient use as per the PBS indications. <i>See above</i>
tranexamic acid	injection	1 g/10 mL	Specialist Anaesthetists, Specialist Intensivists, Specialist Surgical Staff and Cardiac Perfusionists for: a) Major haemorrhage with concomitant hyperfibrinolysis, and b) Prophylaxis of intra- and post-operative bleeding during major surgical procedures where there is a high likelihood of transfusion requirement;

Drug	Form	Strength	Restriction
			or Credentialed Emergency Department Senior Medical Officers to treat hypotensive trauma patients with uncontrolled haemorrhage, preferably within one hour, but no later than 3 hours after trauma; or For use in severe to life threatening bleeding in line with Qld Department of Health guidelines for managing patients on novel oral anticoagulants; or ENT surgeons, or ED medical officers in consultation with the on-call ENT surgeon, for management of post-tonsillectomy haemorrhage (primary or secondary) in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet	500 mg/5 mL	See above
tranexamic acid		500 mg	
	mouthwash	5% 150mL	
tranylcypromine	tablet		
		10 mg	
trastuzumab	injection	60 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		150 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		600 mg/5 mL	Note: Biosimilar brands are available for this particular strength. * For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
trastuzumab emtansine	injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg	See above
		160 mg	See above
travoprost	eye drops		
		0.004%	Specialist Ophthalmologists as monotherapy for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of, or insufficiently responsive to, other intraocular pressure medication.
travoprost + timolol	eye drops		
		0.004% + 0.5%	For reduction of elevated intra-ocular pressure as per the PBS indications.
tretinoin	capsule		
		10 mg	Specialist Haematologists and their advanced training registrars in accord with Health (Drugs and Poisons) Regulations 1996 for use in induction, consolidation and maintenance therapy in patients with newly diagnosed or relapsed acute promyelocytic leukaemia (APML).
triamcinolone	cream		
		0.02%	100g: Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists

Drug	Form	Strength	Restriction
	injection	10 mg/mL 40 mg/mL	Intra-articular and intralesion injection <i>See above</i>
	ointment	0.02%	100g
	paste	0.1%	5g: Specialist Medical and Dental Staff and Country Medical Superintendents
triamcinolone + neomycin + gramicidin + nystatin	ointment	0.1% + 0.25% + 0.025% + ... ointment and ear ointment	Applies to 15g ointment and 5g ear ointment.
triamcinolone acetonide	intraocular injection	40mg in 1mL	Specialist ophthalmologists for intraocular oedematous and neovascular disease of the eye. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
triamcinolone hexacetonide	injection suspension	20mg/mL	Paediatric rheumatologists who have TGA authorisation to prescribe triamcinolone hexacetonide. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i> <i>See above</i>
triclosan	emulsion	1% 200mL	Not for use on neonates
	hand and body wash/skin cleanser	1% 1.5L 1% 125mL 1% 500mL	For use in areas at high risk from MRSA <i>See above</i> <i>See above</i>
	pre-op wash	1% 40mL	
	skin cleanser soap	1% 125g	For use in areas at high risk from MRSA
trifluridine + tipiracil	tablet	15 mg + 6.14 mg 20 mg + 8.19 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i>
trihexyphenidyl (benzhexol)	tablet	2 mg 5 mg	
trimethoprim	tablet	300 mg	
trimethoprim + sulfamethoxazole	injection	80 mg/5 mL + 400 mg/5 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	oral liquid	40 mg/5 mL + 200 mg/5 mL	Patients unable to swallow tablets
	tablet		

Drug	Form	Strength	Restriction
triptorelin	injection	80 mg + 400 mg	Outpatient: * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
		160 mg + 800 mg	
		3.75 mg	
		11.25 mg	
trisodium edetate	injection	22.5 mg	
		1g in 5mL	
tropicamide	eye drops	0.5%	0.5mL: For inpatient use only.
		0.5%	15mL
		1%	0.5mL: For inpatient use only.
		1%	15mL
trypan blue	injection	0.6mg in 0.5mL	Specialist ophthalmologists for use where standard capsulorrhexis is difficult to perform.
tuberculin PPD (Mantoux) acellular intradermal skin test	injection	50 tuberculin units/mL	
typhoid inactivated vaccine	injection	0.5 mL	
urea + lactic acid	cream	10% + 5%	
urea pronalys BP	crystals	99-100% w/w 500g	Specialist Endocrinology Staff for the oral treatment of mild to moderate symptoms of euvolemic hyponatraemia in patients unable to tolerate fluid restrictions or where fluid restrictions have failed <i>See above</i> <i>See above</i>
urokinase	injection	10,000 units	Fibrinolytic management of obstructed IV access; Venous thrombosis; Peripheral arterial occlusion; Haemodialysis shunts <i>See above</i> <i>See above</i> <i>See above</i>
		100,000 units	
		500,000 units	
ursodeoxycholic acid	capsule	250 mg	For proven primary biliary cirrhosis; and for relief of pruritus and improvement of liver function in biochemically proven intrahepatic cholestasis of pregnancy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	oral liquid	50 mg/mL	
ustekinumab			For proven primary biliary cirrhosis.

Drug	Form	Strength	Restriction
valaciclovir	injection	45 mg/0.5 mL 130 mg/26 mL	* For use as per the PBS indications * * For use in accord with PBS Section 100 indications *
	tablet	500 mg	a) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for the treatment of herpes simplex virus in immunocompromised (haematology and oncology) paediatric patients (up to 18 years of age); OR b) Treatment of immunocompetent patients with herpes zoster in whom the duration of rash is less than 72 hours; c) Intermittent treatment of moderate to severe recurrent genital herpes; d) Herpes zoster in immunocompromised patients; e) Ophthalmic herpes zoster; f) Use in accord with PBS Section 100 indications; g) Use in the paediatric population (up to 18 years of age) for: Prophylaxis of viral infection for 12 months following allogeneic bone marrow transplant; Prophylaxis of viral infection for 3 months following autologous bone marrow transplant. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * * For use in accord with PBS Section 100 indications *
valganciclovir	powder for oral liquid		<i>See above</i>
	tablet	50 mg/mL 450 mg	<i>See above</i> <i>See above</i>
valproate	enteric tablet	200 mg 500 mg	
	injection	400 mg	For maintenance treatment of partial epilepsy not controlled by other drugs when oral sodium valproate has already been established but is temporarily not feasible. Not to be used for emergency treatment.
	oral liquid	200 mg/5 mL	Caution: There are reports of fatal hepatotoxicity with this preparation particularly in children
	tablet	100 mg	
vancomycin	capsule	125 mg 250 mg	For the treatment of antibiotic associated colitis due to <i>C. difficile</i> as per the PBS indications. <i>See above</i> <i>See above</i>
	injection	1 g 500 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * <i>See above</i> <i>See above</i>
	tablet	1 mg	For use in Primary Health Care Clinics registered for the PBS Section 100 Remote Area Aboriginal Health Services program.

Drug	Form	Strength	Restriction
		500 microgram	For use in Primary Health Care Clinics registered for the PBS Section 100 Remote Area Aboriginal Health Services program. Note - Varenicline 500microgram tablet is only available in combination with varenicline 1mg tablet.
varicella-zoster live vaccine	injection	1 each	(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant.
varicella-zoster virus immunoglobulin	injection	200 units	Specialist Staff by special arrangement from Red Cross Blood Bank
vasopressin	injection	20 pressor Units in 1mL	
vecuronium	injection	4 mg 10 mg	Specialist Anaesthetists and Country Medical Superintendents Specialist Anaesthetists; ICU and Country Medical Superintendents
vedolizumab	injection	300 mg	* For use in accord with PBS Section 100 indications *
velaglucerase alfa	injection	400 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
venetoclax	tablet	10 mg 50 mg 100 mg	Specialist Haematologists for use as second line therapy as per the PBS indications. Note: This strength also available as part of the venetoclax titration pack. Titration pack restriction: Specialist Haematologists for discharge and outpatient use as second line therapy as per the PBS indications. <i>See above</i> Specialist Haematologists for discharge and outpatient use as second line therapy as per the PBS indications. Note: This strength also available as part of the venetoclax titration pack. Titration pack restriction: Specialist Haematologists for discharge and outpatient use as second line therapy as per the PBS indications.
venlafaxine	modified release capsule	37.5 mg 75 mg 150 mg	For major depressive disorders <i>See above</i> <i>See above</i> <i>See above</i>
verapamil	injection modified release capsule modified release tablet	5 mg/2 mL 160 mg 180 mg 240 mg	

Drug	Form	Strength	Restriction
vigabatrin	tablet	40 mg 80 mg	
	powder for oral liquid		For epilepsy not controlled by other drugs <i>See above</i>
	tablet	500 mg	<i>See above</i>
vinblastine	tablet	500 mg	<i>See above</i>
vincristine	injection	10 mg/10 mL	* For use in accord with PBS Section 100 indications *
	injection	1 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
vindesine	injection		
vinorelbine		5 mg	
	capsule	20 mg 30 mg	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
	injection	10 mg/mL 50 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
vitamin A	capsule 50 000 units	50 000 units	
vitamin A	capsule 5000 units	5,000 units	
vitamin B group with ascorbic acid (ascorbic acid + nicotinamide + pyridoxine + riboflavin + thiamine)	tablet	45 mg + 45 mg + 700 microgram + ...	
vitamin compound "Penta-vite" 30mL			Patients unable to swallow tablets
	liquid	"Penta-vite"	<i>See above</i> <i>See above</i>
vitamin compound "VitABDECK"			For treatment of patients with cystic fibrosis or pancreatic insufficiency
	capsule	"VitABDECK"	<i>See above</i> <i>See above</i>
vitamin compound (containing fat and water soluble vitamins excluding vitamin K) "Cernevit" 5mL	injection	"Cernevit"	

Drug	Form	Strength	Restriction
vitamin compound (fat soluble vitamins) "Vitalipid N Adult" 10mL	injection	"Vitalipid N Adult"	For a complete PN multivitamin, use a fat soluble vitamin preparation together with a water soluble vitamin preparation. <i>See above</i> <i>See above</i>
vitamin compound (water soluble vitamins) "Soluvit N"	injection	"Soluvit N"	For a complete PN multivitamin, use a fat soluble vitamin preparation together with a water soluble vitamin preparation. <i>See above</i> <i>See above</i>
vitamin compound with minerals "Centrum Advance"	tablet	"Centrum Advance"	For use in patients with a designated clinical need where Vitaminorum brand is considered unsuitable. <i>See above</i> <i>See above</i>
vitamin compound with minerals "Centrum Kids"	chewable tablet	"Centrum Kids"	Patients unable to swallow tablets <i>See above</i> <i>See above</i>
vitamin compound with minerals "Supradyn"	effervescent tablet	"Supradyn"	For use in patients unable to tolerate tablets. <i>See above</i> <i>See above</i>
vitamin compound with minerals "Vitaminorum"	tablet	"Vitaminorum"	
vitamin compound with minerals RENAL "Kidney Vital"	tablet	"Kidney Vital"	Nephrologists or nephrology nurse practitioners for use in patients on dialysis as replacement for the combination of folic acid, vitamin B group with ascorbic acid and cholecalciferol. <i>See above</i> <i>See above</i>
vitamin, fat soluble compound in tocopherol peg suspension	chewable tablet	"AquaDEKs"	Paediatricians, in consultation with CHQ's Paediatric Gastroenterology and Hepatology Service or Cystic Fibrosis Clinic, for infants and children with cholestasis (biliary atresia, alagilles, cystic fibrosis) and FSV deficiency resistant to standard oral FSV supplements. (Children should have documented deficiency of Vit K [abnormal Prothrombin time correctable with Vit K IMI], A, D and E on blood testing.) * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	liquid	"AquaDEKs"	<i>See above</i>
	soft capsule	"AquaDEKs"	<i>See above</i>
		"AquaDEKs"	<i>See above</i>
vitamins, minerals and trace elements with carbohydrate	powder for oral liquid	6 g	Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of the QCH neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
voriconazole	injection		

Drug	Form	Strength	Restriction
		200 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications for oral voriconazole formulations; b) prophylaxis of invasive fungal infections including both yeasts and moulds - in patients unable to tolerate posaconazole - as per the PBS indications for oral voriconazole formulations, and in lung transplant patients.
	powder for oral liquid	40 mg/mL	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications; b) prophylaxis of invasive fungal infections including both yeasts and moulds - in patients unable to tolerate posaconazole - as per the PBS indications and in lung transplant patients.
	tablet	50 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications; b) prophylaxis of invasive fungal infections including both yeasts and moulds - in patients unable to tolerate posaconazole - as per the PBS indications and in lung transplant patients.
		200 mg	<i>See above</i>
vorinostat	capsule	100 mg	Haematologists for discharge and outpatient use as per the PBS indications
warfarin	tablet		Note: Marevan® brand continues to be the preferred brand of warfarin for use in QH facilities. As warfarin brands are NOT bioequivalent and should not be interchanged, hospital pharmacies may hold small stocks of Coumadin® brand for continuation of therapy in inpatients, if patient's own supply is unavailable.
		1 mg	<i>See above</i>
		3 mg	<i>See above</i>
		5 mg	<i>See above</i>
water for injections	injection	1 L 2 mL glass ampoule 5 mL 10 mL 20 mL 100 mL	
water for irrigation	solution	1 L 2 L 100 mL 500 mL	Urology and Renal Units
wool fat	ointment	1 g/g	
zanamivir	powder for inhalation	5 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for a) treatment of laboratory-proven influenza in hospitalised patients within 48 hours of onset of symptoms and b) prophylaxis of hospitalised contacts of laboratory-proven influenza cases in contacts who are at high risk of influenza related morbidity

Drug	Form	Strength	Restriction
zidovudine	capsule	100 mg	* For use in accord with PBS Section 100 indications *
		250 mg	See above
	oral liquid	50 mg/5 mL	See above
			See above
zinc	capsule	50 mg	
zinc chloride	injection	10.6 mg/2 mL (5.1mg/2mL elemental zinc)	
zinc oxide	cream	100g	
		15.25% w/w, 25g	
	15.25% w/w, 60g		
zinc oxide + maize starch + purified talc + chlorphenesin	ointment	100g	
zinc oxide + peru balsam + benzyl benzoate	powder	25% + 55.85% + 18.07% + ...	
zinc oxide compound paste (paraffin base) with	suppository	300 mg + 50 mg + 33 mg	
zinc oxide compound paste (paraffin base) with	paste	100g	
		Dusting Powder 100g	
zinc sulfate	oral liquid	Clioquinol 1%, 50g	
		Coal Tar Solution 3% 50g	
zinc sulfate	oral liquid	Salicylic Acid 2% and Dithranol 0.1% 100g	
		Salicylic Acid 2% and Dithranol 0.25% 100g	
zinc sulfate	oral liquid	11.3mg (elemental zinc) per mL, 50mL	For use when prescribed by a Burns Unit specialist and when zinc sulfate capsules cannot be used
ziprasidone	capsule		For use as per the PBS indications following failure of brexpiprazole, risperidone, olanzapine, amisulpride or lurasidone.
		20 mg	See above
		40 mg	See above
		60 mg	See above
		80 mg	See above
zoledronic acid	injection	4 mg/5 mL	(a) For use in accord with PBS Section 100 indications; (b) Paediatricians for the treatment of (i) Osteogenesis imperfecta OR (ii) Primary or secondary osteoporosis in paediatrics with evidence of significant skeletal fragility (e.g. vertebral compression fractures or ≥ 2 low trauma long bone fractures). * When medicines are used in ways other than as specified in the TGA approved product

Drug	Form	Strength	Restriction
		4 mg/100 mL 5 mg/100 mL	information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * * For use in accord with PBS Section 100 indications * For outpatient or day therapy use for osteoporosis when oral bisphosphonates cannot be tolerated or their use is inappropriate; and for Paget disease as per the PBS indications.
zonisamide	capsule	25 mg 50 mg 100 mg	Neurology Staff for the treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptics as per the PBS indications. <i>See above</i> <i>See above</i> <i>See above</i>
zuclopenthixol acetate	injection	50 mg/mL 100 mg/2 mL	Specialist psychiatrists for prolonged acute behavioural disturbance that has not responded to initial treatments as per the Queensland Health guidelines for acute behavioural disturbance management <i>See above</i> <i>See above</i> <i>See above</i>
zuclopenthixol decanoate	injection	200 mg/mL	Specialist Psychiatrists where other antipsychotic agents are ineffective or contraindicated